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Outline of the study 
Anti-doping programs seek to preserve what is intrinsically valuable about sport. This 
intrinsic value is often referred to as “the spirit of sport”, which is the celebration of the 
human spirit, body and mind and is characterised by values such as ethics, fair play, honesty, 
health, fun, team work, courage and many others. Doping, which is not only the detection of 
prohibited substances but also its possession and use, failing or tampering a doping test or 
refusing a control, is considered as fundamentally against the spirit of sport. 
As a result of this definition, lists of prohibited substances and methods have been developed 
to keep the spirit of sport as pure as possible. Since the introduction of the first doping test in 
the early 1960’s and the development of anti-doping rules by the UCI in the same period, 
doping rules have been extensively revised by the IOC and currently by WADA. These rules 
are very extensive and include numerous classes defined as doping agents, such as anabolic 
steroids, stimulants, diuretics and EPO, and also prohibited methods as blood doping. 
Doping control generally operates a strict liability principle. In other words, the presence of a 
banned substance, or its metabolite, in a urine or body fluid constitutes and doping offence. In 
a refinement of this principle, several substances now have a requirement for laboratories to 
report their presence only above a specified urinary concentration. Some of these substances 
are regulated by a urinary threshold level because they are, or may be, endogenous. Examples 
of those substances are testosterone and 19-norandrosterone, the major metabolite of 
nandrolone. Other substances can be present as a constituent in the daily diet, such as caffeine 
and ephedrine, and are only restricted when large urinary concentrations indicate the 
deliberate intake of this substance to enhance performance. 
In an attempt to run faster, jump higher or throw further athletes are always seeking for means 
to accomplish this goal. Since the mid 1990’s the use of diverse types of nutritional 
supplements has become very popular in an attempt to optimise performance. The most 
important factor behind the explosive growth of the supplement market was the passage of the 
Dietary Supplement Health and Education Act (DSHEA) which makes it possible to market 
numerous products as nutritional supplements as long as no statements are made that these 
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products prevent, treat or cure a specific disease. Other factors behind the growth of this 
market is the easy access through the internet and the ever-improving results and record 
performances of top-level athletes who are promoting the use of supplements. 
However, the uncounselled use of these dietary supplements by athletes is not always without 
risk as some cases have proven that positive doping tests can be obtained as a result of the use 
of (deliberately) contaminated nutritional supplements. Seven professional tennis players for 
instance, tested positive for the nandrolone metabolite norandrosterone. This positive doping 
test was attributed to the use of a nutritional supplement which was distributed among those 
players by ATP-accredited physicians. As a result, all seven athletes were acquitted from a 
doping offence. Similar stories can be found in athletics where a female marathon runner 
tested positive for anorexic agents after the use of a contaminated nutritional supplement and 
in cycling where an improperly prepared supplement seemed to contain methadone.  
Following these facts, it can be concluded that a zone can be situated between uncontested 
doping products, such as injectable anabolic steroids, diuretics and growth hormone, and 
products with doubtful effects on the performance or products not listed on the WADA list of 
prohibited substances. This area is defined as “the grey zone” in this thesis. The substances 
situated in this “grey zone” are in most cases substances with a urinary threshold level, or 
compounds that are allowed if a proper medical cause justifies their use, such as 
corticosteroids. Nutritional supplements (un)intentionally contaminated with doping 
substances are also considered as part of this area if the supplement label does not specifically 
mentions the presence of the contested agent. 
The aim of this work is an evaluation of the “grey” area in doping control. In this thesis, some 
substances that are situated at the borderline, i.e. substances with urinary threshold levels, will 
be discussed as well as the complex situation that arises from contaminated nutritional 
supplements and their influence on the outcome of a doping test. In addition, the declared use 
of medication, i.e. substances allowed as a result of a proper medical cause, on the doping 
control forms filled out during a doping control will also be considered. 
The introduction part of this thesis focuses on the validation and identification criteria used in 
doping control to allow the unequivocal determination of substances. These criteria, which are 
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in accordance with WADA identification criteria set for accredited doping control 
laboratories, are applied throughout this thesis. 
The second part of this thesis focuses on two doping substances with a urinary threshold level. 
The first is caffeine, a substance present in numerous products incorporated in our daily diet 
such as coffee, tea and chocolate. In addition, caffeine has proven to enhance performance at 
doses between 3 and 6 mg/kg body weight. As a result of the reported misuse of high doses, 
the use of caffeine was considered as a doping offence in the past when its urinary 
concentration exceeded 12 µg/ml. However, this substance has been removed from the 
WADA list of prohibited substances from January 1st 2004, because the effect of caffeine on 
performance was said to be small. Because caffeine is frequently promoted as an ergogenic 
aid and as a tool to accomplish weight reduction, the removal could have resulted in an 
increased use of this drug. This study aimed to find out if differences in urinary caffeine 
concentration could be observed before and after its removal from the list of prohibited 
substances. Therefore, a statistical evaluation was made between concentration obtained 
during doping control in the period 1993-2002 and results monitored in 2004. 
A second substance with a urinary threshold level according to WADA criteria is morphine. 
Morphine was isolated from opium, the dried juice obtained from the green capsules of the 
plant Papaver somniferum, as the active compound that is capable of alleviating pain. 
Nowadays, morphine is used as pain relief in cancer treatment or to treat post-surgery pain. 
Because of those painkilling effects morphine can be misused in sport and is therefore 
classified as a doping agent in class S7 of the WADA list of prohibited substances with a 
urinary threshold level of 1 µg/ml. However, several of its possible precursors, such as 
codeine and ethylmorphine, are not prohibited. In addition, investigations have shown that the 
use of poppy seed, originating from the plant Papaver somniferum, might result in the 
detection of morphine. However, results shown in those studies are depending on the origin of 
the investigated poppy seeds. Because no data was available on the use of these poppy seeds 
and other parts of the plant Papaver somniferum in relation to doping control an excretion 
study was set up to investigate if doping positive results for morphine could be obtained after 
the use of herbal products in the daily diet. These products are a cake containing high amounts 
of poppy seeds and two commercially available teas containing parts of the plant Papaver 
somniferum. 
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Besides substances with a urinary threshold level, this thesis mainly focuses on nutritional 
supplements. Nutritional supplements are defined as food supplying in one or more nutrients 
in a concentrated form, such as minerals and vitamins, which are theoretically present in the 
daily diet. Although the use of these supplements is strongly discouraged by several official 
authorities, studies dealing with the prevalence of use have shown that supplement intake 
increases year after year. Especially athletes, ranging from amateur to elite level tend to use 
these supplements to compensate for an inadequate diet or to improve their performance. 
Nutritional supplements are not listed on the WADA list of prohibited substances. 
Nevertheless, the use of these substances is strongly discouraged because of the possible 
contamination of these supplements with components prohibited by national and international 
sports authorities. 
In a first chapter of the investigation on nutritional supplements an extensive review of the 
literature was made dealing with the use of dietary supplements and the problems associated 
with mislabelling of these products, with special attention to substances that are prohibited 
according to the WADA anti-doping rules. 
Following the results obtained from the review of the literature it seemed necessary to 
develop methods capable of detecting (un)intentional contamination with products listed on 
the WADA list of prohibited substances in nutritional supplements. The second and third 
chapter in the part on nutritional supplements therefore aimed at the development of sensitive 
methods for the detection of both anabolising agents and stimulants as these are the 
substances that are most frequently reported in the literature. As no validated methods where 
described before, an additional goal was to validate these methods according to quality 
criteria as set in an ISO 17025 accredited laboratory. 
Chapter 4 on nutritional supplements describes four supplements in detail that have found to 
be contaminated with one or more prohibited substances. In addition, the influence of these 
contaminated nutritional supplements on the outcome of a doping test was investigated. This 
was done by establishing urinary detection times for the doping substances not mentioned on 
the product label. This chapter also summarises the overall results obtained using the 
developed methods during 4 years of supplement testing in the Ghent Doping Control 
Laboratory. 
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Similar to known anabolic agents frequently promoted in the U.S. numerous designer steroids 
are also frequently released on the supplement market. As routine screening methods for 
anabolic steroids in doping control traditionally rely on GC/MS in the SIM mode the 
detection of these new substances in unlikely to occur. One of these new so called nutritional 
supplements is 6-OXO, an aromatase inhibitor with steroidal structure, which is described in 
detail in chapter 5 of Part III. The main goal of the research on this supplement was to 
elucidate its metabolism and to determine markers for misuse of this substance in doping 
control analysis. This was done by setting up an excretion study using this supplement. 
A final part of this work focuses on the declared use of medication on the doping control 
forms filled out at a doping control. These substances are in most cases substances allowed in 
sport or substances allowed if a proper medical cause justifies their use. The latter can be 
considered as part of the “Grey zone” in doping and are of major interest in this work. A 
statistical evaluation of the results obtained from the doping control forms filled out at a 
doping control in the period 2002 –2005 should allow for a general view on the medication 
used by athletes, and more specifically should point out if different kinds of medication are 
used in different areas of sport. Special attention was given to the use of β-agonists, used to 
treat asthma, and corticosteroids, frequently used to deal with inflammation, as these 
substances require a therapeutic use exemption. 
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1. Introduction 
The ultimate objective of method validation is to provide evidence that the analytical method 
does what it is intended to do. It is essential to use well defined and fully validated analytical 
methods to obtain reliable results that can be satisfactorily interpreted. All analytical methods 
described in this thesis were validated. A distinction can be made between quantitative and 
qualitative methods. This chapter describes all parameters tested during validation procedures 
before analysing routine samples. 
Besides the criteria set for validation, criteria for the identification of substances have to be 
specified. According to ILAC-G7, the identification of a prohibited substance must result 
from the direct comparison with a reference material analysed in parallel or series with the 
test sample using a mass spectrometric technique [1]. Similar criteria are required for WADA-
accredited laboratories [2]. In addition to the validation parameters, a brief description of the 
identification criteria used for the identification of substances detected throughout this thesis, 
in compliance with WADA requirements, is also described. 
2. Method Validation 
2.1. Quantitative methods 
2.1.1. Calibration curve 
Calibration curves are established in blank material previously tested for the presence of the 
substance. Threshold levels should be within the range of the calibration curve. Each 
calibration curve consists of at least 5 levels (calibrator), including a zero value. The detection 
range of the calibration curve should at least be from 50 % to 200 % of the threshold level. 
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Mathematically, linear calibration curves can be described as: 
baxy +=  
with: y = ratio area under the curve of analyte/internal standard 
x = ratio of concentration analyte/internal standard 
a = slope 
b = intercept 
If analytes are naturally occurring in the negative matrix (e.g. caffeine in urine; cfr: Part II 
Chapter 1) calibration curves can be established in water providing the slopes of the 
calibration curve in water and in the matrix do not significantly differ 
For validation purposes, each calibrator should be analysed in triplicate. The coefficient of 
correlation r of the calibration curve should exceed 0.98. 
2.1.2. Trueness 
Trueness can be defined as the similarity between the measured and the theoretical value. 
Trueness is measured by the analysis of spiked blank samples. At least 3 samples (≥ 6 is 
recommended) have to be analysed on the lowest and highest calibrator level as well as on the 
threshold. Trueness can be expressed as a percentual deviation of the average measured value 
from the true value. Maximal tolerances are +/- 15 % [3]. 
2.1.3. Precision 
Precision can be divided in repeatability and reproducibility. Precision is expressed by the 
relative standard deviation (RSD) calculated from the determination of a number (n ≥ 6) of 
analyses of an identical sample. 
2.1.3.1 Repeatability 
The repeatability is defined as the similarity between successive measurements obtained 
under identical circumstances (same operator, same method, same equipment, same time of 
analysis). Therefore at least 3 (6 is recommended) negative samples are spiked with the 
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components of interest at the level of lowest and highest calibrator level as well as on the 
threshold. The repeatability may not exceed the limit value of 2/3 RSDmax with RSDmax 
calculated from the Horwitz equation: 
)log5.01(2max
CRSD −=  
2.1.3.2 Reproducibility 
The reproducibility is the level of correspondence between results obtained with the same 
analytical method but analysed by a different analyst and spread in time. Therefore, samples 
spiked at the same levels as for the repeatability are analysed by different persons. This allows 
for the determination of the between-day RSD. The obtained value may not exceed RSDmax. 
An analytical method is robust if small variations in analytical conditions do not result in 
significant differences. The robustness of an analytical method is determined via the 
reproducibility. 
2.1.4. Limit of quantification 
The limit of quantification (LOQ) of an analytical method is the lowest measured level, 
different from zero, which can be determined in a reproducible way. For quantitative methods 
this concentration is equal to the lowest point of the calibration curve and may not exceed half 
of the threshold level. 
Sensitivity is a term often misused instead of LOQ. A method is said to be sensitive if small 
variations in concentrations cause large variations in response and is in fact equal to the slope 
of the calibration curve . 
2.1.5. Limit of detection 
The limit of detection (LOD) of an analyte is the lowest concentration, different from zero, 
which can be detected, but not necessarily quantified according to criteria of trueness and 
precision. In this theses, the LOD is arbitrarily set at half of the LOQ.  
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2.1.6. Selectivity and specificity 
The selectivity and specificity of an analytical method describes the ability to distinguish the 
analyte from other substances present. 
An analytical method is specific if it is able to determine the analyte without interference of 
endogenous substances or other interferences. Therefore, negative matrices (n ≥ 6) are 
analysed and no interferences should occur neither at the retention time of the analyte(s) nor 
at the retention time of the internal standard. 
An analytical method is selective if it is capable of distinguishing the analyte of interest from 
other (spiked) components belonging to the same class of substances. Therefore, negative 
matrices are spiked with these substances. Based upon relative retention time and/or MS ion 
ratios, the positive identification of the analyte should not be hampered by these related 
substances. 
2.2. Qualitative methods 
Qualitative methods are validated according to the procedure described by Verwaal et al. [5]. 
This validation procedure includes the determination of the LOD and tests for selectivity and 
specificity. 
2.2.1. Limit of detection 
The determination of the LOD is described by Eurachem [6]. According to these guidelines, 
the LOD is the lowest concentration that can be determined with a statistical certainty ≥ 95% 
(n ≥ 10). Therefore, negative samples are spiked at different levels and a response curve is 
established. The LOD is the lowest concentration with a score ≥ 95%. The tested levels 
should at least be: 2 x LOD, LOD, ½ x LOD and negative samples. 
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2.2.2. Selectivity and specificity 
Similar to quantitative methods selectivity and specificity have to be determined. The 
procedure for qualitative methods is described by Verwaal et al. [5]. The minimum 
concentration of related substances spiked in a negative matrix should at least be twice the 
LOD in testing for selectivity. 
Specificity is determined by the analysis of negative matrices used to establish the LOD of the 
analytical method. 
3. Identification criteria 
3.1. Retention time criteria 
The retention time (RT) is characteristic for a substance. Hence, retention times of the analyte 
in a sample and of the reference compound should be comparable, if analysed under the same 
conditions. The use of the relative retention time (RRT), calculated by dividing the retention 
time of a substance by the retention time of an internal standard, can be helpful to differentiate 
between substances with similar mass spectra. Nowadays, capillary GC and HPLC are the 
most frequently used chromatographic techniques. Table 2.2.1 summarises the criteria set up 
by WADA for these chromatographic techniques [2]. 
Table 3.1.1 Maximum tolerance for deviations in retention time (RT) and relative 
retention time (RRT) between an analyte in a sample and the reference compound. 
 Maximum allowed deviation  
GC 1 % or 12 s for RT whichever is smaller 
 1 % for RRT  
HPLC 2 % or 24 s for RT whichever is smaller 
 2 % for RRT  
Less stringent criteria are applied for HPLC because capillary gas chromatography (GC) has 
shown to provide a higher reproducibility in retention times than HPLC. 
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3.2. Mass spectral criteria 
Mass spectrometry (MS) is a detection technique based upon the fragmentation of a molecule 
in an electric field, generating a fragmentation pattern of the molecule with can be considered 
as a fingerprint. 
Although a mass spectrum can be regarded as unique for a substance, different substances can 
have the same mass spectrum [7]. The mass spectrum of an analyte can slightly differ 
depending on instrumental parameters, matrix and concentration. Therefore, strict criteria 
have to be set for several parameters allowing the unequivocal identification of a substance. 
As for the retention time, WADA has set criteria for mass spectrometric detection [2]. 
The mass spectrometer can be operated in scan mode, detecting all masses within a set 
interval, or in SIM mode. In the latter, only a limited number of ions are monitored. Mass 
spectra acquired in the scan mode are preferred over SIM-spectra. In both scan and SIM 
mode, at least three diagnostic ions are needed for the unequivocal determination of a 
substance. WADA describes diagnostic ions as molecular ion or fragment ions whose 
presence and abundance are characteristic of the substance and thereby may assist in its 
identification [2]. A second ion belonging to the same isotopic cluster may also be used as 
diagnostic only when the peculiarity of the atomic composition of the fragment so justifies 
(e.g. presence of Cl, Br or other elements with abundant isotopic ions). When full scan mass 
spectrometry is used, all diagnostic ions with a relative abundance greater than 10 % in the 
reference spectrum must be present in the spectrum of the unknown substance. In addition, for 
both SIM and scan spectra the relative abundance of three diagnostic ions in the analyte may 
not differ by more than the tolerance windows shown in Table 2.3.2 compared to the relative 
intensities of the same ions obtained from a spiked urine, a reference collection or a reference 
material. 
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Table 3.2.1 Maximum tolerance windows for relative ion intensities ensuring 
identification. 
Relative Abundance 
(% of base peak) 
GC/MS (EI) GC/MS (CI), GC/MSn , 
LC/MS , LC/MSn 
> 50 % ± 10 % (absolute) ± 15 % (absolute) 
25 % to 50 % ± 20 % (relative) ± 25 % (relative) 
< 25 % ± 5 % (absolute) ± 10 % (absolute) 
In some cases, SIM is required to detect substances at the MRPL. The signal to noise ratio of 
the least abundant ion must be greater than 3:1. The relative abundance of the ion is 
determined by peak area or height in the integrated selected ion chromatograms. The relative 
intensities of any of the diagnostic ions should meet the criteria given in Table 2.3.1. An 
additional diagnostic ion with a relative abundance of less than 5 % in the reference must be 
present in the unknown. 
As it is well known that the relative abundances of diagnostic ions are concentration 
dependent, the concentration of the substance in a reference sample should be comparable to 
the concentration of the analyte in the sample. 
A second derivatisation and/or ionisation technique is required if less than three diagnostic 
ions are present. 
In MSn a precursor ion is selected and fragmented into product ions. The combination of the 
selection of the precursor ion and mass selection or scanning of the product ions results in 
increased specificity. According to WADA criteria, the collision conditions should be selected 
to ensure the presence of the precursor ion in the MS/MS spectrum [2]. The combination of 
one product ion with its precursor ion can be sufficient for identification purposes. 
However, if more than one product ion is monitored, the relative abundance of these ions shall 
not differ by more than the percentages in Table 2.3.1 The signal to noise ratio of the least 
intense diagnostic ion should be greater than 3:1. Similar as for SIM methods, any additional 
diagnostic ion in the reference spectrum with a relative abundance smaller than 5 % should 
also be present in the spectrum of the analyte. Again, if unique diagnostic product ions are not 
available, another derivatisation, ionisation or fragmentation technique should be used. 
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Chapter 1: Caffeine 
1.1. Introduction 
Caffeine (1,3,7-trimethylxanthine) is according to pharmacological criteria the most common 
drug of abuse used in the world today. Besides colas, chocolate and energy drinks, the main 
source of caffeine is coffee. In addition, caffeine, just as theophylline, is readily available as 
an over the counter drug in numerous countries in its pure form as “wake-up” pills [1]. Also, 
multiple nutritional supplements, promoted as having a performance enhancing and 
stimulating effect, became available the last decade and contain caffeine. Some of these 
products include, besides caffeine, extracts of guarana (Paullinia cupana), a South American 
plant which has been shown to contain caffeine [2]. According to European regulations, 
caffeine can be added to sport/energy drinks in levels up to 320 mg/l. A complete list of the 
caffeine content of numerous drinks including coffee, teas, cola energy drinks and chocolate 
products has been published [2]. Highest concentrations were found in tea which contains up 
to 630 mg/l. Cola drinks, very often used by athletes during competition, contain from 33 to 
213 mg/l and coffee between 210 and 340 mg/l. 
Ingestion of caffeine in order to improve athletic performance is common use among athletes. 
A survey conducted in Canada revealed that 35% of 11-18 year-old students questioned 
believed that caffeine could enhance their performance and 25% admitted using caffeine to 
enhance their athletic performance [3]. There are also reports that top endurance athletes use 
Coca-cola in the late stage of a race as a source of caffeine for the ergogenic effect 
(http://www.sportsci.org/news/news9711/martin.html). 
1.1.1. Performance enhancing effects of caffeine 
A brief overview of the history of caffeine in sport sciences is given by Perkins and Williams 
[4]. They show that current issues regarding the use of caffeine in sports are not new. The last 
decennia the performance enhancing effects after ingestion of caffeine on endurance sports 
have been discussed in numerous papers [5-8]. Generally spoken, caffeine tends to have a 
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positive influence on this type of performance [9-13]. This hypothesis is supported by most, 
but not all studies [14, 15]. Nevertheless, there seems to be a consensus on caffeine having an 
ergogenic effect on endurance exercise when fatigue occurs in 30 to 60 minutes. 
Less and more inconsistent data was found on the impact of caffeine on short term exercise. 
Collomp et al. reported no significant effect of caffeine on maximal and mean power during a 
30 s Wingate test [16], so did Paton et al. [17]. On the other hand, other investigations showed 
a performance enhancing effect of caffeine in short term exercises [18-20]. The most obvious 
reason for this discrepancy is the difficulty to quantify the effect as the potential improvement 
is small and difficult to measure. 
It is not clear whether caffeine improves muscular strength or not. Jacobs et al. reported 
muscular endurance improvement after ingestion of caffeine, but this was in combination with 
ephedrine [21]. In spite of lacking evidence many strength athletes use caffeine to increase 
their performance. It is not clear whether an improvement in strength is obtained or the rate of 
fatigue is diminished. 
In almost all investigations caffeine was ingested one hour before the start of the experiment 
[22, 23]. In this way, the plasma caffeine peak concentration is situated during the exercise. 
However, it is not known if this is the best timing to maximize the ergogenic effect of caffeine 
because caffeine is slowly metabolised and individuals maintain a high level for 3 to 4 hours 
[24]. It has been suggested to wait for 3 hours, when the caffeine induced lipolysis results in 
the highest free fatty acid level [7]. 
An ergogenic effect can be obtained after the ingestion of caffeine in doses in the range 3-6 
mg/kg. Bruce et al. reported that doses of 6 and 9 mg/kg were equally effective in increasing 
performance [25]. The lowest reported dose found to be ergogenic was 2.1 mg/kg [11]. 
Simultaneously, it was concluded that doses of 3.2 and 4.5 mg/kg had a greater effect than 2.1 
mg/kg. Repeated ingestion seems questionable because a single dose of caffeine elevates the 
circulating plasma levels of caffeine for several hours [24]. Only two studies investigated the 
effect of a divided dose of caffeine on performance [12, 26]. The results in both studies 
suggest that ingesting a divided dose of caffeine during an endurance exercise has no 
ergogenic effect on performance over a bolus of caffeine given before exercise. 
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Until now, the mechanism by which caffeine releases its ergogenic effects is not revealed 
completely. Several parameters including adenosine receptor antagonism, epinephrine release, 
elevated free fatty acid levels etc. are proposed and have been discussed extensively in the 
literature [8, 24]. 
The most popular and also most used form of caffeine is coffee. Caffeine levels in instant 
coffee vary between 210 and 340 mg/l [2], although higher concentrations (up to 1.6 g) were 
reported in dripped coffee and espresso [1]. So 1 litre of coffee corresponds with caffeine 
doses used in the previously mentioned publications investigating the ergogenic effect of 
caffeine. Surprisingly, Graham et. al [9] showed that when caffeine was ingested together 
with decaffeinated coffee or as coffee itself, no ergogenic effect was reported although similar 
plasma methylxanthine concentrations were noticed. So a change in the metabolic pathway 
can not be responsible for this phenomenon. It appears that some component(s) present in 
coffee interfere with the ergogenic properties of coffee. More investigations have to be 
performed. 
It is generally accepted that caffeine should not be added to beverages which are designed to 
stimulate fluid replacement during exercise because of the diuretic properties of caffeine as 
this can lead to dehydration [27, 28]. However, Wemple et al. proved that caffeine does not 
exhibit its diuretic properties during endurance exercise [29]. The diuretic effect is only 
observed at rest. So athletes can use caffeine containing beverages in endurance exercise to 
improve their performance without the concern for diuresis. 
In conclusion, caffeine can be a powerful ergogenic aid not only in competition, but also in 
training sessions. 
1.1.2. Caffeine and doping 
As a result of the reported misuse of high doses, caffeine was listed as a doping agent in class 
I A “Stimulants” by the IOC with a urinary threshold level of 15 µg/ml in 1984. This 
threshold level was reduced in 1985 to 12 µg/ml [30]. Starting from January 1st 2004 caffeine 
was removed from the list of prohibited substances. Dosages of 3-6 mg/kg used in the above 
mentioned papers did not result in urinary concentrations close to the former threshold level 
of 12 µg/ml. 
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Removing caffeine from this list could have resulted in an increased use of caffeine. If the 
goal of drug testing in sport is to prevent unfair advantage, to encourage ethical behaviour and 
to protect the health of the athletes, caffeine should remain on the list of prohibited 
substances. A complete ban of caffeine from sports is not possible due to the presence of the 
drug in numerous dietary products. Setting a threshold level is more realistic. 
Before the removal of caffeine from the doping list no data was available on the distribution 
of caffeine in urine samples tested for doping control. This study aims at the evaluation of the 
urinary caffeine concentrations measured before and after the removal of caffeine from the 
WADA doping list. 
1.2. Experimental 
1.2.1. Chemicals and reagents 
Caffeine was a gift from Merck (Darmstadt, Germany). β-OH-ethyltheophylline was 
purchased from Sigma (St. Louis, MO, USA). All other reagents (dichloromethane, methanol, 
ammonia, sodium chloride, ammonium chloride and tetrahydrofurane) were of analytical 
grade. 
Ammonia buffer (pH 9.5) was prepared by the addition of ammonia to a saturated ammonium 
chloride solution until the desired pH was obtained. 
1.2.2. Chromatographic conditions 
The HPLC system consisted of a Model P4000 liquid chromatograph, a Model AS 3000 auto 
sampler and a Spectra Focus forward optical scanning detector set at 275 nm, all from TSP 
(Fremont, CA, USA). The column was a Hypersil 5 ODS, 100 x 3 mm I.D., 5 µm 
(Chrompack, Antwerp, Belgium) with an appropriate precolumn (10 x 2 mm I.D., 40 µm, 
C18). The loop volume was 20 µl. The mobile phase was a mixture of tetrahydrofurane and 
water (1/100; v/v) at an isocratic flow rate of 1.0 ml/min. 
Part II: Doping substances with a threshold level 
1.Caffeine 
 19
1.2.3. Urine analysis 
All urine samples were analysed according to the procedure described by Delbeke et al. [31]. 
Briefly, 100-120 mg of sodium chloride, 50 µl of internal standard (β-OH-ethyltheophylline 
100 µg/ml, aqua bidest) and 100 µl of ammonium buffer (pH 9.5) were added to 1 ml urine. 
Extraction was performed by rolling with 5 ml of the dichloromethane-methanol (9/1; v/v) 
mixture for 20 minutes. After centrifugation, the organic layer was separated and evaporated 
under oxygen free nitrogen at 40°C. The residue was dissolved in 200 µl mobile phase. 20 µl 
was injected onto the chromatographic system. The method allowed for the separation of 
theobromine, theophylline, paraxanthine and caffeine. 
1.2.4. Statistical analysis 
A statistical analysis was made of the caffeine concentrations before and after the removal of 
caffeine from the WADA doping list. 
All data were ranked numerically and divided into intervals of 0.25 µg/ml to create a caffeine 
distribution, concentrations below the LOQ (before: N = 3002 , after: N = 942) were 
considered as not detected. To evaluate the difference between sports a log-transformation of 
the concentrations was necessary. Therefore, all values below the LOQ were excluded. This 
allowed for the determination of an average concentration with a standard deviation on the 
concentrations above the LOQ (before: N = 8359 ; after: N = 3691). Comparison of those 
sports of which more than 200 samples were analysed was done by a one-way ANOVA using 
the Tukey HSD test comprised in the SPSS software package (SPSS 12.0, SPSS Inc., 
Chicago, USA). 
Comparison of the results obtained before (N = 11361) and after the removal (N = 4633) of 
caffeine from the WADA doping list was done using an F-test to determine the variances, 
followed by an appropriate student t-test for the most abundantly tested sports in both periods. 
1.3. Analytical method validation 
The method was validated. An equally weighted linear calibration curve was constructed in 
the range from 0-20 µg/ml (0, 4, 8, 12, 16, 20 µg/ml) by plotting the ratio of the peak height 
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of caffeine to the peak height of the internal standard (β-OH-ethyltheophylline). Therefore 
aqua bidest samples spiked with the appropriate amounts of caffeine standards were analysed. 
This matrix was used because of the impossibility to obtain caffeine free urine. A statistical 
evaluation was performed, using a two sided F-test followed by an appropriate student t-test, 
showing that the slope of a calibration curve made in aqua bidest does not differ significantly 
from the slope of a calibration curve made in urine. Each concentration was analysed in 
triplicate, the averages were used to create the calibration curve. The correlation coefficient of 
the obtained calibration curve was 0.9981. The deviation of the mean measured concentration 
from the theoretical concentration (trueness) was far below the maximal value of 15 % [32]. 
The precision was evaluated by the determination of the repeatability and the reproducibility. 
To measure the repeatability 6 samples at three different concentrations (1, 5 and 12 µg/ml) 
were analysed. The relative standard deviation, an indicator of the repeatability, for each of 
those concentrations never exceeded the limit values derived from the Horwitz equation [33]. 
Measured concentrations, relative standard deviations and maximal limits for the repeatability 
are listed in Table 1.3.1. 
Table 1.3.1 Method repeatability. 
Theoretical concentration (µg/ml) 1.00 5.00 12.00 
Average measured concentration (µg/ml) (n=6) 0.96 4.89 11.97 
SD (µg/ml) 0.075 0.100 0.374 
RSD (%) 7.8 2.0 3.1 
2/3 RSDmax (%) 10.7 8.4 7.3 
Accuracy (%) -3.8 -2.2 -0.3 
The reproducibility was examined by analysing 12 samples at 5 µg/ml. This was done by two 
different analysts, at different times. The results for the reproducibility are summarized in 
Table 1.3.2. The original limit values calculated by the Horwitz equation are used while for 
the repeatability the margin was narrowed to two third of the calculated value. For both 
repeatability and reproducibility the accuracy was measured and is listed in Tables 1.3.1 and 
1.3.2. A limit value of 15 % is used. 
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Table 1.3.2 Method reproducibility. 
Theoretical concentration (µg/ml) 5.00 
Average measured concentration (µg/ml) (n=12) 5.07 
SD (µg/ml) 0.145 
RSD (%) 2.9 
RSDmax (%) 12.6 
Accuracy (%) 1.4 
The limit of quantification was defined as the lowest point where caffeine could be detected in 
a repeatable way. Therefore six samples of aqua bidest spiked with caffeine at 0.05, 0.1 and 
0.25 µg/ml were analysed. Table 1.3.3 summarises the repeatability at these low 
concentrations. 
Table 1.3.3 Method repeatability at low concentrations. 
Theoretical concentration (µg/ml) 0.05 0.1 0.25 
Average measured concentration (µg/ml) (n=6) / 0.099 0.24 
SD (µg/ml) / 0.01 0.008 
RSD (%) / 10.22 3.39 
2/3 RSDmax (%) / 15.08 13.14 
Accuracy (%) / -0.58 -2.14 
Caffeine was not detected in 3 out of the 6 samples spiked at 0.05 µg/ml. On the other hand, 
the obtained values for accuracy and the relative standard deviation at a concentration of 0.1 
µg/ml are lower than the limit values of 15 % and 15.08 % respectively, resulting in an LOQ 
of 0.1 µg/ml. 
Selectivity and specificity were tested by the analysis of a system blank (H2O), a quality 
control sample (H2O) spiked at 12 µg/ml and 10 different urines. Stock solutions of both 
caffeine and β-OH-ethyltheopylline were also tested. A peak purity analysis showed that the 
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UV-spectra of both internal standard and caffeine did not change significantly over the 
chromatographic peak in all analysed urine samples showing that no co-elution of matrix 
components occurred. In addition, match values of the average UV-spectra of the 
chromatographic peaks higher than 95% were obtained when compared with the reference 
spectrum. Analysis of the reference solutions showed no interferences of other substances. 
Hence the method is selective and specific. 
1.4. Results 
1.4.1. 1993-2002 
Caffeine concentrations were determined in 11361 urine samples, originating from in-
competition doping tests by the Flemish Community and several sport federations including 
IAAF, UCI and UEFA. Figure 1.4.1 shows the distribution (intervals: 0.25 µg/ml) of caffeine 
in athletes’ urine specimens. Caffeine was below the LOQ in 3002 (26.42%) samples. Urinary 
caffeine concentrations ranged from 0 to 29.94 µg/ml. 
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Figure 1.4.1 Distribution of caffeine levels in the urine of 11361 athletes tested for 
doping control during the period 1993-2002. Caffeine concentrations <LOQ of 0.1 µg/ml 
and >15 µg/ml are not shown. 
The histogram of the logarithmic transformation of the concentrations above the LOQ is 
represented in Figure 1.4.2. These adjustments allow for the data to adapt into a gaussian 
form. Based on the transformed data an average concentration of 1.22 µg/ml with a standard 
deviation of 2.45 µg/ml is obtained. 
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Figure 1.4.2 Distribution of log-transformed urinary caffeine concentrations in 8359 
urine samples exceeding the LOQ of the analytical method. 
Transformed caffeine concentrations are compared using ANOVA for those sports in which 
more than 200 samples were analysed between 1993 and 2002. The number of samples 
analysed, the resulting average concentration and standard deviation after transformation, and 
percentage of values below the LOQ for each of those sports are given in Table 1.4.1. 
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Table 1.4.1 Average caffeine concentration and standard deviation after transformation, 
and percentage of values below LOQ in sports with more than 200 samples analysed 
(1993-2002). 
Sport N Average 
concentration 
(µg/ml) 
Standard 
deviation 
(µg/ml) 
Percentage below 
LOQ (%) 
Cycling 4344 1.34 2.44 22.17 
Athletics 643 1.06 2.62 32.50 
Swimming 215 0.90 2.37 45.12 
Soccer 1295 1.05 2.23 27.80 
Basketball 478 1.04 2.34 32.01 
Volleyball 641 1.20 2.39 20.90 
Bodybuilding 255 1.72 2.49 26.27 
Results of comparison of these sports using a one-way ANOVA (Tukey HSD post hoc test) 
are presented in Table 1.4.2. 
Table 1.4.2 Comparison of mean urinary caffeine concentrations between sports with N 
> 200 before the removal of caffeine from the WADA doping list. a 
 
Cycling 
1.34 µg/ml 
Athletics 
1.06 µg/ml 
Swimming
0.90 µg/ml 
Soccer 
1.05 µg/ml 
Basketball
1.04 µg/ml 
Volleyball 
1.20 µg/ml 
Bodybuilding
1.72 µg/ml 
Bodybuilding # # # # # #  
Volleyball = = # = =   
Basketball # = = =    
Soccer # = =     
Swimming # =      
Athletics #       
Cycling        
a post hoc test: Tukey HSD test. = no significant difference (α = 0.05). # significant difference 
(α = 0.05). 
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Sixteen athletes (0.14%) delivered a urine sample with a caffeine concentration exceeding the 
doping threshold of 12 µg/ml. In 2 out of them the concentration was above 20 µg/ml. The 
distribution of the positive caffeine results amongst different sports is given in Table 1.4.3. 
Table 1.4.3 Number of positive samples and highest detected urinary caffeine 
concentration during the period 1993-2002. 
Sport 
 
Number of positives
 
Percentage positives
 
Highest concentration
(µg/ml) 
Cycling 4 0.09 15.0 
Bodybuilding 3 1.18 29.9 
Powerlifting 3 2.05 16.9 
Volleyball 2 0.31 17.7 
Athletics 1 0.16 14.7 
Soccer 1 0.08 18.6 
Weightlifting 1 2.17 12.3 
Gymnastics 1 0.81 20.1 
1.4.2. 2004 
Similar as for the period 1993-2002, caffeine concentrations were determined in 4633 samples 
originating from in-competition doping tests by the Flemish and French NADOs in Belgium 
and The Netherlands and several federations including IAAF, UCI and UEFA. 
The distribution (intervals 0.25 µg/ml) of caffeine in athletes’ urine specimens is shown in 
Figure 1.4.3. Caffeine concentrations below the LOQ were found in 942 (20.33%) out of the 
4633 samples. Urinary caffeine concentrations ranged from 0 to 20.84 µg/ml. 
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Figure 1.4.3 Distribution of caffeine levels in the urine of 4633 athletes tested for doping 
control during 2004. Caffeine concentrations < LOQ of 0.1 µg/ml and > 15 µg/ml are not 
shown. 
Samples with a urinary caffeine concentration ≥ 4 µg/ml, a caffeine concentration found in 
urine samples from moderate to frequent coffee drinkers [34], were compared between several 
sports and between this period (2004) and the previously examined period (1993-2002) (Table 
1.4.4). 
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Table 1.4.4 Percentage of samples with a urinary caffeine concentration ≥ 4µg/ml in 
different sports in 1993-2002 and 2004. 
Sport 1993-2002 2004
Overall 7.01 7.55 
Cycling 8.89 11.18
Athletics 6.07 4.76 
Swimming 2.79 1.33 
Soccer 3.32 4.79 
Basketball 5.02 3.03 
Volleyball 6.71 7.60 
Bodybuilding 13.73 13.51
Powerlifting 19.86 18.56
A log-transformation allowed the data (concentrations above LOQ) to adapt into a Gaussian 
form. Based on the transformed data an average concentration of 1.12 µg/ml with a standard 
deviation of 2.68 µg/ml was obtained. 
Transformed caffeine concentrations were compared using ANOVA for the most frequently 
tested sports in 2004. Major sports in the previously examined period (1993-2002) were 
included in this comparison. The number of samples analysed, average concentration and 
standard deviation after transformation and percentage of samples with a urinary caffeine 
concentration below the LOQ for these sports are given in Table 1.4.5. 
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Table 1.4.5 Average caffeine concentration and standard deviation after transformation 
and percentage of values below the LOQ in frequently tested sports in 2004. 
Sport 
 
N 
 
Average 
concentration 
(µg/ml) 
Standard 
deviation 
(µg/ml) 
Percentage 
below LOQ 
(%) 
Cycling 1467 1.40 2.60 16.84 
Athletics 357 0.95 2.74 20.73 
Swimming 75 0.45 2.24 48.00 
Soccer 438 1.00 2.53 18.95 
Basketball 165 0.83 2.41 29.70 
Volleyball 171 1.03 2.75 8.77 
Bodybuilding 37 1.35 2.98 27.03 
Boxing 135 0.87 2.65 21.48 
Judo 93 0.83 2.52 35.48 
Motor sports 86 1.12 2.41 26.74 
Handball 98 1.00 2.68 10.20 
Gymnastics 76 0.72 2.53 34.21 
Powerlifting 97 1.71 2.55 9.28 
Results of the comparison of those sports using a one-way ANOVA test (Tukey HSD post 
hoc test) are presented in Table 1.4.6. 
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Six athletes (0.13%) delivered a urine sample with a caffeine concentration higher than the 
former threshold level of 12 µg/ml. Five of them had a urinary caffeine concentration higher 
than 16 µg/ml. 
A comparison was made between the results obtained before and after the removal of caffeine 
from the WADA doping list of prohibited substances. The resulting caffeine concentrations, 
percentages of samples with a urinary caffeine concentration below the LOQ and percentages 
of positive results for the most frequently tested sports are summarised in Table 1.4.7. 
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Table 1.4.7 Comparison of the average urinary caffeine concentrations (µg/ml), 
percentage of samples with a urinary caffeine concentration below the LOQ and 
percentage of positive results based on the 12 µg/ml threshold level in frequently tested 
sports in the period 1993-2002 and in 2004. 
Average Concentration Percentage < LOQ Percentage Positives **
1993-2002  2004 1993-2002 2004 1993-2002 2004 
Cycling 1.34 1.40 22.17 16.84 0.09 0.27
Athletics 1.06 0.95 32.50 20.73 0.16 0.28
Boxing 1.01 0.87 35.23 21.48 0 0
Judo 0.97 0.83 43.60 35.11 0 0
Swimming  0.90 0.45* 45.12 48.00 0 0
Motor Sport 1.14 1.12 39.33 26.44 0 0
Soccer 1.05 1.00 27.80 18.95 0.08 0
Basketball  1.04 0.83* 32.01 29.70 0 0
Volleyball 1.20 1.03 20.90 8.77 0.31 0
Handball 1.27 1.00 18.35 11.49 0 0
Bodybuilding 1.72 1.35 26.27 27.03 1.18 2.70
Gymnastics 0.59 0.72 68.29 34.21 0.81 0
Powerlifting 1.74 1.71 17.12 9.28 2.05 0
* Significant difference in average concentration (α=0.05) between 1993-2002 and 2004 
** Positive according to the former threshold level of 12 µg/ml 
1.5. Discussion 
Because at low urinary caffeine levels no distinction can be made between caffeine use 
intended to improve athletic performance and normal caffeine use of coffee and tea, WADA 
removed caffeine from the list of prohibited substances from January 1st 2004 on. However, 
some WADA-accredited laboratories (not the Ghent Doping Control Laboratory) were asked 
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to continue monitoring caffeine levels in order to control if caffeine concentrations above the 
former threshold level would be detected after the removal of this drug from the WADA-list 
of prohibited substances. In this study all caffeine concentrations in the period 1993-2002 
have been evaluated and were compared to results obtained in 2004. 
1.5.1. 1993-2002 
Of all samples analysed in the Doping Control Laboratory (DoCoLab - UGent) during this 
period, only in-competition samples were screened for caffeine, resulting in 11361 samples 
originating from 90 different categories of sport. The distribution of the urinary caffeine 
concentrations was positively skewed (Figure 1.4.1). 
In order to compare the caffeine concentrations amongst different sports the data 
(concentrations below LOQ were not included) was log-transformed into a gaussian form. 
This allowed for the determination of an overall average concentration of 1.22 µg/ml with a 
standard deviation of 2.45 µg/ml resulting in an apparent threshold level of 11.02 µg/ml 
(average + 4 x SD). Hence, the former caffeine threshold level of 12 µg/ml seemed 
reasonable. 
Only those sports with more than 200 samples analysed over the period 1993-2002 were 
included in this study. From the results in Table 1.4.1, a large variation in average caffeine 
concentration between sports (cfr bodybuilding and swimming) can be observed as well as 
within each sport (cfr standard deviation). 
Overall concentrations found in bodybuilding are significantly higher than in other sports 
including cycling and ball sports (Table 1.4.2). This could be due to the fact that caffeine in 
combination with ephedrine is advertised as a fat burner. Several studies have demonstrated 
that ephedrine, particularly in combination with caffeine, is effective in promoting weight loss 
without adverse effects [35, 36]. Numerous bodybuilding sites on the internet promote the 
ephedrine – caffeine – aspirin stack (ECA-stack) for its fat burning effect. These stacks are 
also commercially available on these sites. This could be an explanation for the significantly 
higher concentrations found in bodybuilding when compared to other sports. 
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Also caffeine concentrations found in cycling are significantly higher than in other sports, 
except bodybuilding and volleyball (Table 1.4.2). Use of caffeine by cyclists is popular in the 
late stage of a race for its a stimulating properties and ergogenic effect on endurance 
performance [5, 7-9, 11-13]. 
Most positive cases in the period 1993-2002 were found in cycling (Table 1.4.3), but taking 
into account the number of samples being analysed this only accounts for a small percentage. 
Strength sports including bodybuilding, powerlifting and weightlifting are the sports where 
the highest percentage of positive cases were noticed. 
1.5.2. 2004 
In total 4633 samples originating from in-competition controls tested in the Ghent Doping 
Control Laboratory in 2004 were screened for caffeine. These samples originate from 56 
different sports. Percentages of caffeine values higher than 4 µg/ml, a caffeine concentration 
found in moderate to frequent coffee drinkers [34] were found to be higher in cycling and 
strength sports compared to the overall percentage and to values observed in other tested 
sports, indicating the popularity of caffeine in those particular sports. Compared to the 
previously examined period, the overall percentage remained approximately the same while 
the percentage in cycling has increased. The percentages in the other tested sports remained 
roughly the same after the removal of caffeine from the WADA doping list (Table 1.4.4). 
The distribution of the urinary caffeine concentrations in 2004 was positively skewed (Figure 
1.4.3). Comparison of the caffeine concentrations amongst different sports in 2004 was 
achieved by a log-transformation, allowing the data to adapt into a gaussian form. Urinary 
caffeine concentrations below the LOQ were not included in this transformation. These 
samples accounted for 20.33% of all samples analysed in 2004, 6 % less than in the period 
1993-2002 (26.42%). The transformation resulted in an overall average concentration and a 
standard deviation of respectively 1.12 µg/ml and 2.68 µg/ml with a calculated apparent 
threshold level of 11.84 µg/ml (average + 4 x SD). Similar handling of the data in the period 
1993-2002 has indicated an average urinary caffeine concentration of 1.22 µg/ml and an 
apparent threshold level of 11.02 µg/ml. These values approach the former threshold level of 
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12 µg/ml, indicating that this threshold level was an acceptable criterion to discriminate abuse 
from use. 
Comparison of the caffeine concentrations after transformation was performed between the 
most frequently tested sports in 2004 (Table 1.4.5). Large variations in average caffeine 
concentrations between sports (e.g. swimming and powerlifting) as well as within each sport 
(standard deviation) were observed. 
As can be seen in Table 1.4.6, overall concentrations in powerlifting were significantly higher 
than in almost all other sports including athletics and ball sports. As already mentioned in 
§1.5.1 the use of caffeine in strength sports, often in combination with ephedrine, is popular 
among strength athletes as a fat burner. The commercial availability of caffeine on internet 
sites promoting the ECA-stack could be indicative for the higher concentrations of caffeine 
found in powerlifting. 
Similar to the period 1993-2002 caffeine concentrations in cycling were significantly higher 
when compared to most other sports. The use of caffeine by cyclists is popular in the late 
stage of a race for its stimulating and performance enhancing effects [5, 8, 9, 11, 12]. 
From the comparison of average caffeine concentrations, percentages of samples below the 
LOQ and percentages of positive results in 2004 and in the previously examined period 
(Table 1.4.7) it appears that in cycling and gymnastics caffeine concentrations have increased 
after the removal of caffeine from the doping list although the increase is not significant on 
the 95% confidence interval. Caffeine concentrations in swimming and basketball however 
were significantly lower in 2004 when compared to the period 1993-2002. 
A trend towards a lower percentage of samples with a urinary caffeine concentration below 
the LOQ of 0.1 µg/ml was also observed in all sports except swimming and bodybuilding. 
The higher percentage of concentrations below the LOQ in swimming is reflected in the 
significant decrease in average caffeine concentration after the removal of caffeine from the 
WADA doping list. In bodybuilding caffeine concentrations below the LOQ increased and the 
average concentration decreased although the percentage of positive results increased in 2004. 
This trend could be due to the low number of samples analysed in bodybuilding in 2004. 
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Six samples were found to contain a urinary caffeine concentration higher than the former 
threshold level of 12 µg/ml. Four of them (0.27%) were found in cycling (Cmax: 20.84 µg/ml), 
one (0.28%) in athletics (Cmax: 16.59 µg/ml) and one (2.70%) in bodybuilding (Cmax: 17.70 
µg/ml). The increase in percentage of positive samples in cycling is in accordance with the 
significantly higher average concentrations found in cycling. No other doping substances 
were detected in the urine samples exhibiting a caffeine concentration higher than the former 
threshold level of 12 µg/ml. In the samples with a urinary caffeine concentration higher than 4 
µg/ml four samples contained a diuretic agent, 3 of them were found in strength sports. Six 
samples contained a stimulant, 4 of them were ephedrine. Out of the samples containing the 
stimulant ephedrine, the maximal caffeine concentration was found in bodybuilding (Ccaf = 
11.78 µg/ml), confirming the previous statement that the combination of both drugs in 
strength sports seems to be common practice. 
1.6. Conclusion 
Analysis of 11361 urine samples collected for doping control purposes before the removal of 
caffeine from the doping list resulted in caffeine concentrations far below the former 
threshold level of 12 µg/ml. Significantly higher caffeine concentrations were found in 
bodybuilding and cycling compared to other frequently tested sports. 
From the study conducted in 2004 it can be concluded that the overall percentage of samples 
below the limit of quantification has decreased in 2004. Nevertheless, the overall average 
caffeine concentration did not significantly differ compared to the period 1993-2002 resulting 
in an apparent threshold level similar as calculated in the previously examined period. These 
apparent threshold levels approach the former threshold level of 12 µg/ml. 
Caffeine concentrations in individual sports have decreased after the removal of caffeine from 
the doping list except for cycling and powerlifting. In 1993-2002 caffeine concentrations in 
those sports were also significantly higher than in other sports highlighting the purported 
stimulating and ergogenic effects of caffeine in those particular sports. 
Generally, caffeine concentrations did not increase after the removal of caffeine from the 
WADA doping list and consequently the misuse of caffeine did not increase. As the misuse of 
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caffeine did not increase after the removal from the WADA doping list one could conclude 
that a threshold level is not necessary. On the other hand, average caffeine concentrations 
remained far below the former threshold level indicating that dietary caffeine does not result 
in high urinary caffeine concentrations. Hence, caffeine concentrations higher than 12 µg/ml 
remain indicative for misuse. If the goal of drug testing is to prevent unfair advantage, to 
encourage ethical behaviour and to protect the health of the athletes, the position of caffeine 
with the previous threshold level of 12 µg/ml on the doping list should be reconsidered. 
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CHAPTER 2: MORPHINE 
Adapted from: 
• W. Van Thuyne, P. Van Eenoo and F.T. Delbeke, Urinary concentrations of morphine 
after the administration of herbal teas containing Papaveris fructus in relation to 
doping analysis. J. Chromatogr. B, 2003. 785: 245-251. 
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Chapter 2: Morphine 
2.1. Introduction 
The knowledge of practices and remedies for alleviating pain dates back to the earliest times. 
Although Babylon, Egypt and mythological Greece have disclosed rare and scanty evidence 
of their use, Greece and Rome, on the other hand have given us numerous detailed documents 
concerning analgesic preparations and their efficacy. 
These preparations, as described by Galenus and Dioscorides, were obtained mostly from 
plants. The most important include mandrake, henbane, certain varieties of hemp and Papaver 
somniferum. 
Regarding analgesic properties the opium poppy, originating from Papaver somniferum, was 
certainly the plant with the widest and most justified reputation. Opium and its diverse 
preparations, entering Europe in the Middle Ages by Arab medicine, have always been 
identified as the most effective remedies against pain. Opium is the dried juice obtained by 
making incisions in the green capsules of the Papaver somniferum. Varieties of this plant, 
growing in the Balkans, Asia Minor, Persia, India, China, etc., can be used for the preparation 
of opium. 
This raw product was used in medicine for centuries, in the form of tinctures, elixirs and 
compound powders, without the knowledge that only one constituent was responsible for the 
activity and differed in activity according to the origin of the plant. 
At the beginning of the nineteenth century, Sertürner in Germany, Derosne and Séguin in 
France accomplished the isolation of the active constituent of opium [1-3]. These findings 
passed unnoticed and it was only the second publication of Sertürner in 1817 [4], describing 
the active principle as “morphine”, that gave rise to a large number of studies. 
The discovery of morphine was of great importance because it was for the first time that a 
basic substance had been isolated from a plant as well as the first indications that the activity 
of a complex herb was attributed to a clearly identified chemical product. The name 
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“alkaloid”, resembling an alkali, was adopted for this whole group of basic substances. Large 
numbers of alkaloids were discovered subsequently. 
Already in 1803, Derosne had described a precipitate obtained by the action of potassium 
carbonate on an aqueous extract of opium which he called “salt of opium” [2]. According to 
Sertürner this salt of opium was acid meconate of morphine [1]. According to Pelletier it was 
narcotine. This alkaloid was later isolated from opium but, in spite of its name, did not 
possess any narcotic activity.  
Another work of historical importance was Séguin’s communication to the Académie des 
Sciences in 1804, in which he described the isolation and characterisation of morphine. 
Because this work was not published until 1814 [3], the discovery of morphine was attributed 
to Sertürner and not to Séguin. 
2.1.1. Detection of morphine 
GC/MS is one of the recommended analytical techniques for the identification, quantification 
and confirmation of opiates including morphine in urine [5-8]. Hydrolysis is required to 
obtain unconjugated morphine, as morphine is excreted in urine as 3- and 6-glucuronide 
(Figure 2.1.1). Enzymatic hydrolysis with β-glucuronidase has proven to give the best result 
[9]. 
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Figure 2.1.1 Metabolic pathway of morphine and analogues. 
To accomplish GC detection of morphine, the phenolic hydroxy group of morphine must be 
derivatized before GC separation. Various derivatization procedures, including 
trimethylsilylation have been described in the literature [10]. 
2.1.2. Morphine and doping 
Morphine is a narcotic analgesic commonly used for the short-term treatment of post surgery 
pain and in long terms for the pain relief of cancer patients [11]. Because of these painkilling 
effects morphine can be misused by athletes during training or in competition to overcome 
pain associated with strenuous exercise. This was the major reason why morphine was 
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included in the IOC list of banned substances [12]. Before 1991, the presence of morphine in 
human urine, irrespective of its concentration, resulted in a positive doping test. This changed 
in 1991 because the UCI introduced a 1 µg/ml threshold level for morphine as well as for 
codeine, one of the precursors of morphine (Figure 2.1.1). 
The rules were later on adapted to the rules that are now in force. At present the use of 
codeine and ethylmorphine, another morphine precursor, is allowed while morphine is 
forbidden in concentrations higher than 1 µg/ml. 
Already in 1991 a study was carried out by Delbeke et al. [13] proving that morphine positive 
urine samples could be delivered six to nine hours after the administration of a therapeutic 
dose of codeine. A study by Selavka [14] dealt with the possible contribution of poppy seed 
containing food to positive opiate urinalysis results. This “poppy seed defense” was mainly 
used by job-applicants controlled by the U.S. Department of Defense or by the National 
Institute on Drug Abuse [15-17]. Several other experiments were also carried out on the 
detection of opiates, mainly morphine, after the use of various poppy seed containing food 
products including cakes and bread rolls [18-22]. The major results from these investigations 
were that morphine was detected after the use of poppy seed incorporated in food products but 
the resulting concentrations of morphine in urine were too low to result in a positive urine 
sample. Another outcome from these studies was that the morphine concentration of poppy 
seeds substantially differed depending on the origin of the investigated sorts. Although several 
studies dealt with the detection of morphine after the use of poppy seed containing food [14-
18, 20-22], no other related studies were found describing the possible contribution of other 
parts of the plant Papaver Somniferum in positive opiate results. 
The objective of the present study was to determine whether doping positive urine samples 
could be delivered after the administration of “poppy cake” and of herbal teas containing parts 
from the plant Papaver Somniferum. The quantitative GC-MS method was validated 
according to procedure described in Part I. 
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2.2. Experimental 
2.2.1. Reagents 
Morphine-3-glucuronide was purchased from Lipomed (Arlesheim, Switzerland), 
nalorphine.HBr was obtained from Janssen Pharmaceuticals (Beerse, Belgium). The enzyme 
preparation β-glucuronidase type HP-2 from Helix pomatia (127 300 U/ml β-glucuronidase) 
was obtained from Sigma (St. Louis, MO). N-methyl-N-trimethylsilyltrifluoroacetamide 
(MSTFA) was bought from Chem. Fabrik. Karl Bucher (Waldstetten, Germany). All other 
chemicals were of analytical grade. 
Grounded poppy seeds (Geriebene Mohn) were bought from Backmit (Vienna, Austria). 
Two herbal teas were bought as over-the-counter products at a local chemist. The labeled 
content of the first tea (A) (Tisane Ardennaise, Tilman S.A., Bomal, Belgium) was as follows: 
Papaveris fructus : 15% - Crataegi folium 12.5% - Passiflorae mexico herba 10% - Viscum 
album 7.5% - Oleae europaea folium 13.75% - Cynodon dactylon rhizae 12.5% - Triticum 
rhizae 1.25% - Frangulae cortex 13.75% - Glycyrrhizae radix 13.75%. The recommended 
dosage was 1-3 cups a day. The content of the second tea (B) (Thé de sapin, Laboratoires 
Colin S.A., Blegny, Belgium) was: Rubi fructicosi folium 31.4% - Carraghene 24% - 
Papaveris fructus 14.7% - Thymi serpylli herba 7.8% - Eucalypti folium 7.8% - Glycyrrhizae 
radix 6.9% - Anisi stellati fructus 3% - Hederae terrestris herba 1.2% - Erysimi herba 1.2% - 
Capilli veneri herba 1% - Salviae folis 1% - Cum pini essent imbuta. A daily dosage of 1 to 3 
cups was recommended. 
2.2.2. Gas chromatographic conditions 
The GC/MS analysis was conducted in full scan mode (m/z 50 – 550) on an Agilent 6890 gas 
chromatograph directly coupled to an Agilent 5973 mass selective detector (Agilent, Palo 
Alto, USA). The GC column was an Agilent-Ultra 1 (J&W, Folsom, USA), 100 % 
methylsilicone column with a length of 17 m, an internal diameter of 0.2 mm and a film 
thickness of 0.11 µm. Helium was used as the carrier gas (linear velocity: 41 cm/s). A total of 
0.5 µl was injected splitless. The oven temperature program was as follows: 70°C (0 min) – 
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70°C/min → 96°C (1 min) – 20°C/min → 320°C (1 min). The electron energy was set at 70 
eV and the ion source temperature was 230°C. 
2.2.3.  Urine analysis 
One ml of a sodium acetate buffer (pH 5.2, 1 M) and 50 µl β-glucuronidase were added to 3 
ml of urine. The mixture was hydrolyzed during 2.5 hours at 56°C. After cooling, 50 µl of the 
internal standard (nalorphine, 20 µg/ml, MeOH) and 0.5 ml of the ammonium buffer (pH 9.5) 
were added. Extraction was performed with 5 ml of the mixture CH2Cl2/MeOH (9/1; v/v) by 
rolling for 20 minutes. After centrifugation (1200 g, 5 min) the organic layer was separated, 
dried over anhydrous Na2SO4 and evaporated under OFN. The residue was derivatized with 
100 µl MSTFA at 80°C for 10 min and transferred to an autosampler microvial. 
2.2.4. Morphine content of tea 
0.5 ml of the ammonium buffer (pH 9.5) and 50 µl of the internal standard nalorphine (20 
µg/ml, MeOH) were added to 3 ml of the prepared tea. Extraction was performed with 5 ml of 
CH2Cl2/MeOH (9/1; v/v) by rolling for 20 minutes. The organic layer was separated after 
centrifugation (1200 g, 5 min), dried over anhydrous Na2SO4 and evaporated under OFN. The 
residue was derivatized with 100 µl MSTFA at 80°C for 10 min. The herbal teas were 
extracted and analyzed in duplicate by the described method. Tea A was diluted 20 times with 
distilled water, tea B 30 times. 
2.2.5. Excretion protocols 
A home made cake was prepared containing 200 g of grounded poppy seeds, according to a 
recipe on the package of the grounded poppy seeds (Geriebene Mohn, Backmit, Austria). 
Urine samples were collected before (0 h) and quantitatively up to 12 h after the start of the 
experiment. An additional sample was taken after 24 h. 
Twelve table spoons of tea A were infused in 12 cups of boiling water for 10 minutes after 
which the liquid was sieved. Each volunteer had two cups of this tea of approximately 120 
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ml/cup. Urine samples were collected before (0h) and quantitatively after 1, 2, 4, 6, 9, 12 h. 
An additional sample was taken after 24 h. 
Tea B was prepared by pouring 1.5 l boiling water over a filter containing 22 table spoons of 
the tea. Each volunteer drank two cups of tea of each 130 ml. Urine sampling was similar as 
in the previous experiment except that no sample was taken after 24 h. 
2.3. Analytical Method Validation 
Under the described chromatographic conditions, morphine as well as the internal standard 
nalorphine gave sharp peaks with retention times of 9.35 min and 9.84 min respectively 
(Figure 2.3.1). 
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Figure 2.3.1 Extracted ion chromatogram of morphine-bis-TMS (m/z 429) and 
nalorphine-bis-TMS (m/z 455) in urine 1h after the administration of herbal tea B. 
Quantification of morphine in the samples was done by the determination of the ratio of 
abundances of the molecular ion m/z 429 of TMS-derivatized morphine to m/z 455 of the 
internal standard nalorphine. Unequivocal determination in doping analysis is mostly based 
on full scan mass spectrometry. The spectrum of TMS-derivatized morphine is shown in 
Figure 2.3.2. 
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Figure 2.3.2 Mass spectrum of TMS-derivatized morphine. 
Diagnostic ions besides the molecular ion are the ions with m/z 236, 287, 324, 401 and 414. 
Based on WADA criteria a maximal relative deviation of 20 % (m/z 287 , 324 and 401) and 
an absolute deviation of 10 % (m/z 236) in the intensities of these diagnostic ions was used as 
a qualitative criterion for the relative abundances when compared to a quality control sample 
spiked with morphine at 1 µg/ml [23]. All samples in the method validation and the excretion 
studies in which morphine was detected fulfilled this qualitative criterion. 
An equally weighted linear calibration curve (not forced through zero) was established in the 
concentration range from 0 to 2 µg/ml (0, 0.25, 0.50, 1.00, 1.50 and 2.00 µg/ml) by plotting 
the relative abundances of the ions m/z 429 and m/z 455 for morphine and nalorphine, 
respectively. Therefore, blank urine, checked for the absence of morphine and nalorphine, 
spiked with the appropriate amount of morphine standards (100 µg/ml and 10 µg/ml in 
MeOH), was analysed. Each concentration was analysed in triplicate, the averages were used 
to construct the calibration curve. The correlation coefficient of the calculated calibration 
curve was 0.9983. The deviation of the mean measured concentration from the theoretical 
concentration (trueness) was far below the maximal value of 15 % [24]. 
The precision was evaluated by the determination of the repeatability and the reproducibility. 
To measure the repeatability 6 samples at three different concentrations (0.25, 1.00 and 2.00 
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µg/ml) were analysed. The relative standard deviation, an indicator of the repeatability, for 
each of the three concentrations (0.25, 1.00 and 2.00 µg/ml) never exceeded the limit values 
derived from the Horwitz equation [25]. Measured concentrations, relative standard 
deviations and maximal limits for the repeatability are listed in Table 2.3.1. 
Table 2.3.1 Method repeatability. 
Theoretical concentration (µg/ml) 0.25 1.00 2.00 
Average measured concentration (µg/ml) (n=6) 0.25 0.95 2.04 
SD (µg/ml) 0.01 0.03 0.06 
RSD (%) 3.82 3.09 2.97 
2/3 RSDmax (%) 13.10 10.67 9.61 
Accuracy (%) 0.19 -5.03 1.94 
The reproducibility was examined by analysing 6 samples in triplicate at the same 
concentrations as for the repeatability. This was done by two different analysts, at different 
times. The results for the reproducibility are summarized in Table 2.3.2. The original limit 
values calculated by the Horwitz equation were used while for the repeatability the margin 
was narrowed to two third of the calculated value. The accuracy was measured for both 
repeatability and reproducibility and is listed in Table 2.3.1 and Table 2.3.2. A limit value of 
15 % is used as for the trueness of the datapoints from the calibration curve. 
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Table 2.3.2 Method reproducibility. 
Theoretical concentration (µg/ml) 0.25 1.00 2.00 
Average measured concentration (µg/ml) (n=18) 0.24 0.91 1.99 
SD (µg/ml) 0.01 0.04 0.05 
RSD (%) 2.88 4.30 2.59 
RSDmax (%) 19.65 16.01 14.42 
Accuracy (%) -2.53 -9.49 -0.42 
Selectivity was tested by the analysis of negative urine spiked with structurally related 
compounds such as codeine and ethylmorphine and some other narcotic or stimulating 
compounds including methadone, pholedrine, pethidine, prolintane, etc. 
Specificity was tested by analysing 20 different negative urines. 
No interference by any of the structurally related or other compounds spiked in negative urine 
could be found for morphine as well as for the internal standard nalorphine. Hence, the 
method was selective for morphine as well as for nalorphine. Analysis of 20 different negative 
urines did not result in the detection of matrix interferences, proving the specificity of the 
method. 
The limit of quantification of the method was 0.25 µg/ml or the lowest point of the calibration 
curve where morphine could be detected in a reproducible way. The limit of detection was 
arbitrarily set at 0.125 µg/ml, half the limit of quantification. 
2.4. Excretion Studies 
All excretion studies were approved by the Ethical Committee, University Hospital (Ghent, 
Belgium) (EC/2005-81/sdp) and were performed on healthy volunteers. The purpose of the 
study was explained to each volunteer who where asked not to use morphine, codeine or 
ethylmorphine containing preparations, nor to eat food containing poppy seeds or parts of the 
plant Papaver somniferum for 1 week before the start of each experiment. Excretion studies 
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were performed with a poppy seed containing cake and herbal teas containing parts of the 
plant Papaver somniferum. 
2.4.1. Excretion studies with a poppy seed containing cake 
Each of the 5 volunteers ate 1/8 of the cake. Urinary pH, volume and density were measured 
and all samples were analyzed in duplicate. When appropriate, urine samples were diluted 
with distilled water before extraction in order to obtain a morphine concentration in the range 
of the calibration curve. 
Urinary excretion profiles after the use of the “poppy-cake” are given in Figure 2.4.1. 
Morphine could be detected in the urine of all volunteers already 1 h after the start of the 
experiment and remained detectable in all volunteers until 12 h. In subject 4 the doping 
threshold level of 1 µg/ml was attained 2 hours after the administration while in subject 2 and 
3 positive findings according to the doping threshold level of 1 µg/ml were reached up to 6 h 
after the start of the experiment. In two other volunteers the current doping threshold level 
was never attained. 
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Figure 2.4.1 Urinary excretion profiles of morphine after the use of poppy-cake. 
This study shows that the use of poppy seeds can result in the detection of morphine as 
previously described in the literature [14-16] and more importantly to adverse analytical 
findings for morphine. 
2.4.2. Excretion studies with herbal teas 
Both tea A and B were prepared following the instructions on the package. All urine samples 
were either analyzed directly or stored deep-frozen for later analysis. Urinary pH, volume and 
density were measured and all samples were analyzed in duplicate. When appropriate, urine 
samples were diluted with distilled water before extraction in order to obtain a concentration 
in the range of the calibration curve. 
Analysis of tea A indicated a morphine concentration of 10.4 µg/ml, equivalent to the 
ingestion of 2.5 mg of morphine when two cups of 120 ml were administered. 
The urinary excretion profiles of morphine during the first twelve hours after the 
administration of herbal tea A are shown in Figure 2.4.2. Morphine could be detected in the 
urine of all volunteers already after one hour and remained detectable for at least 24 hours. 
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Subject 1 delivered a doping positive urine sample after 6 hours while morphine in the urine 
of the other 4 volunteers exceeded the 1 µg/ml doping threshold already one hour after 
drinking the tea. The maximum morphine concentration found after drinking this herbal tea 
was 4.34 µg/ml. Morphine positive urine samples were detected up to six hours. All subjects 
tested doping negative for morphine after 9 h. 
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Figure 2.4.2 Urinary excretion profile after the ingestion of two cups of tea A in 5 
subjects. 
Urinary excretion and excretion rates of morphine during the first 12 hours after drinking this 
tea are given in Table 2.4.1. 
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Table 2.4.1 Excreted amounts (mg) and rates (mg/h) of morphine in the urine of 5 
subjects after drinking herbal tea A. 
Time interval Excreted Amount (mg) Excretion Rate (mg/h) 
(h) 1 2 3 4 5 1 2 3 4 5 
0 – 1 0.18 0.30 0.17 0.14 0.16 0.18 0.30 0.17 0.14 0.16 
1 – 2 0.26 0.41 0.25 0.21 0.32 0.26 0.41 0.25 0.21 0.32 
2 – 4 0.36 0.43 0.28 0.25 0.40 0.18 0.22 0.14 0.12 0.20 
4 – 6 0.13 0.08 0.07 0.11 0.20 0.07 0.04 0.04 0.06 0.10 
6 – 9 0.13 0.12 0.06 0.03 0.11 0.04 0.04 0.02 0.01 0.04 
9 – 12 0.15 0.21 0.07 0.07 0.09 0.05 0.07 0.02 0.02 0.03 
Total 1.21 1.55 0.90 0.81 1.28      
Maximal excretion was obtained after 2 to 4 h. Inter-individual differences in excretion of 
morphine were observed. An average amount of 1.15 mg morphine (0.81 mg – 1.55 mg) was 
excreted during the first 12 h. Based on the ingested amount of 2.5 mg, 46 % (32% - 62%) of 
the administered dose was excreted during that period. 
Similar to the previous experiment, morphine was detected in the urine of all volunteers 
already 1 hour after drinking tea B and remained detectable after 12 hours. The maximal 
detected concentration was 7.44 µg/ml (Figure 2.4.3). Three subjects tested doping positive 
for morphine after 1 h. Similar “positive” results were found until 6 to 9 h after drinking the 
tea, doping negative results were found after 12 h. 
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Figure 2.4.3 Urinary concentration profiles of morphine after the administration of 2 
cups of herbal tea B in 5 subjects. 
The excreted amounts and rates of morphine after the use of herbal tea B are listed in Table 
2.4.2. 
Maximal excretion was obtained after 2 to 4 h. Large inter-individual differences in excretion 
of morphine were observed. Excreted amounts in volunteer 4 are the lowest, but as a result of 
the low urine volume they still result in the highest detected concentrations during the 
excretion study. An average amount of 2.36 mg morphine (1.40 mg – 2.83 mg) was excreted 
during the first 12 h. Based on the ingested amount of 8.51 mg, 27.8 % (16.6% - 33.1%) of 
the administered dose was excreted during that period. 
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Table 2.4.2 Amounts (mg) and excretion rates of morphine in the urine of 5 volunteers 
after drinking herbal tea B. 
Time interval Excreted amount (mg) Excretion rate (mg/h) 
(h) 1 2 3 4 5 1 2 3 4 5 
0 – 1 0.22 0.36 0.44 0.18 0.22 0.22 0.36 0.44 0.18 0.22 
1 – 2 0.48 0.63 0.61 0.31 0.53 0.48 0.63 0.61 0.31 0.53 
2 – 4 0.87 0.88 0.76 0.37 0.82 0.43 0.44 0.38 0.19 0.41 
4 – 6 0.40 0.44 0.36 0.29 0.39 0.20 0.22 0.18 0.15 0.20 
6 – 9 0.29 0.28 0.43 0.16 0.33 0.10 0.09 0.14 0.05 0.11 
9 – 12 0.20 0.13 0.23 0.09 0.10 0.07 0.04 0.08 0.03 0.03 
Total 2.46 2.72 2.83 1.40 2.39      
As illustrated in Figures 2.4.2 and 2.4.3 doping positive results were noticed after drinking 
herbal teas. Unlike tea A, the package of tea B did not mention any sedative or calming effect. 
An athlete should be aware of the presence and the possible detection of morphine after the 
use of these kinds of teas. 
2.5. Conclusion 
Problems with positive doping cases for morphine are frequently connected with the 
therapeutic use of its precursors codeine and ethylmorphine, substances not longer considered 
as doping agents. As codeine and ethylmorphine are allowed, the actual doping rules for 
morphine need to be revised. Hence, the simultaneous presence of morphine and codeine or 
morphine and ethylmorphine should not constitute a doping offence. To differ between the 
accidental intake of morphine by poppy seeds [14], food containing poppy seeds or herbal 
teas and the oral or systemic administration of morphine the actual doping threshold level for 
morphine in urine of 1 µg/ml should be increased. 
Following international doping rules athletes remain responsible for the presence of doping 
substances in their biofluids, irrespective the origin. Hence, athletes should be warned against 
the use of food products containing poppy seeds or herbal teas containing parts from the plant 
Papaver Somniferum. 
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Chapter 1: Introduction 
1.1. Abstract 
Based upon recent sales numbers, nutritional supplements play a key role in the lifestyle of a 
substantial fraction of the population. Besides products like vitamins or minerals, also several 
precursors of anabolic steroids are marketed as nutritional supplements. Another group of 
commercially available supplements are products for weight loss based upon herbal 
formulations originating from Ephedra species. Apart from supplements indicating the 
presence of these active compounds, numerous non-hormonal nutritional supplements were 
found to be contaminated with non-labelled anabolic steroids. Also other stimulating agents 
besides naturally occurring analogues of ephedrine were detected. 
A major group using dietary supplements are sportsmen, ranging from amateur level to elite 
athletes. Besides the possible health risks associated with the use of dietary supplements, 
athletes should take care not to violate the rules of WADA because athletes remain 
responsible for the substances detected in their biofluids, irrespective their origin. 
Several analytical methods were developed to evaluate the presence of doping agents as 
contaminants. This chapter attempts to address the issues concerning the use of nutritional 
supplements and the detection of doping agents as contaminants in dietary supplements. 
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1.2. Introduction 
The definition of nutritional supplements is an important aspect in the discussion of this group 
of products. Although no universally accepted definition is available, nutritional supplements 
can be defined as food supplying in one or more nutrients in a concentrated form, e.g. 
minerals, vitamins, trace elements and other components that are theoretically present in a 
normal and balanced diet [1]. The DSHEA, enacted by the U.S. Congress in 1994, went far 
beyond a logical definition of nutritional supplements such as the definition from Schröder [1] 
and included, besides vitamins and minerals, also herbs or other botanicals, amino acids, 
metabolites, constituents, extracts or combinations of any of such ingredients. Although many 
of these products (particularly herbs) are marketed for their alleged preventive or therapeutic 
effects, the DSHEA has made it difficult to regulate them as drugs. Since the passage of the 
DSHEA, even hormones such as DHEA and melatonin are being sold as dietary supplements. 
Nutritional supplements are frequently offered in an untypical form of food, e.g. tablets, 
capsules, powders or pills. 
The use of nutritional supplements has expanded explosively during the last decade. In 1997 
vitamin sales numbers in Germany were estimated at 500 million euro, while the total sales of 
supplements exceeded 1 billion euro [1]. United States annual sales were estimated at 
U.S.$12-15 billion in the late 1990’s of which U.S.$800 million were spent on sport 
supplements [2, 3]. In the year 2000 approximately 3.1 million kilogram of creatine was sold 
while a decade earlier nobody even heard of it [4]. The global market for supplements in 2001 
was estimated at U.S.$46 billion, the U.S. supplement market in 2000 at U.S.$16.7 billion [5]. 
An important factor behind this growth was the passage of the DSHEA allowing U.S. 
customers free access to supplements [6]. Other factors influencing the growth of the 
supplement market are the easy access through the internet, which makes it possible for users 
all over the world to obtain all products freely available in the U.S., and the ever-improving 
results and record performances of top-level athletes who were promoting the use of 
supplements. 
Part III: Nutritional supplements 
1.Introduction 
 71
1.2.1. Use of nutritional supplements 
Nutritional supplements are used in all layers of the population. General population studies on 
the use of supplements show a use rate of 40% [7]. Nevertheless it seems that these products 
are most frequently used by sportsmen ranging from amateur level to elite athletes [8], the 
category to which they are most aggressively marketed. This high prevalence of use can be 
seen in a study following the Olympic Games held in Sydney in 2000. In this study the 
medication use of 2758 athletes selected for doping control was evaluated. Only the reported 
use the last three days before competition was included. Major findings were that 51% of all 
tested athletes had used vitamins before competition and a large fraction of the tested athletes 
used other nutritional supplements. Some athletes even reported up to 26 different 
supplements on one day [9]. Many surveys dealing with the prevalence of use of nutritional 
supplements among athletes have been published [10-13]. Sobal and Marquart [14] 
comprehensively analysed the supplement use among athletes. Totally 10,274 athletes, both 
male and female, were included in this meta-analysis. Their results show that the mean 
prevalence of supplement use among athletes was 46%. Approximately the same percentage 
was found in adolescents and high school athletes [15, 16]. It is not known whether 
prevalence of use varies widely among gender. Sobal and Marquart [14] found significantly 
higher percentage of use by female athletes compared to male athletes while a study by 
Sundgot-Borgen et al. [17] did not find a significant difference between both sexes. 
Differences can also be observed between sports. Supplement consumption in strength sports 
like weightlifting, powerlifting and bodybuilding is higher than in other sports [14, 18], 
confirming the statement that supplement use is most frequent in sports emphasizing on 
muscle size. However, great care should be taken with results obtained from questionnaires as 
people tend to underrate their use of nutritional supplements [8]. Also the type of question and 
the way those questions were put forward to the athletes could significantly influence the 
outcome. For instance, a higher percentage of runners admitted supplement intake when asked 
to respond to a frequency questionnaire (69%) than when the supplement use was recorded 
during a three day period (48%) [19]. 
Only a few studies have tried to evaluate the frequency of use of nutritional supplements. In a 
summary of 13 studies using time specified terms [14], it appears that most athletes rather 
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take their supplements on a daily or routine basis than occasionally or weekly. These 
supplements are often used more frequently and in higher doses than recommended on the 
label. The rationale behind this behaviour is the popular belief that the more supplements are 
taken, the better a performance will be. 
However, reasons for use of dietary supplements differ according to the investigated 
population. Among high school students, boys tend to use supplements more for athletic 
performance improvement and muscle development than girls do [16]. In general, reasons for 
supplement use among adolescents are: losing weight and/or keeping weight at a certain level 
[14, 15], to gain weight and stimulate muscle development or to compensate for an inadequate 
diet. 
Major reasons for use of supplements by athletes include compensation for an inadequate diet, 
enhancing performance, meeting the abnormal demands during training and/or competition, 
keeping up with opponents and following recommendations by parents, coaches and team 
mates [4, 14]. Athletes are mostly influenced by parents, doctors, coaches and friends, with 
female athletes being more influenced by their parents and male athletes by their coach [16]. 
It is the position of many official authorities, including the American Dietetic Association, 
Dieticians of Canada and UK Sport, that the use of supplements to compensate for needs 
following strenuous exercise is unnecessary when the athlete uses a well balanced diet. 
Supplement use without a specific need, disease or deficiency is not recommended [20]. If 
however athletes persist in using supplements for their purported ergogenic effects it is 
advised to use counselling in product selection and to use them only after careful evaluation 
of the product for safety, efficacy, potency and legality. In some cases, especially when the 
manufacturers’ recommendations are not followed, the use can be harmful. Schwenk and 
Costley [21] described several non-anabolic nutritional supplements and their potential risks 
when used in high doses or without the counselling of a physician. Others have also 
demonstrated that with excessive use most of the supplements rather harm than improve the 
condition of the user [22-24]. 
Again, controversial information can be found on the effectiveness of enhancing sport 
performances for most marketed supplements. Creatine for instance is promoted for its 
performance enhancing effect, although several studies are contradicting [25-28]. 
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1.3. Nutritional supplements and doping 
Besides the relatively harmless products (when used properly) including vitamins, minerals, 
etc., other types of ingredients can be present in nutritional supplements. Ingredients from 
plant origin including ephedrines and caffeine can be present in dietary supplements 
promoting ergogenic effects. Substances from botanical origin, such as morphine, can be 
present in the daily diet. In addition, as a consequence of the passage of the DSHEA, 
prohormones became freely available on the U.S. supplement market. Besides the health risks 
associated with these products, athletes are also at risk of violating doping rules as ephedrine, 
morphine and prohormones figure on the WADA list of forbidden substances [29]. An 
inadvertent doping test resulting from the intake of a supplement can originate from the poor 
knowledge by the athlete of banned substances indicated on the label, from the fact that the 
labelled ingredients indeed contain banned substances (e.g. Ma Huang herbal products contain 
ephedrine) or, more importantly, that the supplement contains a banned substance not 
indicated on the label. 
1.3.1. Prohormones and anabolic androgenic steroids 
As a result of the passage of the DSHEA several anabolic androgenic steroids including 
DHEA, androstenedione, androstenediol and 19-nor-steroids became readily available as 
over-the-counter products in the United States and through the internet in the rest of the 
world. These steroids can be marketed as nutritional supplements as long as the manufacturers 
make no claims about the use of a dietary supplement to diagnose, prevent, mitigate, treat or 
cure a specific disease. On the other hand the DSHEA allowed dietary supplements to bear a 
“statement of support” that: (a) claims a benefit related to a classical nutrient deficiency 
disease; (b) describes how ingredients affect the structure or function of the human body; (c) 
characterises the documented mechanism by which the ingredients act to maintain structure or 
function and (d) describes general well-being from consumption of the ingredients [6]. In this 
way, the U.S. FDA rules are circumvented and prohormones, precursors of testosterone 
(Figure 1.3.1) and nandrolone (Figure 1.3.2), became available on the market. These 
prohormones are converted in the body into their respective anabolic steroids and 
consequently act in the same way as the latter do. Supplement manufacturers claim that these 
products increase serum testosterone concentrations, promote muscle mass and muscle 
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strength, help reducing body fat and enhance mood and sexual performance. However, many 
studies do not confirm these claims [30-34]. Although in several studies an increase in serum 
testosterone levels was measured after prohormone use [35, 36], this does not necessarily 
results in increased muscle mass, strength or sexual performance [32, 36]. In addition, risks 
associated with the use of prohormones are similar to those observed with anabolic steroids, 
e.g. cardiovascular effects, liver tumours, gynaecomastia and aggressive behaviour [37-39]. 
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Figure 1.3.1 Chemical structure of testosterone and some of its precursors. 
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Figure 1.3.2 Chemical structure of nandrolone and some of its precursors. 
Another issue is the labelled content of supplements. Evidence has been given that 
prohormones like androstenedione, sold as nutritional supplements, do not always have the 
content they claim. Table 1.3.1 summarises the labelled versus detected content of 
prohormones, promoted as nutritional supplements. The detected dose rarely approaches the 
labelled dose and in some cases the alleged prohormone can not even be detected. More 
alarming results were obtained in the same studies as it was proven that in several 
supplements steroids, or precursors other than the labelled prohormones were present. 
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Table 1.3.1 Labelled vs. detected content of as nutritional supplements promoted 
prohormones. 
Reference Steroid and dose listed on label Steroids detected Detected 
Amount 
[40] androstenedione*, 100 mg androstenedione* 93.1 mg 
 androstenedione*, 100 mg androstenedione* 82,8 mg 
 androstenedione*, 100 mg androstenedione* 103 mg 
 androstenedione*, 100 mg androstenedione* 90 mg 
 androstenedione*, 100 mg androstenedione* 88 mg 
 androstenedione*, 100 mg androstenedione* 85 mg 
 4-androstene-3,17-dione, 50 mg 4-androstene-3,17-dione 35 mg 
 androstenedione*, 50 mg none 0 
 4-androstene-3,17-dione, 250 mg 4-androstene-3,17-dione 
Testosterone 
168 mg 
10 mg 
[41] 19-norandrostenedione, 50 mg 
19-norandrostenediol, 50 mg 
19-norandrostenedione, 33% 
19-norandrostenediol, 52% 
androstenediol*, 15% 
# 
 androstenediol*, 200 mg androstenediol* 
androstenedione* 
testosterone 
# 
 5-androstenediol 5-androstenediol, 97% 
testosterone, 2% 
# 
 5-androstenediol, 50 mg 
androstenedione*, 250 mg 
19-norandrostenedione, 50 mg 
DHEA, 150 mg 
5-androstenediol 
androstenedione* 
19-norandrostenedione 
# 
 DHEA, 100 mg DHEA, 85% 
androstenedione*, 15% 
# 
 nor-4-androstenedione, 100 mg 
19-norandrostenediol, 100 mg 
nor-4-androstenedione, 25% 
19-norandrostenediol, 25% 
androstenedione*, 42% 
testosterone, 8% 
# 
 19-norandrostenediol, 100 mg androstenedione* # 
[42] 5-androstenediol, 100 mg 5-androstenediol 
androstenedione* 
77.3 mg 
3.3 mg 
 4-androstene-3,17-dione, 250 mg 4-androstene-3,17-dione 
testosterone 
166,3 mg 
10 mg 
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 4-androstene-3,17-diol, 100 mg 4-androstene-3,17-diol 78.5 mg 
 androstenedione*, 100 mg androstenedione* 45.5 mg 
 androstenedione*, 100 mg androstenedione* 51.5 mg 
 androstenedione*, 100 mg androstenedione* 84.5 mg 
 androstenedione*, 100 mg androstenedione* 98.5 mg 
 4-androstene-3,17-dione, 50 mg 4-androstene-3,17-dione 35.3 mg 
 4-androstene-3,17-dione, 3.33 mg 
4-androstene-3,17-diol, 83.33 mg 
5-androstene-3,17-dione, 3.33 mg 
5-androstene-3,17-diol, 3.33 mg 
19-nor-4-androstene-3,17-dione, 3.33 mg
19-nor-5-androstene-3,17-diol, 3.33 mg 
4-androstene-3,17-dione 
4-androstene-3,17-diol 
19-nor-4-androstene-3,17-dione 
1 mg 
35.8 mg 
1 mg 
 5-androstene-3β,17β-diol, 50 mg 
19-nor-4-androstene-3β,17β-diol, 50 mg
19-norandrostenedione, 100 mg 
5-androstene-3β,17β-diol 
19-norandrostenedione 
44 mg 
76.5 mg 
 androstenedione*, 100 mg 
4-androstene-3,17-diol, 100 mg 
androstenedione* 
4-androstene-3,17-diol 
70 mg 
87.5 mg 
 5-androstene-3β,17β-diol, 50 mg 
Tribulus terrestris, 250 mg 
5-androstene-3β,17β-diol 
# 
88.5 mg 
[43] 1-androstene-3β,17β-diol, 100 mg 1-androstene-3β,17β-diol 
boldenone 
DHEA 
19-nor-4-androstenediol 
testosterone 
5α-androstane-3α,17β-diol 
# 
# no information available * position of double bond not specified. 
Results from Kamber et al. [41] show that 35 % (6 out of 17) of prohormone supplements 
contain other substances than indicated on the label. In another study, analysis of a 1-
androstene-3β,17β-diol containing nutritional supplement revealed the presence of 5 other 
anabolic steroids including boldenone and testosterone [43]. 
In several studies the presence of prohormones in non-hormonal nutritional supplements has 
been investigated. Results from an international study showed that 14.8% (94 out of 634 
samples) of the investigated non-hormonal nutritional supplements contained one or more 
anabolic androgenic steroid not declared on the label [44]. The detected substances were 
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DHEA and other precursors of testosterone including 4-androstene-3,17-dione and 4(5)-
androstene-3,17-diol and 26 supplements contained 19-nor-4-androstene-3,17-dione, a 
precursor of nandrolone. A quarter of the contaminated samples showed a total anabolic 
androgenic steroid concentration higher than 5 µg/g. The highest percentages of contaminants 
were found in supplements marketed in the Netherlands (25.8%), Austria (22.7%), UK 
(18.9%) and USA (18.8%). The vast majority of those supplements originated from the USA. 
Supplement producers are not obliged to disclose the information where a supplement has 
been produced. In this way, prohormones or contaminated supplements can enter the 
European market where they are prohibited. Also interesting to note is that more than 20% of 
the non-hormonal supplements bought from prohormone selling companies contained 
anabolic androgenic steroids whereas this percentage was below 10% for companies not 
selling prohormones, indicating that improper cleaning of machinery is responsible for an 
important fraction of the contamination in non-hormonal supplements. 
Other studies reported on the detection of prohormones as contaminants in nutritional 
supplements [45-48]. One of the most commonly detected steroids was 19-nor-4-androstene-
3,17-dione. Its presence may lead to a positive doping test for the nandrolone metabolite 
norandrosterone [40, 44-46, 49, 50]. As will be discussed in Part IV Chapter 4, approximately 
4.8 mg 19-nor-4-androstene-3,17-dione per capsule was found in a supplement from U.S. 
origin. Its presence was not declared on the label. The recommended dosage was 7 capsules 
per day. Ingestion of only 1 capsule would have resulted in a positive doping test according to 
the WADA rules (19-norandrosterone, 2 ng/ml) up to 144 h after the ingestion. Besides these 
highly contaminated nutritional supplements, low concentrations of nandrolone precursors 
could also result in positive doping tests [44]. 
Following a study by Van Eenoo et al. [51], the intake of 4-androstene-3,17-dione, present in 
several nutritional supplements, could result in a positive doping test for 6 to 9 hours after 
administration. 
After the introduction of the prohormones of testosterone such as DHEA on the market 
around 1996 and later prohormones of nandrolone, also boldenone and its prohormones 
became available on the supplement market [43]. Recently oxygenated anabolic steroids such 
as 7-keto DHEA [43] and 4-androstene-3,6,17-trione [52] were detected in over-the-counter 
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nutritional supplements. Moreover, in two recent studies [53, 54] the presence of non-labelled 
metandienone (17α-methyl-androsta-1,4-dion-17β-ol-3-one) in nutritional supplements was 
reported. The use of 17α-alkylated steroids is associated with serious adverse health effects 
similar to the use of other anabolic steroids but 17α-alkylation, which makes the steroid orally 
active, aggravates the situation because of the association with jaundice, hepatic carcinoma 
and peliocis hepatis, a fatal degenerative liver condition [37-39, 55, 56]. Similar remarks can 
be made about 17α-methyltestosterone detected in two nutritional supplements analysed in 
the Ghent Doping Control Laboratory (unpublished results). In addition, the intake of these 
supplements could lead to adverse doping findings. 
Numerous dietary supplements are also marketed as containing a natural testosterone booster 
called Tribulus terrestris, a plant containing saponins and diosgenin. Diosgenin has been used 
as the starting material for industrial hemi-synthesis of androgens, however there is no 
evidence that it is metabolised to androgens in man. In one study investigating the effect of 
Tribulus terrestris combined with androstenedione supplementation no increase in serum 
testosterone concentrations was observed [30]. In addition no effects on the urinary steroid 
profile after the intake of Tribulus terrestris were found [34]. 
From January 20th 2005 the U.S. Congress enacted the Anabolic Steroid Control Act 
publishing a limited list of hormonal substances, including most previously mentioned 
prohormones, which are no longer allowed on the U.S. market. This list is supposed to be 
exhaustive but unfortunately does not contain steroids such as DHEA and the recently 
discovered designer steroid Madol [57]. In addition, new designer steroids such as 6-oxo 
steroids or 7-oxo steroids are also not included in this list.  
Summarising, athletes should be very careful about dietary supplements. Obviously athletes 
should refrain from taking supplements mentioning the presence of one or more prohormones 
or anabolic androgenic steroids, not only for health reasons, but also to avoid positive doping 
tests. In addition, athletes should also take care about the use of non-hormonal supplements as 
numerous studies have demonstrated that these supplements might be contaminated with 
substances resulting in adverse doping tests. 
Following WADA-rules athletes remain responsible for the presence of doping substances in 
their biofluids. To avoid positive doping results following the use of nutritional supplements 
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athletes should address to supplement manufacturers to get a guarantee on the purity of the 
products they use. Only laboratories specialised in doping analysis can provide this guarantee. 
1.3.2. Stimulants 
One of the oldest known medicinal herbs is Ephedra or Ma Huang. Ephedra sinica is the 
primary species that has been used in traditional Chinese medicine and is still being used in 
Ephedra preparations and extracts around the world. The 6 optically active alkaloids present 
in Ephedra species, ranging from 0.02 % to 3.4 % of the plant material, are summarised in 
Figure 1.3.3 [58]. 
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Figure 1.3.3 Chemical structure of the 6 optically active alkaloids present in Ephedra 
species. 
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Decades ago, ephedrine was used for its bronchodilating effect to treat asthma [59]. Today, 
other and more effective products, including beta-agonists, have replaced ephedrine in the 
treatment of asthma. Nevertheless, ephedrine is still promoted as a dietary supplement. The 
use of ephedrine containing supplements promoting weight loss or athletic performance 
enhancement has garnered a lot of success. For instance, more than U.S.$1 billion has been 
spent on Ephedra products in 2000 [60]. 
Effects of herbal ephedrine supplements on weight reduction have been well documented. 
Several studies indicated that the administration of ephedrine to obese people resulted in 
weight loss [61-63]. The influence of ephedrine on performance however is doubtful. Studies 
by Bell et al. [64-68] reported an increase in athletic performance (i.e. increase in exercise 
time to exhaustion, improved time in Canadian Forces warrior test, increased time to 
exhaustion in cycle ergometer trial), but most of those studies were performed in small 
populations and caffeine was frequently co-administered with ephedrine which makes it 
difficult to attribute the obtained effect to ephedrine. In addition, the effect of 
pseudoephedrine, another optically active alkaloid present in Ephedra species and readily 
available as an over-the-counter nasal decongestant, on performance is not proven [69-72]. In 
only one study [73] an improvement in maximum torque performed during an isometric knee 
extension exercise and in peak power during maximal cycle performance was found, but after 
doses exceeding the therapeutic dose making the results questionable. 
On the other hand, numerous reports have been published on adverse effects associated with 
the use of Ephedra alkaloids. Haller and Benowitz [22] reviewed 140 reports of adverse 
effects related to the use of dietary supplements containing Ephedra alkaloids between June 
1997 and May 1999. Out of them, 31 % were considered to be definitely related to the use of 
Ephedra alkaloids and another 31 % were deemed to be possibly related. Ten cases resulted in 
death and 13 others in permanent health damage. Most frequently reported adverse effects 
were hypertension, palpitations, tachycardia, stroke and seizures. Furthermore, ephedrine can 
increase heart rate as well as glucose and insulin concentrations, and in combination with 
caffeine it could increase systolic blood pressure [74]. Although misuse is the most probable 
cause of adverse effects, side effects were also observed in subjects involved in clinical trials 
with controlled doses [62, 65, 67]. As a result of those reports the FDA has issued warnings 
regarding possible side effects of Ephedra alkaloids [75] and several regulatory actions 
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against Ephedra and ephedrine alkaloids aiming at the regulation of these compounds have 
been implemented in the USA [58]. After having warned the general public of the risk 
associated with the use of ephedrine alkaloids and sending warning letters to manufacturers of 
these supplements on December 30th, 2003 the FDA issued a regulation prohibiting the sale of 
dietary supplements containing Ephedrine alkaloids that became effective on April 11th, 2004. 
However, traditional Asian medicine containing Ephedra alkaloids was excluded from this 
rule and can still be sold on the U.S. market. In addition, a U.S. federal judge struck down the 
FDA ban [75] on Ephedra containing supplements in favour of a supplement producing 
company on April 13th 2005. This makes the implementation of this ban doubtful and opens 
the way for other producers to continue their marketing strategies on ephedrine containing 
supplements. 
Despite these regulatory efforts a study by Bents et al. [76] has demonstrated that the use of 
stimulants amongst U.S. college hockey players remains high with 46 % reporting the use of 
pseudoephedrine and 38 % were using ephedrine. 
Similar to other supplements, variation may occur between the labelling of the dietary 
supplement and the content. Gurley et al. [77] showed that markedly different amounts of 
Ephedra alkaloids were found in many commercial dietary supplements and even significant 
batch-to-batch variation occurred. In 7 out of the 20 supplements analysed the exact amount 
of total Ephedra alkaloids was not given and in 80 % of the analysed samples the ephedrine 
content was even not mentioned on the label. Similar results were noticed by Haller et al. 
[78]. Not mentioning the active compound on the label of a nutritional supplement could 
result in serious complications for athletes, e.g. positive doping tests, as they are probably not 
aware of the fact that Ma Huang contains Ephedra alkaloids. In addition, some supplements 
declaring Ma Huang on the label seem not to be as “natural” as they claim, as only ephedrine 
was present [79], indicating an eventual deliberate addition of this substance instead of using 
herbal products. 
Besides alkaloids originating from the Ephedra plant other substances with stimulating 
properties have been detected in nutritional supplements. Already in the 1980’s a Belgian 
female marathon runner tested positive for the stimulant phentermine. Analysis of the 
consumed food supplement promoting weight loss revealed the presence of the anorexic 
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agents phentermine and fenfluramine [80]. A study conducted by the Dutch Ministry of 
Health, Welfare and Sports preceding the Olympic Winter Games in Salt Lake City (2002) 
resulted in the detection of MDMA, or XTC, in a supplement. 
In conclusion not only naturally occurring stimulants including ephedrine and analogues, but 
also synthetic amphetamine analogues and related compounds can be present in nutritional 
supplements. 
Stimulants belong to the classes of prohibited substances according to WADA rules [81]. A 
threshold level for ephedrine and methylephedrine of 10 µg/ml and a level of 5 µg/ml for 
norpseudoephedrine have been introduced to avoid unintentional positive doping results. 
Nevertheless, because of the wide variety in ephedrine concentrations found in nutritional 
supplements and the numerous side effects, athletes should be very cautious using this kind of 
nutritional supplements and they should be aware of the possibility that supplements can be 
contaminated with various prohibited substances. One case of a positive doping test resulting 
from the administration of a botanical food supplement has been described [82]. 
Also, numerous nutritional supplements promoted for performance enhancement and 
stimulating effects contain caffeine. Some of these products comprise, besides caffeine, 
extracts of guarana (Paullinia cupana), a South American plant which has been shown to 
contain caffeine [83]. Caffeine has a positive influence on endurance sport. This is frequently 
observed in run/cycle to exhaustion tests but also in swimming and tennis [84-87]. As a result, 
extensive research has been done to investigate the mechanisms by which caffeine exerts its 
performance enhancing effects. Although not completely resolved, it appears that the caffeine 
antagonism of adenosine receptors is an important factor in the comprehensive mechanism of 
action of caffeine [88]. Before January 1st, 2004 the use of caffeine containing nutritional 
supplements could have resulted in positive doping test as caffeine was listed by the IOC as a 
doping agent in class I A “Stimulants” with a threshold level of 12 µg/ml. This is not longer 
an issue because from January 1st, 2004 on caffeine was removed from the WADA list of 
forbidden substances. Nevertheless, athletes should take care when using caffeine because 
excessive use is associated with withdrawal effects and negative effects on the cardiovascular 
system [88]. 
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1.4. Analysis of nutritional supplements for doping contaminants 
Numerous methods have been developed to analyse herbal preparations for the presence of 
Ephedra alkaloids or to evaluate the labelled content of Ephedra sinica (Ma Huang) 
containing supplements. These methods include TLC [89], immunoassays [41, 82], GC [90-
92], HPLC [78, 79, 93-98] and CE [99]. Identification is best achieved using mass 
spectrometry. Identification of the ephedrines using GC/MS is not possible without 
derivatisation, which could be considered as a technical drawback. On the other hand, in 
several HPLC methods sodium dodecyl sulphate or triethylamine as a constituent of the 
mobile phase are used to increase the theoretical plate number, hampering the HPLC 
combination with mass spectrometry due to overloading of the ion source. Only one method 
has been described for the identification of Ephedra alkaloids in dietary supplements using 
LC/MS [94]. 
Not only naturally occurring stimulants as ephedrines are detected in supplements, but also 
synthetic analogues related to amphetamine such as MDMA and phentermine. 
Several methods for the detection of stimulants in urine using HPLC have been published 
[100-104]. GC-methods routinely used for the detection of stimulants for doping control 
purposes, have also been described [105-109]. Based on GC with NPD detection for screening 
purposes in urine, Parr et al. descibed a method for the screening of stimulants and other 
nitrogen containing doping relevant drugs in nutritional supplements [110]. Confirmation of 
positive screening results was done with GC/MS after selective derivatisation using MSTFA 
and MBTFA. Besides ephedrines, amphetamines and related compounds, this method also 
allows for the identification of methylecgonine, formed during alkaline extraction, as a 
marker for cocaine. The only drawback of this method is the relatively high limit of detection 
for some compounds including MDA, cocaine and strychnine as some authorities, such as 
NZVT (http://www.necedo.nl/nzvt/thenetherlandssecuritysystemnutritionalsupplements) 
require better analytical sensitivity. The development of an LC/MS method for the screening 
of stimulants in dietary supplements might be a solution. 
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Analysis of nutritional supplements for the presence of anabolising agents has been described 
in several papers. Catlin et al. [40] and Green et al. [42] used HPLC to detect contaminants in 
nutritional supplements marketed as prohormones but the method was restricted to 5 
prohormones of testosterone and nandrolone. Using this method the detection of low 
concentrations of contaminants seems questionable as the dietary supplements were diluted 
numerous times. 
A more frequently applied analytical technique for the identification of prohormones in 
dietary supplements is GC/MS, similar to the screening methods for anabolic steroids in urine 
for doping control purposes. Full scan MS methods were able to detect contaminants in the 
milligram range [41, 46, 53] while the use of SIM methods allowed more sensitive 
identification of impurities [44, 45, 47, 48]. 
Geyer et al. [44] described a method for the screening of 12 compounds including 
testosterone and prohormones, nandrolone and prohormones, prohormones of boldenone and 
5α-dihydrotestosterone. LODs ranged between 5 ng/g and 100 ng/g. These LODs allow for 
the determination of trace contaminations in “non-hormonal” nutritional supplements. 
Two validated methods have been published for the screening of 28 different anabolizing 
agents including testosterone and prohormones, nandrolone and prohormones, esters of both 
compounds, stanozolol and metandienone [47, 48]. Although until now only one ester of 
testosterone (testosterone undecanoate) is available for oral administration, these methods are 
capable of detecting other esters of testosterone and nandrolone as well, when they should 
become available on the supplement market. A distinction was made between solid [47] and 
aqueous [48] nutritional supplements. LODs ranged from 2 ng/g to 40 ng/g for solid 
supplements while for aqueous supplements LODs were between 1 ng/ml and 10 ng/ml. 
These LODs meet the requirements of official authorities such as the Dutch NZVT system. 
Methods developed for the identification of trace contaminants rely on liquid/liquid 
extraction. Geyer et al. [44] used a method based on mixing nutritional supplements with 
methanol. Afterwards an extractive clean-up using pentane and methanol was used. Other 
methods use an alkaline extraction with NaOH and pentane/diethylether [47] or 
K2CO3/NaHCO3 and pentane/diethylether [48]. 
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Nutritional supplements form a heterogeneous group of products available in different forms. 
Consequently, analysis of nutritional supplements for anabolic steroids has proven to be very 
difficult due to the different matrices. Problems most frequently occur with solid nutritional 
supplements or oil based supplements [48]. Parr et al. [111] reported several possible 
solutions for problems occurring during extraction and analysis of supplements. The proposed 
modifications include extra derivatisation, additional clean-up steps, alternative sequence of 
injection and reduction of the matrix. In this way improvements could be obtained. However, 
still 10.4 % of all investigated samples could not be analysed. A possible solution for those 
problems could be a pre-analysis fractionation using HPLC as described by De Cock et al. 
[46]. Promising results in the clean-up step were obtained by Geisendorfer and Gmeiner [112] 
using GPC prior to GC/MS analysis. This method allowed for the determination of 12 
different anabolic steroids and prohormones without the occurrence of matrix problems. 
Although the obtained LODs (20 – 50 ng/g) were not in compliance with the requirements of 
some authorities (NZVT) this method seems to be very promising. 
1.5. Conclusion 
The use of nutritional supplements seems unnecessary when athletes use a well balanced diet. 
Nevertheless, according to supplement sales numbers the use of these supplements has 
exploded in the last decade. Athletes are influenced by parents, coaches, competitors and high 
financial stakes to improve their performance. Aggressively marketed dietary supplements 
promising the athlete to jump higher, run faster or throw further seem to be a helpful tool. As 
long as products such as vitamins or minerals are used combined with a proper medical 
support this use is rather harmless. The use of prohormones, available on the supplement 
market as a result of several loopholes in the 1996 DSHEA, is of greater risk. Besides the 
serious health effects associated with these products, athletes should also take into account 
that they have to pass a doping control test. Therefore, the use of supplements by athletes in 
general is dangerous as numerous nutritional supplements are contaminated with anabolizing 
agents or stimulants. According to the WADA doping rules athletes are held responsible for 
the substances detected in their biofluids, irrespective of the origin. The development of 
methods capable of detecting contamination of nutritional supplements with doping relevant 
substances by specialised doping control laboratories is of utmost importance. At present 
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athletes or supplement producing companies have the possibility to have their supplements 
tested. 
Although several analytical methods are now available further improvements are needed 
because presently a fraction of the supplements cannot be analysed, according to the 
requirements of some testing authorities, due to matrix problems. In this perspective, 
additional research has to be done to solve these problems and to give athletes the best 
guarantee they can get. 
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Chapter 2: Detection of prohormones in nutritional supplements 
2.1. Abstract 
A sensitive and selective method for the screening of 32 different compounds including 
testosterone, nandrolone and prohormones, stanozolol and metandienone in both solid and 
aqueous nutritional supplements is described. The different substances are extracted from 
solid nutritional supplements by liquid-liquid extraction with a mixture of pentane and freshly 
distilled diethylether (9/1; v/v) after dissolving the supplement in NaOH (1N). In liquid 
matrices the substances are extracted by liquid-liquid extraction with a mixture of pentane and 
freshly distilled diethylether (1/1; v/v) after alkalinisation with a NaHCO3/K2CO3 (2/1; w/w) 
buffer. The anabolizing agents are derivatised with a mixture of MSTFA/NH4I/ethanethiol 
(320/1/2; v/w/v), routinely used for the determination of anabolic steroids in urine. The TMS-
derivatives are analysed by GC/MS in the SIM mode. The limits of detection were in the 
range 2 to 40 ng/g for solid nutritional supplements and 1 to 10 ng/ml for aqueous nutritional 
supplements. Examples of solid and aqueous nutritional supplements analysed by these 
methods were found to contain several forbidden substances according to the current WADA 
doping regulations. All detected compounds, except dihydrotestosterone, could be confirmed 
by GC/MS/MS, proving that the proposed methods are capable of detecting anabolizing 
agents in both solid and aqueous dietary supplements. 
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2.2. Introduction 
Nutritional supplements are food, supplying in one or more nutrients in a concentrated form 
such as minerals, vitamins, enzymes, that are theoretically present in a normally balanced diet 
[1]. Usually, they are offered in an atypical form like powder, tablets or capsules. Also 
commercially available and very popular are sports and energy drinks and the recently 
commercialised creatine serums. During the last decade the use of nutritional supplements has 
increased tremendously [1-3]. 
Several factors are at the origin of the present situation by which the use of nutritional 
supplements by athletes has become a matter of concern. The ever increasing aim for success 
by athletes is stimulated by the high financial stakes in elite sport. On the other hand, since the 
adoption of the DSHEA in 1994 [4], prohormones became commercially available on the U.S. 
supplements market. According to the rules of the WADA, and formerly the IOC, these 
prohormones belong to the prohibited class of anabolic steroids [5] due to potential risks 
associated with prohormone use similar to those observed with the use of anabolic steroids [6-
8]. 
Recently, evidence was found that several of these prohormones were present in “non-
hormonal” nutritional supplements like vitamins, minerals and amino acids, prohormones that 
were not even declared on the label of these supplements [9-11]. In an international IOC study 
94 nutritional supplements out of 634 (14,8%) were found to contain one or more 
prohormones not mentioned on the label [12]. In two other studies, high doses of the anabolic 
steroid metandienone were found in supplements [13, 14], in both cases the presence of this 
anabolic steroid was not mentioned on the label. The presence of these prohormones may lead 
to a positive doping test especially for the nandrolone metabolite norandrosterone [9-11]. As a 
result of the increasing use of nutritional supplements and the detection of several 
prohormones in non-hormonal supplements banned by international sport federations and the 
lack of standard methods according to ISO17025, validated methods for the screening of 
anabolizing agents in both solid and aqueous nutritional supplements were needed and are 
described here. 
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2.3. Experimental 
2.3.1. Reagents 
5α-androstane-3α,17β-diol, 19-nor-4-androstene-3,17-dione, 5α-androstane-3β,17β-diol, 4-
androstene-3,17-dione, boldenone, androsterone and testosterone were obtained from Sigma 
(St. Louis, MO, USA). 19-nor-4-androstene-3β,17β-diol, 19-nor-5-androstene-3β,17β-diol, 
1,4-androstadiene-3,17-dione, 1-androstene-3,17-dione, 19-nor-5-androstene-3,17-dione, 4-
androstene-3β,17β-diol, metandienone, 5-androstene-3β,17β-diol, 5-androstene-3,17-dione, 
4-androstene-19-ol-3,17-dione and 7-keto-DHEA were bought from Steraloids (Newport, 
USA), DHEA from Serva (Heidelberg, Germany) and DHT from Piette International 
Laboratories (Drogenbos, Belgium). Nandrolone and stanozolol were bought from NARL 
(Pymble, Australia). Clenbuterol was obtained from Boehringer Ingelheim (Ingelheim am 
Rhein, Germany). 17α-methyltestosterone, testosterone propionate, testosterone isocaproate, 
testosterone decanoate, testosterone phenylpropionate, testosterone undecanoate, nandrolone 
decanoate and nandrolone phenylpropionate were obtained from Organon (Oss, The 
Netherlands). Nandrolone laurate, was from Intervet International (Boxmeer, The 
Netherlands) and 1-testosterone was from Promochem (Molsheim, France). MSTFA was 
purchased from Chem. Fabrik Karl Bucher (Waldstetten, Germany). All other chemicals were 
of analytical grade. 
Nutritional supplement X (creatine serum, aqueous dietary supplement) was from US origin. 
The labelled content of this supplement was: creatine serum 50 mg/ml, inositol 20 mg/ml, D-
glucose 20 mg/ml, glucosamine sulphate 20 mg/ml, magnesium ascorbate 20 mg/ml, calcium 
pyruvate 10 mg/ml, citrusbioflavonoids 10 mg/ml, green tea extract 10 mg/ml, guarana extract 
10 mg/ml, L-arginine 10 mg/ml, L-carnitine 10 mg/ml, L-glutamine 10 mg/ml, Siberic 
ginseng 10 mg/ml, royal jelly 6 mg/ml, vitamin B5 3.6 mg/ml, zinc gluconate 2 mg/ml, 
chromium gluconate 2 µg/ml, vitamin B12 0.6 µg/ml. Other ingredients were water, 
glycerine, sorbitol and aromas. The recommended dosage was 5 ml to be used 10 minutes 
before exercise, only on training days. 
Nutritional supplement Y (solid dietary supplement) was also from US origin. The labelled 
content of the supplement was: Mucuna pruriens (Dopa Bean), standardized 15% L-Dopa 
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666.6 mg, α-glycerylphosphorylcholine 100 mg, Bacopa monniera extract, standardized 20% 
bacosides A&B 50 mg per serving. Other ingredients were fructose, sorbitol, natural flavor, 
steraic acid, magnesium stearate, cellulose, croscarmellose and sucralose. The recommended 
dosage was 4 capsules, one serving per day. 
2.3.2. Gas chromatography-mass spectrometry conditions 
The GC/MS analysis was conducted in the SIM mode on an Agilent 6890 gas chromatograph 
directly coupled to an Agilent 5973 mass selective detector (Agilent, Palo Alto, USA). Three 
ions, each with a dwell time of 25 ms, were monitored for each compound. The GC column 
was an HP-Ultra 1 (J&W, Folsom, USA), 100 % methylsilicone column with a length of 17 
m, an internal diameter of 0.2 mm and a film thickness of 0.11 µm. Helium was used as the 
carrier gas (linear velocity: 41 cm/s). A total of 0.5 µl was injected splitless. The oven 
temperature program was as follows: 120°C (0 min), 70°C/min → 181°C (0 min), 4°C/min → 
234°C (0.1 min), 30°C/min → 300 °C (10 min). The electron energy was set at 70 eV and the 
ion source temperature was set at 230 °C. 
Confirmation of positive results was done using GC/MS/MS on a Varian 3800 gas 
chromatograph directly coupled to a Varian Saturn 2000 mass spectrometer. The GC-column 
was a Varian CP-Sil 24 CB low bleed column (50% phenyl, 50% dimethylpolisyloxane) with 
a length of 30 m, an internal diameter of 0.25 mm and a film thickness of 0.15 µm. Helium 
was used as the carrier gas (linear velocity 41.6 cm/s). The oven temperature program was as 
follows: 120°C (0 min), 70°C/min → 170°C (0 min), 4°C/min → 260°C (0. min), 30°C/min 
→ 270 °C (0 min). The mass spectrometer was used in the MS/MS mode with an emission 
current of 80 µA. The dissociation parameters are as shown in Table 2.3.1. 
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Table 2.3.1 Dissociation parameters in GC-MS/MS confirmation. 
Component Precursor Ion
(m/z) 
Excitation storage level
(m/z) 
Excitation Amplitude
(Volts) 
androsterone (IS) 434 165 100 
DHEA 432 150 65 
5-androstene-3β,17β-diol 434 180 85 
2.3.3. Analysis of nutritional supplements 
5 ml of the aqueous nutritional supplement were made alkaline with 1 g of a NaHCO3/K2CO3 
(2/1; w/w) buffer. After stirring, 50 µl of the internal standard androsterone (2 µg/ml, MeOH) 
was added, followed by 5 ml of a pentane/diethylether mixture (1/1; v/v). After extraction by 
rolling for 1 h and centrifugation, the organic layer was separated and evaporated under 
oxygen free nitrogen at 40 ± 5°C. The residue was derivatized with 100 µl 
MSTFA/NH4I/ethanethiol (320/1/2; v/w/v) at 80°C for 30 min and transferred to an 
autosampler microvial. 
Solid nutritional supplements (1 g) were extracted by vigorously shaking with 5 ml of 1 N 
NaOH in a screw capped tube. Tablets were grounded before extraction. After shaking, 50 µl 
of the internal standard androsterone (2 µg/ml, MeOH) was added together with 5 ml 
pentane/diethylether (9/1; v/v). After rolling for 1 h, 0.5 – 1.0 g of anhydrous Na2SO4 was 
added before centrifugation. Afterwards, the organic layer was separated and dried under 
oxygen free nitrogen. The residue was derivatized with 100 µl MSTFA/NH4I/ethanethiol 
(320/1/2; v/w/v) at 80°C for 30 min and transferred to an autosampler microvial. A total of 
0.5 µl was injected on the chromatographic system. 
2.3.4. Analytical method validation 
The analytical method validation for the screening of 32 compounds in both aqueous and 
solid supplements was performed according to Eurachem guidelines [15] on twenty different, 
randomly chosen aqueous and solid nutritional supplements. 
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To determine the LODs, ten different aqueous nutritional supplements were spiked with a 
reference mixture at different concentrations in the range 1 – 40 ng/ml (1, 2, 5, 10, 20 and 40 
ng/ml) and 10 different solid supplements in the range 1 – 80 ng/g (1, 2, 5, 10, 20, 40 and 80 
ng/g). Selectivity was tested by the analysis of a reference mixture of 10 different other 
anabolizing agents at a concentration of 200 ng/ml. These compounds were 19-
noretiocholanolone, 17α-trenbolone, oxymesterone, 3’-OH-stanozolol, mesterolone, 
salbutamol, terbutaline, etiocholanolone, 5β-androst-1-ene-17β-ol-3-one and oxandrolone. 
Specificity was tested by the analysis of the 20 different nutritional supplements. 
2.4. Results and Discussion 
All screened compounds are given in Table 2.4.1. They include prohormones of testosterone 
and nandrolone, most commonly found in nutritional supplements [9-11], esters of both 
compounds, stanozolol and metandienone. Under the described chromatographic conditions, 
the internal standard androsterone-bis-TMS gave a sharp peak with a retention time of 10.81 
min. The GC relative retention times and ions monitored (3 per compound) are given in Table 
2.4.1. 
Table 2.4.1 GC relative retention times and monitored m/z values for trimethylsilylated 
compounds. 
Compound RRT m/z 
clenbuterol 0.46 335.1 , 300.1 , 86.1  
androsterone (IS) 1.00 434.3 , 419.3 , 329.2 
5α-androstane-3α,17β-diol 1.03 436.4 , 331.2 , 241.2  
19-nor-5-androstene-3β,17β-diol 1.05 330.2 , 240.2 ; 225.1 
19-nor-4-androstene-3β,17β-diol 1.06 420.3 , 330.2 , 240.2  
1-(5α)-androstene-3,17-dione 1.09 430.3 , 415.3 , 194.1 
DHEA 1.11 432.3 , 417.3 , 327.2  
19-nor-4(5)-androstene-3,17-dione 1.12 416.3 , 401.2 , 194.1  
4-androstene-3β-17β-diol 1.12 434.3 , 405.3 , 143.1  
1-testosterone 1.13 432.3 , 417.3 , 194.1 
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5-androstene-3β-17β-diol 1.14 434.3 , 344.3 , 239.2  
5α-androstane-3β,17β-diol 1.15 436.4 , 421.3 , 241.2  
nandrolone 1.15 418.3 , 403.3 , 194.1  
1,4-androstadiene-3,17-dione 1.16 428.3 , 413.3 , 323.2 
DHT 1.17 434.3 , 405.3 , 143.1  
4(5)-androstene-3,17-dione 1.19 430.3 , 415.3 , 234.1  
boldenone 1.19 325.2 , 229.1 , 206.1  
testosterone 1.22 432.3 , 417.3 , 209.0 
metandienone 1.33 444.3 , 339.2 , 206.1  
17α-methyltestosterone  1.35 446.3 , 356.2 , 301.2  
4-androstene-19-ol-3,17-dione 1.36 518.4 , 428.3 , 415.3  
7-keto-DHEA 1.38 518.3 , 429.2 , 296.1 
testosterone propionate 1.41 416.3 , 401.3 , 343.2 
stanozolol 1.55 472.4 , 457.3 , 143.1 
testosterone isocaproate 1.56 458.4 , 443.3 , 343.2  
nandrolone decanoate 1.78 500.4 , 485.4 , 329.2  
nandrolone phenylpropionate 1.79 478.3 , 463.3 , 194.1 
testosterone decanoate 1.82 514.4 , 499.4 , 343.2  
testosterone phenylpropionate 1.83 492.4 , 477.3 , 105.0  
testosterone undecanoate 1.90 528.5 , 513.4 , 343.2  
nandrolone laurate 1.96 528.5 , 513.4 , 329.2  
4-androstene-3,17-dione and 5-androstene-3,17-dione can not be separated because of the 
formation of identical derivatives using the derivatisation mixture as described in §2.3.3 
(Figure 2.4.1). The same applies for 19-nor-4-androstene-3,17-dione and 19-nor-5-
androstene-3,17-dione. 
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Figure 2.4.1 Derivatisation of 4-androstene-3,17-dione and 5-androstene-3,17-dione with 
MSTFA/ethanethiol/NH4I. 
For screening purposes at least two ion traces were monitored for every substance. The 
presence of a substance is suspected and the sample consequently forwarded to confirmatory 
analysis, if the relative abundance of the ion traces is similar to the relative abundance of the 
ion traces in the reference (20% relative margin). As an extra criterion, a maximal allowed 
deviation in relative retention time of 1% was used. 
The validation was performed according to the Eurachem guidelines [15]. According to these 
rules, the LOD is defined as the concentration where an analyte can be detected with a 
certainty of 100% (using the above mentioned criteria) in ten spiked supplements. The 
resulting LODs are summarised in Table 2.4.2.  
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Table 2.4.2 LODs for 32 different compounds in both solid and aqueous nutritional 
supplements. 
compound LOD 
Solid 
(ng/g) 
LOD 
Liquid
(ng/ml) 
compound LOD 
Solid 
(ng/g) 
LOD 
Liquid
(ng/ml) 
DHEA 2 1 stanozolol / 10 
1,4-androstadiene-3,17-dione 10 1 metandienone 10 2 
19-nor-4-androstene-3,17-dione 2 1 5α-androstane-3β,17β-diol 10 2 
5-androstene-3β-17β-diol 5 2 testosterone phenylpropionate 10 2 
nandrolone 5 1 testosterone isocaproate 20 / 
dihydrotestosterone 5 1 testosterone propionate 5 1 
4-androstene-3,17-dione 2 1 testosterone undecanoate 2 1 
testosterone 2 1 testosterone decanoate 2 1 
19-nor-5-androstene-3,17-dione 2 1 nandrolone decanoate 5 2 
5-androstene-3,17-dione 2 1 nandrolone phenylpropionate 5 2 
4-androstene-3β-17β-diol 10 1 nandrolone laurate 5 1 
5a-androstane-3α,17β-diol 5 1 methyltestosterone 2 1 
7-keto-DHEA / 2 1(5α)-androstene-3,17-dione 5 2 
boldenone 10 2 1-testosterone 5 1 
4-androstene-19-ol-3,17-dione / 2 19-nor-5-androstene-3β,17β-diol 10 1 
clenbuterol 10 1 19-nor-4-androstene-3β,17β-diol 10 1 
Several analytes can be detected at a concentration of 1 ng/ml in aqueous nutritional 
supplements. The highest LOD for aqueous supplements was 10 ng/ml, a concentration far 
below LODs obtained with a previous full scan method [9]. 
For solid nutritional supplements 9 analytes could be detected at a concentration of 2 ng/g. All 
other compounds could be detected at or below 20 ng/g. 
LODs could not be defined for 7-keto-DHEA, stanozolol and 4-androsten-19-ol-3,17-dione in 
solid nutritional supplements and for testosterone isocaproate in aqueous nutritional 
supplements due to matrix interferences in one sample. 
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Specificity and selectivity were tested according to the procedure described by Verwaal et al. 
[16]. For a qualitative method, the analysis of different negative matrices used to determine 
the LOD is sufficient to test for the specificity. No matrix interferences were found at the 
retention times of the validated analytes nor at the retention time of the internal standard 
androsterone. Selectivity was tested by the analysis of several related compounds. According 
to Verwaal et al. [16] the concentration of these compounds must be at least twice the LOD of 
the determined analytes. In this study, a concentration of 200 ng/ml was used. No interference 
of the related compounds was observed at the retention times of the different compounds and 
the internal standard androsterone. Hence, this method seems to be specific and selective. In 
conclusion, it seems that this method is reliable and sensitive for the screening of anabolizing 
agents in both aqueous and solid nutritional supplements. The method fulfils all criteria set by 
NZVT (http://www.necedo.nl/nzvt/thenetherlandssecuritysystemnutritionalsupplements) 
Previous analysis of nutritional supplement X with a full scan method [9] did not result in the 
detection of one or more prohormones. Therefore, this matrix was used as a negative matrix 
during the validation procedure. Surprisingly, the test for specificity resulted in the detection 
of DHEA in very low concentrations. Screening results for DHEA in nutritional supplement 
X in comparison to a reference are shown in Figure 2.4.2. 
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Figure 2.4.2 Screening results for DHEA in nutritional supplement X. (A) Nutritional 
supplement X and (B) DHEA. 
Confirmation of this screening result was obtained using GC/MS/MS. The resulting product 
spectrum of DHEA in nutritional supplement X compared to a reference is given in Figure 
2.4.3. Because DHEA was confirmed in nutritional supplement X, the method was further 
validated by replacing this matrix by another negative nutritional supplement. 
A B 
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Figure 2.4.3 Product spectrum (precursor m/z 432) of DHEA in nutritional supplement 
X. (A) nutritional supplement. (B) DHEA. 
The method for solid nutritional supplements was applied to nutritional supplement Y and 
resulted in the detection of DHEA, 19-nor-4(5)-androstene-3,17-dione, 5-androstene-3β,17β-
diol, DHT, 4(5)-androstene-3,17-dione and testosterone. As an example the ion 
chromatogram of 5-androstene-3β,17β-diol in nutritional supplement Y in comparison to a 
reference is shown in Figure 2.4.4. Confirmation of the screening results was performed by 
GC/MS/MS. The resulting product spectrum of 5-androstene-3β,17β-diol is shown in Figure 
2.4.5. All other compounds, except dihydrotestosterone, were also confirmed by GC/MS/MS. 
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Figure 2.4.4 Screening results for 5-androstene-3β,17β-diol in nutritional supplement Y. 
(A) nutritional supplement. (B) 5-androstene-3β,17β-diol. 
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Figure 2.4.5 Product spectrum (precursor m/z 434) of 5-androstene-3β,17β-diol. (A) 
nutritional supplement Y. (B) 5-androstene-3β,17β-diol. 
2.5. Conclusion 
Following international doping regulations, athletes remain responsible for the presence of 
doping substances in their biofluids. Because several studies have shown that nutritional 
supplements can be contaminated with prohormones, athletes should be very cautious using 
nutritional supplements. The developed sensitive and validated screening methods for the 
detection of anabolizing agents in both aqueous and solid nutritional supplements could be 
helpful for manufacturers and distributors to avoid unintended contamination of their products 
and to give that guarantee to their customers. 
It can be concluded that the described screening methods are capable of detecting 
contamination with prohormones at very low levels as the obtained LODs of 29 analytes are 
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below 20 ng/g for solid nutritional supplements and below 10 ng/ml for 31 analytes in liquid 
supplements. The application of these methods showed the presence of low level 
contamination in an aqueous supplement and multiple contamination of a solid supplement. 
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Chapter 3: Detection of stimulants in solid nutritional supplements 
3.1. Abstract 
Nutritional supplements are frequently used by athletes and can contain substances banned by 
WADA. The aim of this study was to develop a screening method for the detection of 
stimulants in solid nutritional supplements. 
Analyses were performed using high pressure liquid chromatography coupled to an ion trap 
mass spectrometer with an APCI interface after acidic clean-up and basic liquid/liquid 
extraction with diethylether. The mass spectrometer was operated in full scan MS/MS using 
positive ionisation. LODs were equal to or below 50 ng/g for all compounds except strychnine 
(100 ng/g). The suitability of the method for routine application was illustrated by the analysis 
of two suspected samples. 
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3.2. Introduction 
As described in the 1994 DSHEA [1] and defined by Schröder [2], nutritional supplements are 
food supplying in one or more nutrients in a concentrated form, e.g. vitamins, minerals, herbs 
or other botanicals, amino acids, metabolites, constituents, extracts or combinations of any of 
such ingredients, that are theoretically present in a normal balanced diet. As a result herbal 
preparations, frequently promoted for their alleged preventive and/or therapeutic effects were 
not considered as drugs [3]. One of the oldest, and best known, medicinal herbs is Ephedra or 
Ma Huang (Ephedra sinica). This herb was frequently used as a constituent in traditional 
Asian medicine and is still being used in herbal preparations today. The major active 
components are 6 optical active compounds including ephedrine, pseudoephedrine and 
norephedrine [4]. Today, herbal preparations containing parts of Ephedra sinica are 
frequently promoted for their performance enhancing effects or their positive influence on 
weight reduction. Although the effect of ephedrine on weight reduction has been documented 
[5-7], the influence on performance is doubtful [8-10] while numerous reports have been 
published describing the health risks associated with the use of ephedrine. A study by Haller 
and Benowitz [11] gave an overview of 140 adverse reports associated with the use of dietary 
supplements containing ephedra alkaloids. 
Besides alkaloids originating from the Ephedra plant, other stimulating agents have been 
detected in nutritional supplements. Analysis of a nutritional supplement used by a Belgian 
female marathon runner who tested positive during a doping control, revealed the presence of 
the anorexic agents phentermine and fenfluramine [12]. In addition, analysis of nutritional 
supplements for use by elite athletes preceeding the Olympic Games in Salt Lake City 
indicated the presence of MDMA, or XTC, in one nutritional supplement. 
Stimulants belong to the classes of prohibited substances according to WADA doping rules 
[13]. Athletes using contaminated supplements are at risk of violating the current doping 
rules. Analytical methods for the detection of prohomones in nutritional supplements have 
previously been published [14, 15]. Parr et.al [16] described a GC method for the detection of 
various stimulating agents in nutritional supplements based upon screening methods routinely 
used in doping control. Detection of stimulants using GC can only be accomplished with 
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nitrogen-phosphorus detection (GC/NPD) or mass spectrometry (GC/MS) after selective 
derivatisation. Because the obtained LODs [16] are not always in compliance with 
requirements made by official authorities (http://www.necedo.nl/nzvt), the aim of this study 
was to develop a LC/MS screening method for the detection of stimulants in solid nutritional 
supplements as an alternative for existing GC methods. 
3.3. Experimental 
3.3.1. Chemicals and reagents 
The internal standard (IS) 3-bromophenethylamine and strychnine were obtained from Sigma 
(Bornem, Belgium). MDA, MDEA and MDMA were obtained from the Portuguese doping 
control laboratory (Lisbon, Portugal). Norephedrine.HCl, norpseudoephedrine.HCl, 
pseudoephedrine.HCl and methamphetamine.HCl were purchased from Merck (Darmstadt, 
Germany). Amphetamine sulphate was purchased from Smith-Kline & French Laboratory 
(Philadelphia, USA). Ephedrine.HCl was obtained from Hoechst AG (Frankfurt, Germany) 
and fenfluramine.HCl from Laboratoires Servier (Orleans, France). 
Analytical grade hydrochloric acid, potassium hydroxide, acetic acid and diethylether were 
from Merck (Darmstadt, Germany). n-Pentane was obtained from Biosolve (Valkenswaard, 
The Netherlands). HPLC grade methanol was from Acros (Geel, Belgium) and HPLC grade 
water from Fischer (Loughborough, UK). 
Methanolic HCl (1M) was prepared by the addition of 3.9 g acetylchloride (Sigma) using a 
dropping funnel, during a period of 20 minutes while stirring, to 50 ml methanol p.a. (Acros 
Organics, Geel, Belgium) cooled to 0°C. The solution was stored between 0 and 8 °C. 
Nutritional supplement X was from Dutch origin. The labelled content was Tribulus Terrestris 
750 mg. The recommended dose was 1-3 capsules per day. 
Nutritional supplement Y, also from Dutch origin was promoted as a herbal mixture. The 
manufacturer recommended 2-4 capsules a day. 
Part III: Nutritional supplements 
3. Detection of stimulants in solid nutritional supplements 
 126
3.3.2. Liquid chromatography – mass spectrometry conditions 
A Thermo Separation Products (TSP) Model P4000 quaternary pump equipped with a TSP 
Model AS 3000 autosampler with a 100 µl sample-loop and connected to a ThermoFinnigan 
LCQ-Deca® mass spectrometer was used (all from Thermo Separation Products, Thermo, San 
Jose, CA, USA). 
A Nucleosil C18 column 3 mm x 100 mm, 5 µm (Varian, St.-Katelijne-Waver, Belgium), 
protected with a Chromsep guard column 2 x 10 mm (Varian), was used for chromatographic 
separations. 50 µl was injected on the chromatographic system using push loop injection. 
The mobile phase consisted of 1% acetic acid (solution A) and methanol (solution B). 
Gradient elution at a flow rate of 0.4 ml/min was as follows: 90% A for 2 min, linear to 20% 
in 6 min, isocratic for 3 min followed by an increase to 90% in 0.5 min. The equilibration 
time before the next injection was 6.5 min and the total run time was 18 min. 
Ionisation of analytes was carried out using APCI. The capillary and vaporizer temperature 
were set at 120 and 350 ºC, respectively. The discharge current was 5 µA. The sheath gas was 
maintained at 50 units and no auxillary gas was used. 
Tuning of the capillary voltage, tube lens, octapole lenses and entrance lens was automatically 
done on the protonated molecular ion of amphetamine. 
In MS/MS experiments the isolation width was set at 3.0, the activation q at 0.250 and the 
activation time at 30 ms. The collision energy was set in order to fully fragment the precursor 
ion. 
3.3.3. Extraction procedure 
Extraction was based on a previously described method [16]. Briefly, 50 µl of the internal 
standard 3-bromophenethylamine (10 µg/ml, MeOH) were added to 1 g of grinded 
supplement, followed by the addition of 5 ml of 1M HCl. Liquid-liquid extraction was 
performed by rolling for 10 min with 4 ml n-pentane. After centrifugation the organic layer 
was discarded. Two ml of 5 M KOH were added to the remaining aqueous layer and a second 
liquid-liquid extraction was performed using 5 ml diethylether by rolling for 10 min. After 
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centrifugation the organic layer was transferred to a new tube and 100 µl of methanolic HCl 
(1M) was added after which evaporation was performed under OFN at 40 ºC. The residue was 
dissolved in 200 µl of mobile phase. 
3.3.4. Analytical method validation 
The validation was carried out according to Eurachem validation guidelines [17] on 10 
randomly chosen solid nutritional supplements. These supplements were spiked at 4 different 
levels with the studied stimulants. Final concentrations were 20, 50, 100 and 200 ng/g. The 
samples were extracted as described above. The LOD was defined as the lowest concentration 
where a compound could be identified in all samples. Selectivity was tested by analysing 
several other doping agents including other stimulants, anabolic agents, beta-blockers, 
narcotics, diuretics and corticosteroids. Specificity was tested by analysing 10 blank 
nutritional supplements used to determine the LOD. 
3.4. Results and Discussion 
All stimulants included in this screening method contain an amine function and can be 
extracted with good recoveries at the alkaline pH value used in this method [18]. Nutritional 
supplements often consist of complex matrices and are composed of multiple ingredients, 
including vitamins, amino acids and herbal extracts. Because of the basic amine moiety of 
stimulants, a selective acid extraction was used to remove unwanted neutral and acid 
compounds. In doping analysis diphenylamine is commonly used as IS for the analysis of 
amphetamine type drugs [19, 20]. However this substance is lost during the acid clean up 
step. Therefore, 3-bromophenethylamine, a compound with similar functionalities as the 
compounds of interest was used as the internal standard. 
Methanolic HCl was added to the organic phase before the evaporation step to avoid 
undesired loss due to the volatility of amphetamine type drugs [21]. 
The use of MeOH instead of acetonitrile, as organic modifier was preferred because MeOH 
allowed for the isomers ephedrine-pseudoephedrine and norpseudoephedrine- norephedrine to 
be partially separated. 
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For the determination of the diagnostic ions direct infusion was performed. Therefore a 
solution of 5 µg/ml, producing a fairly distinguished protonated molecular ion [M+H]+, was 
directly infused into the mass spectrometer. For all compounds protonated molecular ions 
were observed in full scan MS. Because MS/MS often results in improved sensitivity this 
technique was applied for all compounds. Retention times and monitored diagnostic ions are 
presented in Table 3.4.1. 
Table 3.4.1 RTs, instrument parameters and LODs. 
Substance  RT 
(min) 
PI 
[M+H]+
CE DI LOD (ng/g) 
bromophenethylamine* 8.13 200 25 183 - 
amphetamine 6.61 136 25 119 20 
ephedrine 5.20 166 30 148 50 
fenfluramine 9.44 232 30 159 50 
MDA 7.10 180 25 163 50 
MDEA 7.88 208 28 163 50 
MDMA 7.52 194 27 163 20 
methamphetamine 7.28 150 30 119 50 
norephedrine 3.79 152 25 134 50 
norpseudoephedrine 4.36 152 25 134 50 
pseudoephedrine 5.67 166 30 148 50 
strychnine 8.23 335 37 264 100 
CE: collision energy, PI: precursor ion for MS/MS, DI: diagnostic ion 
* IS 
As indicated in Table 3.4.1, the obtained LODs were equal to or lower then 50 ng/g for all 
compounds excepting strychnine (100 ng/g). These LODs are lower than the detection limits 
obtained in previous studies using GC/MS [16] and are in compliance with the requirements 
of some testing authorities (http://www.necedo.nl/nzvt). 
Ion chromatograms obtained after analysis of a quality control sample spiked with all 
compounds at a concentration of 100 ng/g are given in Figure 3.4.1. 
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Figure 3.4.1 Quality control sample spiked with all components at 100 ng/g. 
The method seems to be very selective as no interferences were detected when other doping 
products including other stimulants, anabolic agents, beta-blockers, narcotics, diuretics and 
corticosteroids were analysed. The specificity, tested by the analysis of 10 different blank 
dietary supplements, was satisfactory as no matrix interferences were noticed at the retention 
time of the 11 analytes tested in this method, nor at the retention time of the internal standard. 
The method was applied to the analysis of two solid supplements. In the first sample from 
Dutch origin, containing the alleged natural steroid enhancer Tribulus terrestris (supplement 
X), ephedrine and pseudoephedrine were detected (Figure 3.4.2). 
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Figure 3.4.2 Positive screening results for ephedrine and pseudoephedrine in supplement 
X. 
In a second sample also from Dutch origin, the presence of non-labelled strychnine was 
found. Although not mentioned on the label extracts from Strychnos nux vomica, a natural 
source of strychnine, were probably added to the supplement (Figure 3.4.3). 
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Figure 3.4.3 Positive screening results for strychnine in supplement Y. 
3.5. Conclusion 
A sensitive screening method for the detection of 11 stimulants using LC/MS/MS was 
developed and validated. This method can be applied as a screening method for the routine 
analysis of stimulating agents in nutritional supplements. The obtained LODs are in 
compliance with the requirements of the NZVT. The method resulted in the detection of 
ephedrine and pseudoephedrine in supplement X and of strychnine in supplement Y. 
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Chapter 4: Case Reports 
4.1. Introduction 
Since the introduction in the 1980s of a general screening method for anabolic steroids in 
doping analysis, the detection of long acting injectable preparations in urine became rather 
easy [1-3]. In order to circumvent a positive test athletes therefore switched to injectable 
testosterone or oral preparations that were rapidly cleared from the body. It was reported that 
in the 80s scientists in the German Democratic Republic, knowing that a test would soon be 
adopted to detect the use of testosterone, developed short acting testosterone preparations and 
nasal sprays containing the testosterone precursor androstenedione [4]. 
Another way to circumvent the doping tests was the use of prohormones, especially 
precursors of testosterone, while the orally short acting precursors of nortestosterone also 
seemed to be attractive to the cheating athlete. 
One of the first hormonal supplements that became available in the USA was DHEA in 1996. 
Thereafter the list steadily expanded and now includes DHEA, 4-androstenedione, 4-
androstenediol and 5-androstenediol as well as the nandrolone precursors 19-
norandrostenedione and 19-norandrostenediol. Their introduction on the U.S. market and the 
internet trade were the direct result of the 1994 DSHEA. Originally this Act was designed to 
allow people the use of common vitamin supplements. However through several loop-holes in 
the law, any substance that is natural to the body can be sold according to this Act. In this way 
consumers, including professional athletes and people using substances for cosmetic reasons, 
are increasingly provided with untested, unproven and potentially lethal products. Moreover 
as these supplements contain anabolic steroids, their use can confront athletes with sanctions 
from international sports authorities. 
Another issue with prohormones and sports is related to nutritional supplements contaminated 
with prohormones [5-9]. In this chapter supplements tested by DoCoLab (UGent) with in-
house methods for the detection of non-labelled anabolising agents in nutritional supplements 
will be discussed. For some of them urinary detection times for doping substances, which 
were not indicated on the labels, were established. 
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4.2. Experimental 
4.2.1. Contaminated nutritional supplements 
Two nutritional supplements from U.S. origin were bought. 
The labelled content of supplement A was as follows: seven capsules contain garcinia 
cambogia 2000 mg, l-carnitine 1100 mg, guarana extract 1025 mg, citrus aurantium extract 
300 mg, l-phenylanaline 300 mg, dandelion root 250 mg, choline bitartrate 200 mg, cayenne 
powder 60 mg, vanadyl sulphate 15 mg, vitamin B6 10 mg and “much more”. The 
manufacturer recommended seven capsules on a daily basis. 
Supplement B was a pyruvate supplement and the recommended dose was one tablet per day. 
Two other nutritional supplements, C & D, were from Czech origin. Supplement C, was a 
pyruvate Ca supplement used by an athlete suspended after a positive nandrolone doping test. 
According to the manufacturer’s recommendations the optimal dose was three capsules before 
exercise and three more 4 hours later. 
Supplement D, was sent by the Czech Agriculture and Food Inspection Authority. This 
supplement was a creatine pyruvate produced by the same company as supplement C. The 
recommended dosage was 6 – 8 capsules per day. Supplement C and D arrived at the 
laboratory within an interval of 1.5 years. 
4.2.2. Analysis of nutritional supplements 
All supplements were in solid form and were extracted and analysed using GC/MS as 
described in Part IV Chapter 2. The GC/MS analysis of supplement A was hampered by 
matrix effects. To overcome this problem an additional HPLC fractionation was performed 
after the traditional liquid-liquid extraction. The HPLC system consisted of a SP 8800 ternary 
pump (Spectra-Physics, CA, USA), an SP 8880 autosampler and a Spectra Focus forward 
optical scanning detector (UV3000) set at a wavelength range of 220-360 nm. A 100 x 3 mm 
I.D. column packed with octadecyl silica (5 µm Nucleosil, Chrompack, Belgium) with an 
appropriate guard column was used. The column was held at room temperature. The loop 
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volume was 20 µl. The mobile phase consisted of acetonitrile and acetic acid (1% in H2O) at a 
flow rate of 1 ml/min. The gradient program was as follows: initial acetonitrile 2% for 4 min, 
increased to 32% in 6 min, finally to 45% in 6.5 min and hold for 4 min. Afterwards the 
column was equilibrated for 10 min with 2% acetonitrile. The residue obtained after liquid-
liquid extraction was dissolved in 200 µl of mobile phase. A total of 20 µl was injected on the 
chromatographic system. The fraction between 15.2 and 18.3 min was collected, evaporated 
and derivatised with 100 µl MSTFA/NH4I/ethanethiol (380/1/2; v/w/v) for 1 h at 80°C after 
which the GC/MS analysis was performed in full scan mode (m/z 40 – 780). 
No additional clean-up was needed for supplements B, C en D. GC/MS screening of those 
supplements was performed in SIM-mode as described in Part II Chapter 2. 
4.2.3. Quantification of prohormones 
The concentration of prohormones in the supplements was determined in the homogenized 
content of 10 capsules or tablets using an equally weighted linear calibration curve 
constructed in the range 0 to 500 ng/g. Therefore a negative nutritional supplement (carbo 
energizer orange, Performance, Nutrico, Belgium) was spiked with testosterone, DHT, 
DHEA, 4(5)-androstene-3,17-dione, nandrolone, 19-nor-4(5)-androstene-3,17-dione and 5α-
androstane-3,17-dione and analysed at 5 different levels (0, 50, 100, 250 and 500 ng/g) 
according to the described method. The quantification and qualifier ions for each compound 
are summarised in Table 4.2.1. If necessary, samples were diluted to obtain concentrations 
within the range of the calibration curve. Quantification was performed using the same 
GC/MS method, except that the MS was operated in the full scan mode (m/z 40 – 780) instead 
of SIM. 
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Table 4.2.1 Quantification ion and qualifier ions (m/z) used in the quantification of 
different trimethylsilylated compounds in nutritional supplements. 
compound Quant. Ion Qual. ion 1 Qual. ion 2 
testosterone 432 417 209 
DHT 434 405 143 
nandrolone 418 403 194 
DHEA 432 417 327 
19-nor-4(5)-androstene-3,17-dione 416 401 194 
4(5)-androstene-3,17-dione 430 415 234 
5α-androstane-3,17-dione 432 417 275 
4.2.4. Excretion study 
Excretion studies were performed with supplements A, B & C according to a strict research 
protocol approved by the Ethics Committee, University Hospital (Ghent, Belgium) (EC/2005-
81/sdp). The purpose of the study was explained to each volunteer. 
One capsule of supplement A was taken by 5 male volunteers. Urine was collected before 
administration and quantitatively during the first 12 h, i.e. 2, 4, 6, 9, 12 h post administration. 
Additional urine samples were collected after 24, 48, 72, 96, 120, 144 and 168 h. 
Two tablets of supplement B were ingested by 2 volunteers. Urine sample collection was as 
for supplement A. 
An excretion study with supplement C was performed in 3 male volunteers. Each volunteer 
took 3 capsules at the beginning of the study, followed by three more 4 hours later, in 
agreement with the recommendations on the package of the supplement. Urine was taken 
before administration and thereafter quantitatively up to 12 hours (0, 1, 2, 4, 6, 9 and 12 h). 
4.2.5. Urine analysis 
Quantification of norandrosterone in urine was as follows: one ml sodium acetate buffer (pH 
5.2, 1M) and 50 µl of β-glucuronidase type HP-2 from Helix pomatia were added to 5.0 ml 
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urine. The mixture was hydrolysed for 2.5 h at 56°C. After the addition of 50 µl of the 
internal standard 17α-methyltestosterone (2 µg/ml, MeOH) and 1 g of NaHCO3/K2CO3 (2:1; 
w/w) extraction was performed by rolling for 20 min with 5 ml n-pentane. After 
centrifugation, the organic layer was evaporated under OFN. The residue was derivatised with 
100 µl MSTFA/NH4I/ethanethiol (380/1/2; v/w/v) for 20 min at 80°C. 
Quantification of norandrosterone and endogenous steroids was done by GC/MS in the SIM 
(dwell time 50 ms) mode on an Agilent MSD-5973 mass spectrometer directly coupled to an 
Agilent 6890 gas chromatograph (Agilent, Palo Alto, USA) equipped with a 17 m crosslinked 
methylsilicone Ultra-1 column (I.D. 0.20 mm, df 0.11 µm) (J&W, Folsom, USA). The oven 
temperature was programmed as follows: 120°C (0 min) – 70°C/min → 181°C (0.2 min) – 
4°C/min → 234°C (0.1 min) – 30°C/min → 300°C (3 min). The electron energy was set at 70 
eV and the ion source temperature at 270 °C. A total of 0.5 µl was injected splitless. 
Quantification of norandrosterone was performed using a 5-point calibration curve in the 
range 1 to 20 ng/ml. Steroid profiling of the urine samples was done using the extraction and 
derivatisation procedure as described for the quantification of norandrosterone, except that 2 
ml urine was used and extraction was performed with diethylether instead of n-pentane. 
Steroid profiling was done using a one point calibration. The mass spectrometer was operated 
in the SIM mode using dwell times of 20 ms. 
4.3. Results and Discussion 
Calibration curves for the quantification of prohormones in nutritional supplements showed 
good linearity (R² between 0.977 and 0.996). A similar correlation coefficient was obtained 
for the quantification of norandrosterone in urine. 
4.3.1. Supplement A 
After evaporation and derivatisation of the collected HPLC fraction the presence of high 
concentrations of 19-nor-4(5)-androstene-3,17-dione and 4(5)-androstene-3,17-dione were 
found in dietary supplement A. Both substances were not mentioned on the product label and 
were confirmed by GC/MS in full scan mode (Figure 4.3.1). 
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Figure 4.3.1 Confirmation of non labelled steroids in supplement A. Total ion 
chromatogram of the collected HPLC fraction (A). Mass spectrum of trimethylsilylated 
19-nor-4(5)-androstene-3,17-dione (B). Mass spectrum of trimethylsilylated 4(5)-
androstene-3,17-dione (C). 
Quantification of the steroids present in supplement A after homogenisation of 10 capsules 
(7.77 g) resulted in concentrations of 0.9 and 6.3 mg/g for 4(5)-androstene-3,17-dione and 19-
nor-4(5)-androstene-3,17-dione, respectively. Hence, one capsule of the dietary supplement A 
contained 0.7 mg 4(5)-androstene-3,17-dione and 4.8 mg 19-nor-4(5)-androstene-3,17-dione. 
Concentrations in the milligram range in this supplement can not be considered as 
contamination related to the production process. Instead they are indicative of the deliberate 
addition of these substances. 
Because 4(5)-androstene-3,17-dione is a precursor of testosterone, an increase in urinary 
testosterone as well as in 4-androstene-3,17-dione concentration can be expected after the 
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ingestion of this supplement [10]. An excretion study conducted with one tablet of 
supplement A however showed no increase in the ratio of testosterone to epitestosterone. Van 
Eenoo et.al [10] stated that the misuse of 4-androstene-3,17-dione can be proven if the ratio of 
4-androstene-3,17-dione to epitestosterone exceeds 1.2. In only one subject this threshold 
level was exceeded from 4 h until 6 h after the administration of one tablet of this supplement. 
(Figure 4.3.2). It remains unclear what the outcome of this test would be if the manufacturer’s 
recommendation of 7 capsules was followed. 
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Figure 4.3.2 Urinary 4-androstene-3,17-dione/epitestosterone ratios in 5 male volunteers 
after ingestion of one capsule of the contaminated dietary supplement A. 
Recently it has been shown that the misuse of exogenous 4-androstene-3,17-dione can be 
detected by screening for 6α-hydroxyandrostenedione [11]. Inclusion of this compound in 
screening methods might have indicated the use of 4-androstene-3,17-dione after the 
administration of one tablet of this supplement although this remains questionable as the 
ingested dose is far below the most frequently used dose of 50 mg [10, 11]. 
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High amounts of 19-nor-4-androstene-3,17-dione, a precursor of nandrolone, in supplement A 
were detected in all subjects by the presence of 19-norandrosterone (the main urinary 
metabolite) (Figure 4.3.3) 
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Figure 4.3.3 Metabolic pathway of 19-nor-4-androstene-3,17-dione. 
The excretion profile of this substance after the ingestion of one capsule of supplement A is 
shown in figure 4.3.4. 
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Figure 4.3.4 Urinary excretion profiles of 19-norandrosterone in five male volunteers 
after the ingestion of one capsule of supplement A. 
According to the WADA urinary threshold level for norandrosterone of 2 ng/ml, doping 
positive results were found up to 144 h after the administration of one capsule of the 
supplement. 
The use of 7 capsules of supplement A, as recommended by the manufacturer, could have 
resulted in even longer detection times and in serious health effects. 
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4.3.2. Supplement B 
The analysis of nutritional supplement B revealed the presence of multiple non-labelled 
prohormones. These substances and their concentration, determined on the homogenised 
content of 10 capsules, are given in Table 4.3.1 
Table 4.3.1 Detected prohormones and concentration in nutritional supplement B. 
Substance Concentration (ng/g) 
DHEA 159 
4(5)-androstene-3,17-dione 78 
testosterone 243 
19-nor-4(5)-androstene-3,17-dione 189 
The concentrations are much lower than in supplement A, eventually indicative for 
undeliberate contamination. 
Urinary steroid profiles did not change significantly after the ingestion of the recommended 2 
capsules. Norandrosterone was detected in urine of both subjects in the 2 h sample. The 
detected concentrations were 0.11 ng/ml and 0.23 ng/ml in subject 1 & 2 respectively. 
Although the concentrations of prohormones in supplement B are too low to result in adverse 
doping findings after administration of the recommended dose, the presence of these 
prohormones should have been mentioned on the product label. According to the U.S. 
Anabolic Steroid Control Act enacted on January 20th 2005, the presence of these steroids is 
illegal and should result in the withdrawal of this nutritional supplement from the market. 
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4.3.3. Supplement C 
Analysis of 10 homogenised capsules of nutritional supplement C resulted in the detection of 
6 prohormones in a concentration range of 67 to 1739 ng/g(Table 4.3.2). 
Table 4.3.2 Concentration (ng/g) and average amount per capsule (ng) in nutritional 
supplement C. 
Compound Concentration
(ng/g) 
Amount/capsule 
(ng) 
DHEA 1047 761 
19-nor-4(5)androstene-3,17-dione 1739 1265 
nandrolone 474 345 
DHT 218 158 
4(5)-androstene-3,17-dione 67 49 
testosterone 408 296 
Confirmation of the screening results was obtained with full scan mass spectrometry. Figure 
4.3.5 shows the confirmation results for DHT in comparison to a quality control sample 
spiked at 50 ng/g. Similar confirmation results could be obtained for the other detected 
compounds. 
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Figure 4.3.5 Mass spectrum of TMS-derivatised DHT in the nutritional supplement (A) 
in comparison to a quality control sample (B). 
DHT is the active metabolite of testosterone and its androgenic activity is 2-3 times higher 
than the parent steroid. In humans, DHT is mainly produced by 5α-reductase from 
testosterone in androgen dependent target tissues. Because this process is irreversible, the 
administration of DHT as a substitute for testosterone may be beneficial because the 
undesired side effects due to the formation of estradiol (female hormone) by aromatase are 
avoided [12]. 
Parameters for the misuse of DHT are the DHT concentration, the ratio of androsterone to 
etiocholanolone and the ratio of 5α-androstan-3α,17β-diol to 5β-androstan-3α,17β-diol. 
These ratios are based upon the fact that DHT solely metabolises to 5α-metabolites and that 
no inter-conversion to 5β-metabolites occurs [12] (Figure 4.3.6). 
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Figure 4.3.6 Metabolic pathway of DHT. 
An excretion study performed in three male volunteers, as described in §4.2.3, did not result 
in an elevated T/E ratio nor in changes in the parameters indicative for DHT misuse. Also no 
changes were found in the urinary parameters indicative for the use of 4(5)-androstene-3,17-
dione. These findings are probably due to the low amounts of these compounds in nutritional 
supplement C. The concentration of 19-nor-4(5)-androstene-3,17-dione however was 
sufficient to result in the detection of 19-norandrosterone. Urinary excretion profiles of 19-
norandrosterone following the administration of nutritional supplement C according to the 
manufacturer’s recommendations are shown in Figure 4.3.7. 
Part III: Nutritional supplements 
4. Case Reports  
 152
0
1
2
3
4
5
6
7
8
9
10
0 3 6 9 12
time (h)
co
nc
 (n
g/
m
l)
volunteer 1
volunteer 2
volunteer 3
threshold
 
Figure 4.3.7 Excretion profile for 19-norandrosterone following administration of 
supplement C. 
19-norandrosterone was detected in the urine samples of all volunteers already 1 h after the 
administration of the first dose. Volunteer 1 & 3 tested positive according to the WADA 
threshold level of 2 ng/ml until 9 h after administration. Previous findings by Geyer et al. [13] 
proving that doping positive urinary concentrations of the nandrolone metabolite 
norandrosterone can be obtained if the total oral intake of nandrolone precursors is higher 
than 1 µg are confirmed in this study. 
4.3.4. Supplement D 
Analysis of nutritional supplement D, from the same supplement producing company as 
supplement C, showed the presence of high amounts of 19-nor-4(5)-androstene-3,17-dione 
(1.7 µg/g). Based upon the results in nutritional supplement C, ingestion of this amount of 19-
nor-4(5)-androstene-3,17-dione will also result in doping positive urine samples. 
Besides the nandrolone precursor a large peak at a retention time of 12.21 min appeared in the 
TIC of the confirmation procedure. Based upon a library search on the underivatised 
component and the mass spectrum obtained after derivatisation, this unknown compound was 
administration 
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identified as 5α-androstane-3,17-dione. Confirmation was obtained by the comparison of the 
supplement with a reference substance as shown in Figure 4.3.8. 
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Figure 4.3.8 Mass spectra of bis-TMS-derivatised 5α-androstane-3,17-dione (A) and of 
the unknown substance in supplement D (B). 
The presence of 5α-androstane-3,17-dione in nutritional supplements has never been reported. 
The detected amount of this substance (453 ng/g), together with the detection of 19-nor-4(5)-
androstene-3,17-dione is rather indicative for the deliberate addition of these compounds 
instead of accidental contamination. 
A 
B 
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4.3.5. Overall Results 
The case studies reported here are only a fraction of the results from supplement testing in our 
laboratory. Since December 2002 until January 2006, 367 supplements were analysed in the 
Doping Control Laboratory (UGent). These supplements were tested for anabolizing agents 
and/or stimulants according to the manufacturers demands, using the validated methods for 
the screening of anabolizing agents and stimulants described in Part III Chapter 2 & 3. 
In most cases supplements were sent by supplements producing companies. Some were 
bought and some others were sent by athletes as a follow-up study after a positive doping test. 
The Doping Control Laboratory (UGent) also acts as one of the two laboratories involved in 
the NZVT-system. This system comprises the Dutch Olympic Committee, the Dutch 
Government, NeCeDo and the branch organisation for supplement producing companies 
(NPN) in a combining effort to supply athletes with supplements free of doping contaminants. 
The total number of samples analysed, the number and percentage of positives analysed until 
January 2006 in the different categories is given in Table 4.3.3 
Table 4.3.3 Number of nutritional supplements analysed, number and percentage of 
positives obtained in the period December 2002 – January 2006. 
 prohormones stimulants caffeine 
N° samples 347 108 16 
N° positives 37 6 3 
% positives (%) 10.7 5.6 18.8 
Caffeine was detected in 3 nutritional supplements. Concentrations in these supplements 
never exceeded 6 mg/g. As indicated in Part II Chapter 1 these amounts would not result in 
positive doping findings and are of minor importance after the removal of caffeine from the 
WADA doping list. However, not indicating the presence of caffeine on the label, which was 
the case in all three supplements, can be considered as misinformation towards the consumer. 
Six nutritional supplements contained one or more stimulants. Four of them contained non-
labelled ephedrine. Pseudoephedrine, norephedrine, norpseudoephedrine and strychnine were 
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also found. Of all samples analysed within NZVT one sample contained non-labelled 
ephedrine and cathine. 
Out of the 347 samples analysed for prohormones in our laboratory 37 dietary supplements 
contained one or more prohormones (Table 4.3.4). 
Table 4.3.4 Prevalence of prohormones in nutritional supplements in the period 
December 2002 – January 2005. 
Compound Frequency
DHEA 28 
testosterone 18 
4(5)-androstene-3,17-dione 16 
19-nor-4(5)-androstene-3,17-dione 10 
DHT 7 
nandrolone 5 
5-androstene-3β,17β-diol 5 
1-androstene-3,17-dione 3 
17α-methyltestosterone 2 
4-androstene-3β,17β-diol 1 
1-testosterone 1 
5α-androstane-3,17-dione 1 
The results indicate that numerous dietary supplements contain more than one anabolizing 
agent not mentioned on the label. Prohormones of testosterone, more specifically DHEA, 
testosterone and 4(5)-androstene-3,17-dione, were most frequently detetected. Nandrolone 
and its precursors were less detected, but the results of excretion studies in this chapter 
demonstrate that contamination with these prohormones often results in adverse doping 
findings. The detection of 17α-methyltestosterone in two nutritional supplements is alarming 
because of the serious health effects associated with its use. 
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4.4. Conclusion 
Nutritional supplements can be contaminated as a result of improper cleaning of equipment or 
by the use of raw materials not tested for the presence of forbidden substances. In many cases 
the detected concentrations are low and inconsistent over the complete batch. Use of this kind 
of supplements by athletes is of lower risk compared to nutritional supplements intentionally 
contaminated with prohormones. Concentrations of prohormones in intentionally 
contaminated supplements are often very high and can result in positive doping tests if the 
recommendations of the manufacturers are followed. 
The case reports in this chapter prove that the search for anabolizing agents in nutritional 
supplements is of utmost importance. Numerous dietary supplements were contaminated with 
multiple prohormones not mentioned on the label. In addition, a new substance, 5α-
androstane-3,17-dione, previously not detected in supplements was also found. 
Overall results show that a substantial fraction of the supplements tested in the Ghent Doping 
Control laboratory were contaminated with one or more non-labelled substances. 
Besides the serious health effects associated with the use of these products, athletes should be 
aware that the use of contaminated supplements could result in a positive doping test. 
According to WADA doping rules athletes are responsible for the substances detected in their 
biofluids, irrespective of the origin. Hence, the development of methods capable of detecting 
contamination of nutritional supplements with doping relevant substances by specialised 
laboratories is of utmost importance. This guarantee can only be given by the specialised 
doping control laboratories. 
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CHAPTER 5: ANDROST-4-ENE-3,6,17-TRIONE 
Adapted from: 
• W. Van Thuyne, P. Van Eenoo, P. Mikulcíková, K. Deventer, and F.T. Delbeke, 
Detection of androst-4-ene-3,6,17-trione (6-OXO®) and its metabolites in urine by 
gas chromatography-mass spectrometry in relation to doping analysis. Biomed 
Chromatogr., 2005. 19: 689-695. 
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Chapter 5: Androst-4-ene-3,6,17-trione 
5.1. Abstract 
6-OXO®, a new nutritional supplement available on the internet, is advertised as an 
aromatase-inhibitor and contains androst-4-ene-3,6,17-trione as active ingredient. The 
metabolism and excretion of androst-4-ene-3,6,17-trione after administration of the 
“nutritional” supplement 6-OXO® was investigated by GC/MS. The parent drug androst-4-
ene-3,6,17-trione as well as androst-4-ene-6α,17β-diol-3-one and androst-4-ene-6α-ol -3,17-
dione were detected in post administration urine samples. 
Androst-4-ene-3,6,17-trione is an anabolic steroid and an aromatase inhibitor and regarded as 
a doping agent. A selective and sensitive GC/MS method in selected ion monitoring mode for 
the detection of the TMS-enol-TMS –ether derivatives of this substance and the metabolites 
was developed and validated for doping control purposes. LODs of the investigated 
compounds ranged from 5 to 10 ng/ml. The detection time for androst-4-ene-3,6,17-trione and 
androst-4-ene-6α,17β-diol-3-one was 24 h, while androst-4-ene-6α-ol-3,17-dione could be 
detected up to 37 h after administration of the recommended dose. 
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5.2. Introduction 
Aromatase inhibition is a therapeutic target for the selective lowering of estrogen levels in 
patients with estrogen dependent tumours including breast cancer [1, 2]. Several in-vitro 
experiments have shown that the anabolic steroid androst-4-ene-3,6,17-trione exhibits 
aromatase inhibiting-properties [2-4]. 
Similar to many other so-called prohormones [5-7], androst-4-ene-3,6,17-trione recently 
became available as a nutritional supplement. This product is sold as an over-the-counter 
nutritional supplement under the 1994 U.S. DSHEA as androst-4-ene-3,6,17-trione was not 
included in the Anabolic Steroid Control Act. The global distribution of these products via the 
internet has resulted in a huge commercial success for products such as (nor)androstenedione, 
(nor)androstenediol and dehydroepiandrosterone [5]. 
Currently, androst-4-ene-3,6,17-trione is advertised as an aromatase inhibitor capable to cure 
gynaecomastia, an adverse side-effect of anabolic steroids misuse [8] and it is produced by a 
company that has introduced several other anabolic steroids on the supplement market [5, 9]. 
Because of their action and potential misuse, aromatase inhibitors are classified as prohibited 
substances in sports by WADA [10]. Based on its chemical and (claimed) pharmacological 
action, it is clear that androst-4-ene-3,6,17-trione is a prohibited substance in sports. 
Because most anabolic steroids are completely metabolised and no parent drug is excreted in 
urine, detection methods for these metabolites need to be developed [11]. 
At present no data on the in-vivo metabolism of androst-4-ene-3,6,17-trione in humans is 
available. Based upon its structure it is highly unlikely that misuse of this steroid will be 
detected, using routine screening methods for anabolic steroids in WADA-accredited 
laboratories because these laboratories traditionally rely on GC/MS in the SIM mode [12, 13]. 
Although SIM displayed a higher sensitivity compared to full scan GC/MS, it only allows for 
the detection of known substances [12]. This study was set up to elucidate the metabolism of 
androst-4-ene-3,6,17-trione and to determine markers for misuse of this substance in doping 
control analysis. 
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5.3. Experimental 
5.3.1. Reagents 
Reference materials of androst-4-ene-3,6,17-trione (6-oxo-androstenedione), androst-4-ene-
6α-ol-3,17-dione (6α-OH-androstenedione), androst-4-ene-6β-ol-3,17-dione (6β-OH-
androstenedione), androst-4-ene-6α,17β-diol-3-one (6α-OH-testosterone) and androst-4-ene-
6β,17β-diol-3-one (6β-OH-testosterone) were purchased from Steraloids (Newport, USA). 
17α-methyltestosterone was from Organon (Oss, The Netherlands). The enzyme preparation 
β-glucuronidase type HP-2 from Helix pomatia (127 300 U/ml β-glucuronidase), potassium 
acetate and imidazole were obtained from Sigma (St. Louis, MO). MSTFA was purchased 
from Chem Fabrik Karl Bucher (Waldstetten, Germany). All other chemicals were of 
analytical grade. 
One jar of 6-OXO® containing 60 capsules was purchased from Ergopharm (Champaign, 
USA). The labelled content of each capsule was 100 mg of 3,6,17-androstenetrione. The other 
listed ingredient was micro crystalline cellulose. The manufacturer’s recommended daily dose 
was 3 to 6 capsules in cycles of 4 to 6 weeks. 
5.3.2. Analysis of 6-OXO® supplement 
Analysis of the 6-OXO® supplement was performed according to a previously described 
procedure by Van Thuyne and Delbeke [14] except for the internal standard which was 17α-
methyltestosterone and for the amount of supplement tested (100 mg instead of 1 g). 
5.3.3. Urine analysis 
Extraction of the urine samples was performed using liquid-liquid extraction with diethylether 
of 2 ml urine after enzymatic hydrolysis, as described by Van Eenoo et al.[9]. 
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5.3.4. Derivatisation 
The dried residue of the urine samples was derivatised with 100 µl MSTFA/NH4I/ethanethiol 
(320/1/2; v/w/v) at 80°C for 60 min and transferred to an autosampler microvial for GC/MS 
analysis. 
To elucidate the stereochemistry at C6, the samples were derivatised with 100 µl 
MSTFA/potassium acetate/imidazole (1000/20/20; v/w/v) at 80°C for 60 min. 
5.3.5. GC/MS conditions 
The identification of the urinary metabolites was performed in full scan mode (mass range: 
m/z 65-600). Determination of the detection times was done in SIM mode. Both GC/MS 
methods were run on an Agilent 6890 gas chromatograph directly coupled to an Agilent 5973 
mass selective detector (Agilent, Palo Alto, USA). The GC column was an HP-Ultra 1 (J&W, 
Folsom, USA) 100 % methylsilicone column with a length of 17 m, an internal diameter of 
0.2 mm and a film thickness of 0.11 µm. Helium was used as carrier gas in the constant flow 
mode (0.6 ml/min). A total of 1 µl was injected splitless on the chromatographic system. The 
oven temperature program was as follows: 120°C (0 min), 70°C/min → 230°C (0.1 min), 
1.5°C/min → 232°C (0 min), 1.0°C/min → 238 °C (0 min), 30°C/min → 300 °C (2 min). The 
electron energy was 70 eV and the ion source temperature was 230 °C. Three ions were 
monitored for each compound in the SIM mode. Dwell times were set at 50 ms except for the 
ions 520.3, 516.3 and 518.3 which were set at 30 ms. 
5.3.6. Method validation 
To determine the LOD, ten different negative control urines were spiked with the metabolites 
at different concentrations in the range 2 – 50 ng/ml (2, 5, 10, 25 and 50 ng/ml). 
Specificity was tested by the analysis of ten different negative urine samples. Selectivity was 
evaluated by the analysis of a reference mixture of several compounds. These compounds 
were: 9α-fluoro-17α-methyl-androst-4-ene-3α,6β,11β,17β-tetrol, 17α-methyl-androst-4-ene-
11α,17β-diol, 6β-hydroxy-4-chlorodehydro-methyltestosterone, 17α-ethyl-5β-estrane-
3α,17β-diol, 7α,17α-dimethyl-5β-androstane-3α,17β-diol, 16β-OH-stanozolol, salbutamol, 
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clenbuterol, terbutaline, oxandrolone, 17α-trenbolone, pemoline, probenecid, clopamide, 
canrenone, amiloride, triamterene, 16β-hydroxy-furazabol, 7β,17α-dimethyl-5β-androstane-
3α,17β-diol, 6β-hydroxy-metandienone, 4-chloro-androst-4-ene-3α-ol-17-one, 2α-methyl-
5α-androstan-3α-ol-17-one, 1α-methyl-5α-androstan-3α-ol-17-one, 11-nor-∆9-
tetrahydrocannabinol.carboxylic acid, 19-norandrosterone, 19-noretiocholanolone, 17β-
methyl-5β-androst-1-ene-3α,17α-diol, 3’OH-stanozolol, 17α-methyl-5α-androstane-3α,17β-
diol, 17α-methyl-5β-androstane-3α,17β-diol, boldenone, 5β-androst-1-ene-17β-ol-3-one, 
oxymesterone and ethisterone. The concentrations ranged from 80 to 500 ng/ml. 
5.3.7. Excretion study 
Excretion studies were performed in two male volunteers according to a strict research 
protocol approved by WADA and by the Ethical Committee, University Hospital (Ghent, 
Belgium) (EC/2005-81/sdp). 
Subject 1 ingested 1 capsule of the 6-OXO® supplement. Urine samples were collected 
quantitatively during the first 24 hours (0, 2, 4, 6, 8, 10, 12, 24). Additional urine samples 
were taken for 7 days, three times a day (morning, noon, evening).  
Subject 2 took three capsules of the 6-OXO® supplement for three successive days according 
to the manufacturer’s recommendations. Urine samples were collected quantitatively for 72 h 
(0, 2, 4, 6, 8, 10, 12, 24 on each of the three days). Additional urine samples were taken for 7 
more days, three times a day (morning, noon, evening). 
All urine samples were stored at -20°C awaiting analysis. 
5.4. Results and Discussion 
Analysis of the nutritional supplement 6-OXO® revealed the presence of androst-4-ene-
3,6,17-trione and minor amounts of 6ξ-OH-androst-4-ene-3,17-dione. No other compounds 
were detected as contaminants according to the in-house method for the detection of 
anabolising agents in nutritional supplements [14]. 
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As described by van de Kerkhof et al. [15] trimethylsilylation with a mixture of 
MSTFA/NH4I/ethanethiol, as routinely used in doping control laboratories, cannot be applied 
for the selective analysis of the steroids androst-4-ene-6α-ol-3,17-dione and androst-4-ene-
6β-ol-3,17-dione because the stereochemical integrity at C6 is lost due to 3,5-dienol 
formation. Therefore derivatisation using MSTFA, potassium acetate and imidazole was used 
to retain the stereochemical information at C6 resulting in the formation of 2,4-dienol-TMS-
derivatives [16]. The mass spectra of the 2,4-dienol-TMS-derivatives of 6β-OH-
androstenedione and 6α-OH-androstenedione are shown in Figure 5.4.1 and Figure 5.4.2, 
respectively. 
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Figure 5.4.1 Mass spectrum of MSTFA/imidazole/KOAc derivatized 6β-OH-
androstenedione. 
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Figure 5.4.2 Mass spectrum of MSTFA/imidazole/KOAc derivatized 6α-OH-
androstenedione. 
Retention times of 6β-OH-androstenedione and 6α-OH-androstenedione were 6.0 and 6.7 
min, respectively. This additional analysis revealed that the minor compound present in the 
capsules was  androst-4-ene-6β-ol-3,17-dione (6β-OH-androstenedione). 
Identification of urinary metabolites of 6-oxo-androstenedione was performed using GC/MS 
in the full scan mode. For this purpose, the urine sample taken 10 h after the administration of 
three capsules on the third day by volunteer 2 was analysed. Besides 6-oxo-androstenedione 
(Figure 5.4.3) the sample also contained 6ξ-OH-androstenedione (Figure 5.4.4) and 6ξ-OH-
testosterone (Figure 5.4.5). 
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Figure 5.4.3 Mass spectrum of MSTFA/NH4I/ethanethiol derivatized 6-oxo-
androstenedione. 
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Figure 5.4.4 Mass spectrum of MSTFA/NH4I/ethanethiol derivatized 6ξ-OH-androst-4-
enedione. 
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Figure 5.4.5 Mass spectrum of MSTFA/NH4I/ethanethiol derivatized androst-4-ene-
6ξ,17β-diol-3-one. 
Again, similar to 6β-OH-androstenedione in the capsules, the position of the hydroxyl 
function at the C6 of 6ξ-OH-androstenedione and 6ξ-OH-testosterone in the urine samples 
could not be determined with MSTFA/NH4I/ethanethiol as derivatisation reagent. An 
additional analysis using MSTFA/potassium acetate/imidazole however revealed that the 
metabolites were 6α-OH-androsterone and 6α-OH-testosterone. The corresponding 6β-
isomers were not detected in the urine samples. 
Lévesque et al. [17] and van de Kerkhof [18] showed that, in contrast to in-vitro experiments 
where 6β-hydroxylation prevails [19], orally administered androst-4-ene-3,17-dione is 
metabolised in-vivo to 6α-OH-androstenedione. From the results of this study, it can be 
concluded that metabolism of 6-oxo-androstenedione is similar as for androst-4-ene-3,17-
dione (Figure 5.4.6). 
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Figure 5.4.6 In vivo metabolic pathway for androst-4-ene-3,6,17-trione (I) to androst-4-
ene-6α,17β-diol-3-one (III) via androst-4-ene-6α-ol-3,17-dione (II). 
Taking into account the metabolism of androgens in man and particularly the metabolism of 
androst-4-ene-3,17-dione [20], metabolism of 6α-OH-androstenedione to 6α-OH-testosterone 
seems logical. Moreover, 6β-isomers were not detected in the excretion urine, although 
further research on the fate of 6β-OH-androstenedione, the minor component in the capsules, 
is in progress.  
The appearance of 6α-OH-testosterone and especially the parent drug 6-oxo-androstenedione 
in a urine sample can be used as a direct indication of the intake of 6-OXO®. Although van 
de Kerkhof [18] speculated on the theoretical conversion of 6α-OH-androstenedione to 6-
oxo-androstenedione, analogous to the formation of 7-keto-dehydroepiandrosterone from 7ξ-
OH-dehydroepiandrosterone, his study showed that androst-4-ene-3,17-dione administration 
did not result in the detection of 6-oxo-androstenedione. Hence, the detection of 6-oxo-
androstenedione can be used to discriminate between the administration of 6-oxo-
androstenedione and androstenedione. 
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Based upon these findings, a GC/MS method in the SIM-mode was developed to determine 
the detection times of the metabolites after administration of 6-oxo-androstenedione. The GC 
(relative) retention times, monitored ions and respective relative abundances are given in 
Table 5.4.1. Presence of the substances was determined in agreement with criteria on 
chromatography and mass spectrometry as defined in a technical document by WADA [21]. 
Table 5.4.1 RT, RRT, diagnostic ions (relative abundance) and LOD for the 
trimethylsilylated compounds analysed in the selective ion monitoring mode. 
Compound 
RT 
(min) 
RRT Diagnostic ions  
(relative abundance %) 
LOD 
(ng/ml) 
androst-4-ene-3,6,17-trione 7.16 1.05 516 (100), 501 (20), 411 (12) 5 
androst-4-ene-6α-ol -3,17-dione 7.50 1.10 518 (100), 503 (6), 319 (6) 10 
androst-4-ene-6α,17β-diol-3-one 7.77 1.14 520 (100), 505 (11), 319 (5) 5 
The validation of the SIM-method was performed according to Eurachem guidelines [22]. As 
indicated in Table 5.4.1, LODs ranged from 5 to 10 ng/ml, complying with WADA rules 
requiring an MRPL for anabolic steroids of 10 ng/ml [23]. 
The procedure used to test for selectivity and specificity was the same as in Verwaal et al. 
[24]. For qualitative methods, the specificity can be tested by analysing all negative matrices 
used to determine the LOD. No matrix interferences were found, neither at the retention times 
of the analytes, nor at the retention time of the internal standard 17α-methyltestosterone. 
Selectivity was tested by analysing a reference mixture of several structurally related and 
other doping agents. According to the guidelines described by Verwaal et.al. [24], the 
concentration of these analytes must be at least twice the LOD of the determined compounds. 
In this study their concentration ranged from 0.8 µg/ml to 5 µg/ml, clearly complying with 
these requirements. As no interferences were detected at the retention times of the determined 
analytes and the internal standard, it can be concluded that the method is reliable and sensitive 
for the detection of 6-oxo-androstenedione, 6α-OH-androstenedione and 6α-OH-testosterone. 
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Detection times depend on the administration protocols. In the first protocol, where the 
subject took only one capsule of the 6-OXO® supplement, 6-oxo-androstenedione and 6α-
OH-testosterone were both detectable from 2 until 12 hours post-administration and 6α-OH-
androstenedione could be detected up to 29 hours. In the second protocol, where 3 capsules 
were taken during three successive days according to the manufacturer’s recommendations, 6-
oxo-androstenedione and 6α-OH-testosterone remained detectable until 24 hours after the last 
administration, while 6α-OH-androstenedione could be detected up to 37 h after the last 
intake. 
5.5. Conclusion 
Analysis of the 6-OXO® supplement resulted in the detection of 6-oxo-androstenedione and 
in minor amounts of 6β-OH-androstenedione. No other contaminants were detected. 
A GC/MS SIM method was developed and validated meeting WADA requirements. Using 
this method, the ingestion of the supplement, according to the manufacturer’s 
recommendations resulted in the detection of 6α-OH-androstenedione up to 37 h after the 
administration, while 6-oxo-androstenedione and 6α-OH-testosterone could be detected up to 
24 h post administration. Because of the longer detection time and its presence in urine after 
the administration of androstenedione, it is recommended that besides 6-oxo-androstenedione, 
6α-OH-androstenedione is also included in screening methods for doping control purposes. 
The presence of 6-oxo-androstenedione or 6α-OH-testosterone can be used to discriminate 
between the administration of 6-oxo-androstenedione and androstenedione. 
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1. Introduction 
Studies have shown that the use of several categories of medication differs from sport to 
sport. Regarding the percentage of inhaled β-agonist notifications during the Sydney 2000 
Olympic Games for instance, 20% of the triathlon athletes and cyclists declared the use of an 
inhaled β-agonist. Similar results were observed in endurance sports, e.g. cross country 
skiing, during the Nagano 1998 Olympic Winter Games [1]. The emphasis on declared use of 
β-agonists in endurance sports was also noticed in Finnish athletes [2]. Also interesting was 
the higher percentage of inhaled corticosteroids in endurance sports compared to sports 
requiring motor skills [2]. Besides differences between sports, it also appears that the 
medication use can change over time. For instance, the percentage of analgesics declared on 
doping control forms by Turkish soccer players increased from 25.3 % to 34.5 % over a 
period of 3 years [3]. 
In this chapter the results of monitoring the declared medication by athletes from 2002 until 
2005 will be discussed. 
2. Monitored categories 
The most frequently observed categories of medication mentioned on doping control forms 
are: corticosteroids, β2-agonists and analgesic drugs which can be devided in four main 
categories: narcotic analgesics, local anaesthetics, NSAIDs and various central acting non-
opioid drugs such as anti-depressants. 
2.1. Corticosteroids 
Corticosteroids can be divided in two groups: the glucocorticoids and the mineralocorticoids. 
Mineralocorticosteroids affect the water and electrolyte balance. Use of fludrocortisone for 
instance results in increased Na+ reabsorption and increases in K+ and H+ efflux [4]. 
Besides anti-inflammatory and immunosuppressive effects, glucocorticosteroids are so called 
because they stimulate the increase of glucose levels for energy [5]. Glucocorticosteroids are 
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very potent agents used for the short-term treatment of many inflammatory disorders. They 
inhibit both the early and late stage of inflammation. The use of large doses or prolonged use 
of corticosteroids can result in immunosupression, suppression of the patients capacity to 
synthesise corticosteroids, metabolic effects and effects on water and electrolyte balance. 
Some therapeutically used corticosteroids are given in Figure 2.1.1. 
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Figure 2.1.1 Chemical structure of some corticosteroids. 
As a result of their therapeutic effects the use of corticosteroids is widespread. Due to the 
euphoric effects occurring with high doses, corticosteroids were included on the WADA list 
of prohibited substances [6]. Systemic use (intravenous or intramuscular injections, oral, 
rectal) is prohibited while non systemic use including topical application (buccal, nasal, 
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creams and eyedrops) is allowed. Other routes of non systemic applications require an 
abbreviated TUE. Recently, WADA introduced a scientifically unsound reporting level of 30 
ng/ml. In contrast to non systemic use, this level can only be reached after the systemic use of 
corticosteroids. However, laboratories are supposed to detect the non systemic use as well 
which makes the situation even more complicated. 
2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
NSAIDs are among the most widely used therapeutic agents. The structure of the most 
important NSAIDs is shown in Figure 2.2.1. 
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Figure 2.2.1 Chemical structure of some NSAIDs. 
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Although the effectiveness of NSAIDs for the treatment of sport injuries is questionable, they 
are frequently used in sport medicine to treat muscle injuries [7, 8]. Minor effects have been 
reported on exercise [9, 10]. No ergogenic effect might be expected as confirmed in two 
studies [11, 12]. 
The frequent use of NSAIDs by athletes was shown by Corrigan and Kazlauskas who 
reported a percentage of incidence during the Sydney 2000 Olympics of 25.6 %. This was the 
highest percentage of all declared medication [13]. 
Paracetamol is one of the most frequently used non-narcotic analgesic and antipyretic agent. 
Although it only possesses non or weak anti-inflammatory activity, paracetamol shows good 
analgesic and antipyretic effects and is therefore often prescribed. 
In this study, paracetamol will be considered in the NSAID group. 
2.3. β2-agonists 
Beta-agonists are bronchodilators and belong to the group of sympathicomimetics. The 
structure of β2-agonists is closely related to (endogenous) catecholamines. The β2-agonists are 
phenyl β-ethanolamines with different substituents on the amino-group at different positions 
of the phenyl ring [14]. Some of the most frequently used β2-agonists are shown in Figure 
2.3.1. 
Because bronchial smooth muscle is strongly dilated by β2-agonists the use of selective β2-
agonists is important in the treatment of asthma. These drugs are usually administered by 
inhalation of aerosol, powder of nebulised solution. Some are injectable preparations. A 
metered dose inhaler is used for aerosol preparations [15]. 
Two types of β2-adrenoceptor agonists can be used in asthma therapy [16]: 
• Short acting agents, such as salbutamol and terbutaline, which are given by inhalation. 
They are used to control symptoms when needed. Their short-acting properties are a 
result of their high selectivity for the β2-receptor caused by the bulky amino 
substituents like tert.butyl groups [15]. 
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• Long acting agents, such as salmeterol, which are given regularly in adjunctive 
therapy in patients whose asthma is inadequately controlled by glucocorticosteroids 
[16]. 
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Figure 2.3.1 Structure of several β-agonists used in human medicine. 
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Besides the main pharmacological action β2-agonists produce, at higher doses, side-effects on 
protein synthesis and lipolysis resulting in anabolic action [14]. Hence β2-agonists might be 
misused for two reasons: 
• Stimulatory effect on respiration and the central nervous system 
• Growth-promoting action when administered in higher doses. 
In athletes both effects are regarded as performance enhancing. Therefore, the use of β2-
agonists is prohibited in both in- and out-of competition. Exceptions on this rule are 
formoterol, salbutamol, salmeterol and terbutaline which require a TUE when used for the 
treatment of asthma or brochoconstriction [6]. 
2.4. Narcotic analgesics 
The most famous narcotic analgesic is morphine. Morphine is a pure substance obtained from 
opium, an extract from the plant Papaver somniferum. Already in ancient times opium was 
used in medicine to treat headaches, kidney stones and pain as well as to produce euphoria 
and sleep. 
A lot of narcotic analgesics are morphine analogues while some others are synthetic 
derivatives without any structural relationship with morphine (Figure 2.4.1). 
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Drug Substituents    
 3 6 N 14 
morphine -OH -OH -CH3 -H 
heroin -OCOCH3 -OCOCH3 -CH3 -H 
codeine -OCH3 -OH -CH3 -H 
levorphanol -OH -H -CH3 -H (lacks –O- at C4-C5) 
dihydrocodeine -OCH3 -OH -CH3 -H (lacks double bond C7-C8) 
nalorphine -OH -OH -CH2CH=CH2 -H 
nalbuphine -OH -OH -CH2-cyclobutyl -OH (lacks double bond C7-C8) 
naloxone -OH =O -CH2CH=CH2 -OH (lacks double bond C7-C8) 
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Figure 2.4.1 Structure of several narcotic analgesics. 
Narcotic analgesics can be divided into three subcategories according to their pain killing 
properties. Codeine, dihydrocodeine and dextropropoxyphene can be considered as weak 
analgesics while pethidine, pentazocine and tilidine exhibit intermediate analgesia and 
buprenorphine, methadone, hydromorphone and morphine are powerful analgesics [17]. Their 
mechanism of action is linked to their agonist/antagonist action on the µ, δ and κ receptors 
[18]. The most important effect of narcotic analgesics is the influence on the central nervous 
system resulting in analgesia and euphoria. 
As a result of their powerful analgesic effects, morphine and other narcotic analgesics are 
used in sport to overcome pain associated with strenuous exercise. This was the major reason 
why morphine was included in the IOC list of banned substances. Before 1991, the presence 
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of morphine in urine, irrespective of its concentration, resulted in a positive doping test. This 
changed in 1991 when the UCI introduced a 1 µg/ml threshold level for morphine as well as 
for codeine, one of the precursors of morphine. 
At present the use of codeine and ethylmorphine, both morphine precursors, is allowed while 
morphine is forbidden in concentrations exceeding 1 µg/ml [6]. Other narcotic analgesics, 
such as pethidine, buprenorphine and pentazocine are prohibited. 
2.5. Local anaesthetics 
The first applied local anaesthetic was cocaine in the eye by the ophthalmologist Carl Köller 
in 1884 proving the reversible corneal anaesthesia, resulting afterwards in the general use of 
cocaine as an anaesthetic in dentistry and surgery [19]. 
The mechanism of action of local anaesthetics is linked to the blocking of the Na+ channels 
[20, 21]. These molecules consist of an aromatic ring linked by an ester or an amide bond to a 
basic side-chain (Figure 2.5.1). They are weak bases, with pKa values in the range 8-9 and are 
mainly ionised at physiological pH. The activity is strongly pH dependent [22].  
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Figure 2.5.1 Structure of commonly used local anaesthetics. 
Similar to narcotic analgesic, local anaesthetics can be used by athletes to overcome pain 
allowing them to better compete. Until 2004 the use of local anaesthetics was prohibited. 
Afterwards, their use was allowed according to WADA-rules [6]. The use of cocaine, which 
also shows stimulating effects, is however prohibited. 
2.6. Antidepressant drugs 
The main biochemical theory of depression is the monoamine hypothesis, stating that 
depression is caused by a functional deficiency of monoamine transmitters at certain sites in 
the brain. In contrast, mania results from a functional excess of monoamine transmitters [23]. 
Antidepressant drugs can be divided into three categories: Tricyclic antidepressants (TCA) 
which are non-selective inhibitors of monoamine uptake, the selective seretonine reuptake 
inhibitors (SSRI) and monoamine oxidase inhibitors (MAOI). Their mechanism of action is 
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based upon the (selective) blocking of dopamine, noradrenaline and/or seretonine reuptake, 
increasing the concentration of these monoamines in the synaptic cleft. [24, 25]. Currently, 
the use of SSRI antidepressants is very popular. Fluoxetine (Figure 1.2.6) is one of the most 
famous anti-depressants, in general under its brand name Prozac®. 
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Figure 2.6.1 Structure of frequently used anti-depressants. 
Anti-depressants are often misused for their euphoric effects. Amitriptyline is also effective in 
the treatment of asthma, while dopexine causes brochodilatation [26]. Despite these known 
beneficial effects antidepressants are not included in the 2006 WADA list of prohibited 
substances. 
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3. Experimental 
The declared use of medication on doping control forms collected from 2002 until 2005 was 
examined. A database was created based on the active ingredients present in the medication. 
The doping control forms originating from the Flemish Community, the UCI, KBWB, 
DoCoNed from 2002 until 2005 were evaluated. From 2004, samples from the Communauté 
Française (CF) are also included. 
Other monitored parameters besides origin of the sample and active ingredient were gender 
and sport. 
Determination of percentages of use, based upon the total number of analysed samples 
allowed for the comparison in time and between sports. 
4. Results and discussion 
Preliminary results obtained in 2001 showed that the incidence of use of different types of 
medication differs between sports [27]. 14 % of tested athletes have declared the use of one or 
more drugs classified in the above mentioned categories (except β-agonists and 
antidepressants). It was also noticed that the use of corticosteroids was more prevalent in 
cycling compared to other sports [27]. The use of NSAIDs on the other hand was higher in 
ball sports. Based on these preliminary results, a monitoring program was set up. In addition 
the declared use of β-agonists and antidepressants was also evaluated. 
4.1. 2002 
In 2002 a total of 3858 doping control forms originating from different federations and 
NADOs, excepting the CF, were controlled for the presence of medications belonging to one 
of the described categories. In total 19.8 % of the forms showed the presence of one or more 
drugs. In only 3 cases the use of an antidepressant agent was reported. Figure 4.1.1 illustrates 
the incidence per category on the doping control forms from different organisations. It 
appears that the declaration of NSAIDs is substantially higher on the NADO forms and that 
the use of corticosteroids is much higher in cycling (UCI and KBWB). 
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Figure 4.1.1 Percentages of declared use of medication according to controlling 
organisation in 2002. 
Figure 4.1.2 summarises the results in the most frequently tested sports in 2002. It seems that 
the use of NSAIDs and paracetamol is prevalent in athletics and in ball sports with 
percentages exceeding 20 % in volleyball and soccer. The use of narcotic analgesics and 
anaesthetics follows a similar patern although the use of these drugs is low compared to 
NSAIDs. A higher percentage of use of corticosteroids and β-agonists was observed in tennis, 
handball and swimming, but the percentage of use of this type of drug is low when compared 
to cycling. 
Part IV: Medication use in sports 
 
 191
0
5
10
15
20
25
NSAID 14,93 16,36 20,97 21,05 2,86 12,00 4,44 4,05
Narcotics 0,00 1,82 0,81 0,42 2,86 2,67 0,00 0,17
Anaesthetics 0,50 0,00 0,00 0,42 0,00 0,00 0,00 1,94
Corticos 2,99 1,82 2,02 1,47 5,71 5,33 4,44 14,94
Beta-agon 1,49 0,91 1,61 0,84 5,71 6,67 4,44 7,34
Athletics Basketball Volleyball Soccer Tennis Handball Swimming Cycling
 
Figure 4.1.2. Declared use of medication in different sports in 2002. 
In cycling the use of corticosteroids is more prevalent while the use of NSAIDs is 
substantially lower than in most other tested sports. Percentages of anaesthetics are also 
higher in cycling. The percentage of declared β-agonists is also substantially higher than in 
other sports. 
Figure 4.1.3 shows the results obtained in cycling for the different testing authorities. 
Declared corticosteroid use on the UCI doping control forms exceeds 25 %. Also interesting 
to note is the difference in declared use of both corticosteroids and β-agonists in cycling 
amongst different controlling organisations. The higher percentages in samples originating 
from the UCI could be due to the fact that professional cyclists tested by the UCI have to 
show their medical booklet to doping control officers or because the level of the tested 
athletes is higher compared to cyclists selected for doping control by the NADOs. 
Also interesting to note is the higher percentage of use of anaesthetics, most frequently 
lidocaine, in samples originating from the UCI compared to samples from NADOs. Before 
2004 UCI rules stipulated that the use of local anaesthetics, including lidocaine, was only 
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allowed with a proper medical justification and for local use only. Other routes of 
administration were prohibited. This might explain the higher percentages found in samples 
from the UCI. 
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Figure 4.1.3 Percentages of declared use of medication in cycling in 2002 in relation to 
the controlling organisations. 
4.2. 2003 
Analysis of doping control forms in 2003 from the same federations and the NADOs (N = 
4417) showed that 980 athletes (22.19 %) declared the use of one or more monitored 
substances which is approximately 2.5 % higher than in 2002. 5 athletes declared the use of 
an antidepressant. Similar to 2002, the use of NSAIDs (including paracetamol) was the 
highest in samples originating from the Flemish Community and the Netherlands. The use of 
corticosteroids is significantly higher in samples originating from the UCI compared to other 
federations (Figure 4.2.1). 
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Figure 4.2.1 Percentages of declared use of medication  according to controlling 
organisation in 2003. 
From Figure 4.2.2 it can be seen that the use of NSAIDs in most ball sports is higher than in 
other sports, but the difference between sports is not as pronounced as in 2002. Percentages of 
NSAID use increased in 2003 and exceeded the level of 30 % in volleyball. Similar as in the 
previous year, the use of narcotic analgesics, anaesthetics, corticosteroids and β-agonists in 
the most tested sports is low. 
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Figure 4.2.2 Declared use of medication in different sports in 2003. 
Although the incidence of use of corticosteroids in different tested sports is the highest in 
swimming (6.85 %), percentages found in cycling are twice as high. Of all tested cyclists in 
2003 18.03 % have declared the use of one or more corticosteroids. Declared use of 
corticosteroids in samples originating from the UCI is even higher than 33 %, 7.5 % higher 
than in 2002 (Figure 4.2.3). 
Finally, the use of β-agonists is also higher in cycling compared to other sports. Percentages 
of use of NSAIDs, anaesthetics and narcotic analgesics are low compared to the use of 
corticosteroids and β-agonists. 
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Figure 4.2.3 Declared use of medication in cycling in 2003. 
4.3. 2004 
Starting from 2004 samples were also analysed for the CF, increasing the number of 
investigated doping control forms to 5190. Percentages of declared medication belonging to 
the monitored categories increased to 24.57 %, more than 2 % higher than in the previous 
period and even 5 % higher than in 2002. Of those athletes, 16 declared the use of an 
antidepressant. From Figure 4.3.1 it can be concluded that the declared use of medication on 
the doping control forms of the CF is similar to other NADOs (Vl Gem and DoCoNed). 
Similar trends as in the previous tested periods could be observed in the reporting behaviour 
related to the originating federation. Again, the declared use of NSAIDs is the highest on the 
doping control forms from the NADOs while the use of corticosteroids is highest in the 
samples originating from the UCI. Interesting to note is the high percentage of athletes tested 
by the UCI reporting the use of an anaesthetic drug, although starting from 2004, the use of 
local anaesthetics was not longer prohibited by WADA and the UCI. 
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Figure 4.3.1 Percentages of declared use of medication on forms from several controlling 
bodies in 2004. 
Results shown in Figure 4.3.2 confirm the results obtained in the previous periods about the 
use of medication is different sports. Use of NSAIDs in ball sports is again higher when 
compared to other sports such as swimming. It was also observed that the use of NSAIDs in 
volleyball decreased in 2004 to its level obtained in 2002 while the use of NSAIDs in other 
ball sports remained approximately the same. The use of other drugs is similar as in 2002 and 
2003. Percentages of declared corticosteroid use in cycling increased to more than 20 %. 
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Figure 4.3.2 Declared use of medication in different sports in 2004. 
The use of medication in cycling in 2004 was very similar to 2003 (Figure 4.3.3). Percentages 
found in samples originating from the CF are very similar to the percentages found in samples 
from the other NADOs. As for the previously tested periods, the use of corticosteroids and β-
agonists in cycling is the highest in samples originating from the UCI. 
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Figure 4.3.3 Declared use of medication in cycling in 2004. 
4.4. 2005 
Totally 5180 doping control forms were evaluated in 2005. 1278 athletes (24.67 %) declared 
the use of one or more drugs belonging to the categories in this study similar to the result 
obtained in 2004. Also similar as in 2004 is the total number of athletes declaring the use of 
an antidepressant drug. 
From Figure 4.4.1 it can be seen that the use of narcotic analgesics and anaesthetics is rarely 
reported. Use of NSAIDs is again the highest in the samples originating from the NADOs 
while corticosteroid use is again exuberant in samples from the UCI. In 2005 percentages 
even exceed 35 %. 
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Figure 4.4.1 Percentages of declared use of medication on doping control forms of some 
controlling bodies in 2005. 
Similar observations as in the previous periods about the declared use of medication in several 
sports can be made (Figure 4.4.2). Levels of use of NSAIDs and corticosteroids in swimming 
decreased compared to 2004 and 2003 and returned to the values in 2002.  
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Figure 4.4.2 Declared use of medication in different sports in 2005. 
The general use of corticosteroids in cycling in 2005 was 18.92 % or 1.10 % lower as in 2004 
(20.02 %). This is caused by the decreased declaration of these drugs in samples originating 
from the NADOs and the KBWB as the percentage of athletes tested by the UCI declaring the 
use of a corticosteroid increased to 36.49 % (Figure 1.4.12). The use of β-agonists in samples 
from the UCI also increased to its highest level in 4 years. Combinations of both drugs are 
very often reported. Out of the 54 athletes declaring the use of a β-agonist, 50 simultaneously 
declared the use of a corticosteroid. The combination of budesonide – formoterol and 
fluticasone – salmeterol used for the treatment of exercise induced asthma are the most 
popular. Declared use of the other monitored medication in cycling is low and similar as in 
previous periods. 
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Figure 4.4.3 Declared use of medication in cycling in 2005. 
5. Conclusion 
From the results obtained in this study it can be concluded that the declared use of different 
groups of medication depends on the origin of the samples and the tested sports. Generally, 
the use of local anaesthetics and narcotic analgesics is low, with the exception of lidocaine in 
cycling and more specifically in samples originating from the UCI. The use of other drugs is 
more sport depending. It was observed that the declared use of NSAIDs and paracetamol in 
ball sports was higher than in other sports. On the other hand, the declared use of 
corticosteroids in cycling is extremely high with percentages steadily increasing from 25.4 % 
in 2002 to 36.5 % in 2005 in samples taken by the UCI while general percentages of use in 
cycling decreased. The difference between elite and amateur levels may explain this trend as 
UCI mostly tests elite athletes while the different NADOs control athletes at both levels. 
At present almost no athletes are sanctioned for the misuse of corticosteroids because of the 
relatively easy accessibility of a therapeutic use exemption in combination with the WADA 
scientifically unsound reporting level of 30 ng/ml. If trends in corticosteroid use in sports 
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keep on rising in the future a evaluation of the current TUE system and sanctioning should be 
considered. 
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Summary and Conclusion 
Since the introduction of the first doping test in the early 1960’s and the development of anti-
doping rules by the UCI in the same period, doping rules have been extensively revised by the 
IOC and currently by WADA. These rules are very extensive and include numerous classes 
defined as doping agents and prohibited methods. 
In this thesis some substances that are situated at the borderline between allowance and 
prohibition are described. The complex situation with nutritional supplements and their 
influence on the outcome of a doping test is evaluated. 
Analysis in doping control relies on strict criteria. These criteria involve both method 
validation and identification. These parameters are discussed in Part I. 
Besides drugs allowed in sports and drugs allowed for medical treatment, the use of several 
drugs is restricted by a urinary concentration threshold level. Problems associated with 
caffeine and morphine are discussed in Part II. 
Since January 1st 2004 the use of caffeine is allowed in sport. Before, urinary concentrations 
exceeding 12 µg/ml constituted a doping offence. As it is well known that caffeine exhibits 
performance enhancing effects, even at doses resulting in urinary concentrations far below the 
12 µg/ml threshold level, the removal of caffeine from the doping list could have resulted in 
an increased misuse. In order to observe changes in caffeine use in different sports after the 
removal from the doping list, a statistical evaluation was made before and after the 
withdrawal of caffeine. Results obtained in this study (Part II Chapter 1) show that urinary 
caffeine concentrations in the period 1993-2002 were significantly higher in cycling and 
bodybuilding compared to other sports. A similar trend was observed in samples tested in 
2004 highlighting the purported ergogenic and stimulating effects in these sports. In general, 
caffeine concentrations did not increase after the removal of caffeine from the WADA doping 
list. Calculated apparent threshold levels on the other hand show that the use of a threshold 
level of 12 µg/ml is capable of distinguishing use from abuse making the withdrawel of 
caffeine from the doping list questionable. 
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Morphine is prohibited in sports. A urinary threshold of 1 µg/ml is applied. The use of food 
products containing parts of the plant Papaver somniferum, the natural source of morphine is 
studied in Part II Chapter II. Administration of herbal teas resulted in the detection of urinary 
morphine concentrations up to 7.44 µg/ml. Athletes should therefore be very careful with 
herbal products. In addition, WADA and NADOs should warn athletes on the possible risks 
associated with the use of sedative teas or food products containing parts of the plant Papaver 
somniferum. 
Nutritional supplements are discussed in Part III. An extensive review of the literature 
(Chapter 1) showed that, although nutritional supplements are allowed, their use is strongly 
dissuaded for two major reasons. First, it is believed that the use of nutritional supplements is 
unnecessary in a normal balanced diet. Secondly, some nutritional supplements have proven 
to contain doping substances. As a result of the 1994 DSHEA enacted in the USA, steroids 
and prohormones could be distributed as nutritional supplements. Previous research has 
shown that the labelled content of these “nutritional supplements” is not always correct. 
Besides steroids and prohormones, numerous nutritional supplements promoted for weight 
loss contain herbal formulations from Ephedra species. Also other stimulating agents such as 
MDMA (ecstasy) and fenfluramine were detected in supplements. As athletes remain 
responsible for the presence of doping substances in their body fluids, irrespective of their 
origin, it is very important to develop analytical methods capable of detecting contaminants in 
supplements. Two analytical methods for the detection of low range contamination of 
anabolising agents in both solid and liquid nutritional supplements are described in Chapter 2. 
These methods were the first completely validated methods in this field. Totally 32 
components are screened and LODs for 29 analytes range from 2 to 20 ng/g in solid 
supplements and for 31 analytes from 1 to 10 ng/ml in aqueous supplements. 
Besides methods for the detection of anabolising agents, a sensitive LC/MS method for the 
detection of stimulants in solid nutritional supplements was developed (Chapter 3). LODs of 
100 ng/g are far below the requirements of supplement testing organisations. 
Chapter 4 describes several case reports with contaminated nutritional supplements. Several 
excretion studies were carried out proving that the ingestion of contaminated supplements can 
result in adverse doping findings. For instance, the presence of nandrolone precursors can 
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result in positive findings up to 144 h. Supplement producing companies are always trying to 
circumvent international laws and doping rules by introducing new prohormones such as 5α-
androstane-3,17-dione (Chapter 4) and 6-oxo-androstene-3,17-dione (Chapter 5) proving the 
need for continuing research in analysis of nutritional supplements. 
The relatively high percentage of positive samples obtained during 4 years of supplement 
testing also proves the importance of screening for prohibited substances by specialised 
doping control laboratories. 
Although most painkillers are allowed in sport, it seems interesting to evaluate the prevalence 
of these drugs in sports as declared by athletes on the doping control forms. The declared use 
of non-steroidal anti-inflammatory drugs and paracetamol and other frequently reported drugs 
such as corticosteroids, β-agonists, narcotic analgesics and local anaesthetics is described in 
Part IV. The reported use of anti-depressants was also included. Statistical information 
gathered during the period 2002 - 2005 from 18645 athletes is reported. From this data it 
appears that differences in reported medication were observed on doping control forms from 
different federations and/or NADOs and also between sports. More NSAIDs and paracetamol 
were reported in ball sports compared to other sports. The most pronounced difference was 
the high prevalence of corticosteroid use in cycling. Percentages of declared corticosteroids in 
samples originating from the UCI increased year after year to a maximum of 36 % in 2005. It 
appears that corticosteroids were often used in combination with β-agonists. Nowadays the 
use of corticosteroids in sport will only be allowed with a proper medical justification. This 
TUE will be a helpful tool to overcome the past situation of over-consumption with 
uncontrolled prescriptions and declarations by the athletes. 
In general, this work shows that the line between allowed and prohibited medication in sport 
is not always clear. In most cases positive doping findings are caused by the deliberate intake 
of prohibited substances. Athletes using these drugs and methods should be sanctioned. 
Positive doping tests can also result from the accidental intake of a non-labelled prohibited 
substance or (deliberately) contaminated nutritional supplements. According to WADA rules, 
no distinction is made between those athletes and cheaters as the final responsibility relies on 
the athlete. As numerous athletes persist in taken supplements international organisations 
should warn them against the possible doping risks associated with their use. In addition, 
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more strict quality criteria are needed for supplement producing companies. Doping control 
laboratories can play an important role in this process as they have the expertise in this field. 
Structures similar to the NZVT-system disclosing lists of products which can be used without 
the risk of unwanted positive doping results on their website are of utmost importance. 
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Samenvatting en Conclusies 
Sinds de invoering van de eerste dopingtesten in de vroege jaren 1960 en de ontwikkeling van 
een antidoping regelgeving door de UCI in dezelfde periode zijn de reglementen uitgebreid 
gereviseerd door het IOC en momenteel door WADA. Deze regels omvatten naast verboden 
methodes verscheidene categorieën gedefinieerd als dopeermiddelen. 
In dit proefschrift werden enkele substanties besproken die zich op de grens tussen toegelaten 
en verboden bevinden. Bovendien wordt de complexe situatie met voedingssupplementen en 
hun mogelijke invloed op het eindresultaat van een dopingtest geëvalueerd. 
Analyses in dopingcontroles zijn gebonden aan strikte criteria. Deze omvatten zowel methode 
validatie als identificatie. Beide parameters worden besproken in Deel I. 
Naast de geneesmiddelen die verboden zijn in sport en deze die toegestaan zijn voor medische 
redenen is het gebruik van verscheidene producten beperkt door een urinaire drempelwaarde. 
Mogelijke problemen geassocieerd met het gebruik van cafeïne en morfine beschreven in 
Deel II. 
Het gebruik van cafeïne is sinds 1 januari 2004 toegelaten in de sport. Voordien werden 
urinaire concentraties hoger dan 12 µg/ml beschouwd als een dopingmisbruik. Aangezien de 
prestatiebevorderende effecten van cafeïne welbekend zijn, en dit zelfs bij hoeveelheden die 
aanleiding geven tot urinaire concentraties ver beneden de 12 µg/ml drempelwaarde, kan de 
verwijdering van cafeïne van de lijst van verboden producten aanleiding geven tot een 
toegenomen misbruik. Om veranderingen vast te stellen in cafeïnegebruik in verscheiden 
sporten na de verwijdering van de dopinglijst werd een statistische evaluatie gemaakt voor en 
na de verwijdering van cafeïne. De bekomen resultaten (Deel II Hoofdstuk 1) tonen aan dat de 
cafeïneconcentraties tussen 1993 en 2002 significant hoger waren in wielrennen en 
bodybuilding in vergelijking met andere sporten. Een analoge trend werd vastgesteld in de 
stalen geanalyseerd in 2004 wat de veronderstelde ergogene en stimulerende effecten van 
cafeïne in deze sporten benadrukt. Cafeïneconcentraties stegen in het algemeen niet na de 
verwijdering van cafeïne van de WADA dopinglijst. Aan de andere kant tonen berekende 
drempelwaarden aan dat de vroegere drempelwaarde van 12 µg/ml in staat is gebruik van 
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misbruik te onderscheiden wat de verwijdering van cafeïne van de dopinglijst twijfelachtig 
maakt. 
Morfine is verboden in de sport boven een drempelwaarde van 1 µg/ml. Het gebruik van 
voedingsmiddelen die delen van de plant Papaver somniferom bevatten, de natuurlijke bron 
van morfine, is besproken in Deel II Hoofdstuk 2. Toediening van kruidenthees resulteerde in 
de detectie van urinaire morfineconcentraties tot 7,44 µg/ml. Omwille van dit dienen atleten 
voorzichtig te zijn met het gebruik van kruidenmengsels. Daarenboven dienen WADA en de 
NADO’s de atleten te waarschuwen voor de mogelijke risico’s verbonden aan het gebruik van 
slaapbevorderende theesoorten of het gebruik van voedingsmiddelen die delen van de plant 
Papaver somniferom bevatten. 
Voedingssupplementen worden besproken in Deel III. Een uitgebreid overzicht van de 
literatuur (Hoofdstuk 1) toont aan de het gebruik van voedingssupplementen sterk afgeraden 
wordt omwille van twee redenen. Ten eerste wordt aangenomen dat het gebruik van 
supplementen onnodig is bij een normaal uitgebalanceerd dieet. Ten tweede werd aangetoond 
dat voedingssupplementen dopeermiddelen bevatten. Als gevolg van de invoering van de 
DSHEA in de VS in 1994 konden steroïden en prohormonen gedistribueerd worden als 
voedingssupplementen. Onderzoek toonde aan dat de weergegeven inhoud van deze 
“supplementen” niet altijd correct is. Naast steroïden en prohormonen bevatten talloze 
supplementen kruidenmengsels van Ephedra species. Daarnaast werden ook andere 
stimulerende middelen zoals MDMA (ecstasy) en fenfluramine teruggevonden in 
supplementen. Aangezien atleten verantwoordelijk zijn voor de aanwezigheid van 
dopeermiddelen in hun lichaam, ongeacht de oorsprong, is het van groot belang om 
analytische methodes te ontwikkelen die in staat zijn contaminanten in voedingssupplementen 
op te sporen. In hoofdstuk 2 worden 2 analytische methodes beschreven voor de detectie van 
lage hoeveelheden aan anaboliserende componenten in zowel vaste als vloeibare 
supplementen. Deze methodes waren de eerste gevalideerde methodes in dit 
onderzoeksdomein. In totaal worden 32 componenten gescreend en de detectiegrenzen reiken 
voor 29 componenten van 2 tot 20 ng/g in vaste voedingssupplementen en in vloeibare 
supplementen van 1 tot 10 ng/ml voor 31 componenten. 
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Naast methodes voor de detectie van anaboliserende stoffen werd een gevoelige LC/MS 
methode voor de detectie van stimulantia in vaste voedingssupplementen ontwikkeld 
(Hoofdstuk 3). De detectiegrenzen van 100 ng/g zijn ver beneden de vereisten van supplement 
testende organisaties.  
Hoofdstuk 4 beschrijft verscheidene voorbeelden van gecontamineerde 
voedingssupplementen. Excretiestudies toonden aan dat het gebruik van gecontamineerde 
supplementen aanleiding kan geven tot een positief dopingresultaat. Zo kan de aanwezigheid 
van nandrolone precursors resulteren in positieve resultaten tot 144 h na inname. Supplement 
producerende bedrijven zijn ook steeds op zoek om de internationale wetgeving en 
dopingwetgeving te omzeilen door nieuwe prohormonen zoals 5α-androstandion (Hoofdstuk 
4) en 6-oxo-androstene-3,17-dion (Hoofdstuk 5) wat de noodzaak voor onderzoek in dit 
domein benadrukt. 
Het relatief hoog percentage aan positieve stalen bekomen gedurende 4 jaar van 
supplementenanalyse toont eveneens het belang van screenen voor verboden producten door 
gespecialiseerde dopingcontrolelaboratoria aan. 
Hoewel het gebruik van de meeste pijnstillers in de sport toegelaten is, lijkt het interessant het 
voorkomen van deze geneesmiddelen zoals opgegeven door de atleten op de 
dopingcontroleformulieren te evalueren. Het opgegeven gebruik van NSAID’s en paracetamol 
als meest gekende pijnstillers samen met andere frequent gerapporteerde geneesmiddelen 
zoals corticosteroïden, β-agonisten, narcotische analgetica en lokale anaesthetica is besproken 
in Deel IV. Het opgegeven gebruik van antidepressiva werd ook ingesloten. Statistische 
informatie verzameld gedurende de periode 2002 - 2005 van 18645 atleten werd 
gerapporteerd. Vanuit deze gegevens bleek dat verschillen in opgegeven geneesmiddelen 
konden worden waargenomen op de dopingcontroleformulieren van verschillende federaties 
en/of NADO’s en ook tussen sporten onderling. Zo werden meer NSAID’s en paracetamol 
gerapporteerd in balsporten in vergelijking met andere sporten. Het meest uitgesproken effect 
was het hoge gebruik van corticosteroïden in wielrennen. Percentages in stalen van de UCI 
namen jaar na jaar toe tot een maximum van 36 % in 2005. Deze corticosteroïden werden 
vaak gebruikt in combinatie met β-agonisten. Vandaag de dag is het gebruik van 
corticosteroïden in sport enkel toegestaan indien men beschikt over een medische 
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rechtvaardiging. Deze TUE zal een handig middel zijn om een einde te stellen aan de 
vroegere situatie van overconsumptie van ongecontroleerde voorschriften en verklaringen 
door atleten. 
In het algemeen toont dit werk aan dat de lijn tussen toegelaten en verboden medicatie in de 
sport niet altijd duidelijk is. In de meeste gevallen zijn positieve dopingresultaten te wijten 
aan het bewust innemen van verboden substanties. Atleten die van deze praktijken gebruik 
maken dienen onmiddellijk gesanctioneerd te worden. Positieve resultaten kunnen ook 
voortspruiten uit de inname van niet gelabelde verboden substanties of van (moedwillig) 
gecontamineerde voedingssupplementen. Volgens de WADA regelgeving wordt geen 
onderscheid gemaakt tussen deze atleten en valsspelers aangezien de finale 
verantwoordelijkheid bij de atleet ligt. Aangezien talloze atleten doorgaan met het nemen van 
supplementen moeten Internationale organisaties hen waarschuwen voor de mogelijke 
dopingrisico’s verboden aan hun gebruik. Daarenboven dienen strengere kwaliteitseisen 
gesteld te worden aan supplement producerende bedrijven. Door hun ervaring in dit gebied 
kunnen dopingcontrolelaboratoria een belangrijke rol vervullen in dit proces. Bovendien 
blijken structuren analoog aan het NZVT systeem, die een lijst van supplementen die zonder 
risico’s kunnen gebruikt worden op het website plaatsen, van het grootste belang. 
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